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General introduction
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Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are clonal 
expansions of myeloid cells in the bone marrow, blood or other tissues. The 
incidence of AML and CML is shown in Figure 1. AML occurs at any age group, 
but its incidence increases with age. The vast majority of AML occurs in adults, 
especially at >60 years of age. CML also occurs in all age groups and shows 
an increasing incidence with age. Only 5 to 10% of CML cases occur in patients 
younger then 20 years of age. The median age of CML at diagnosis is in the fifth 
and sixth decades of life. 
In the first section, the immunophenotypic characteristics, molecular genetic 
abnormalities and immunogenotypic characteristics of AML and CML are discussed. 
Standard therapy and some innovative treatment modalities of myeloid leukemias 
are reviewed in the second section. Finally, quantitative techniques for the detection 
of minimal residual disease (MRD) and the clinical significance of MRD monitoring 
in AML and CML are discussed.
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Figure 1. Age-specific incidence of AML (closed symbols) and CML (open symbols) in the 
Netherlands (1994-1998). 
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1. IMMUNOPHENOTYPE AND MOLECULAR CHARACTERISTICS
  OF MYELOID LEUKEMIAS
1.1 IMMUNOPHENOTYPE OF MYELOID LEUKEMIA
Immunophenotypic characteristics of myeloid leukemia
The tumor cells in acute leukemia are generally regarded as the malignant 
counterparts of cells in immature and more mature stages of hematopoiesis. 
Analysis of several cellular parameters by flow cytometry enables the determination 
of the differentiation stage of normal and abnormal myeloid cell populations. During 
myeloid differentiation, more or less characteristic markers appear on the cell 
surface membrane, while others disappear.1-4 A hypothetical scheme of myeloid 
differentiation is shown in Figure 2.
By combining the information of several parameters including cell size, 
granularity, and expression levels of surface and intracellular molecules, it is 
possible to identify an immunophenotypic signature of the leukemic cells.5,6 The 
immunophenotypes of the AML subtypes according to the French-American-
British (FAB) classification and the corresponding classes of the World Health 
Organization (WHO) are summerized in Table 1.7-11 Virtually all AML subtypes are 
positive for CD13 and/or CD33 and the majority of AML also expresses CD65 and 
cytoplasmatic myeloperoxidase.12-14 Markers used for additional characterization 
are CD11b, CD11c, HLA-DR, CD14, CD15 (particularly myeloid/monocytic lineage), 
CD36, CD71, and CD235a (erythroid lineage), and CD41, CD42 and CD61 
(megakaryocytic lineage).3,15,16 HLA-DR expression is negatively associated with 
AML-M3.13,17 The majority of CD34+ AML blasts co-express the CD133 antigen.18,19 
An example of flow cytometric immunophenotyping of an AML at diagnosis is given 
in Figure 3.
Leukemia associated immunophenotypes in myeloid leukemia
The discrimination between leukemic myeloid cells and normal bone marrow 
myeloid cells is based on so-called leukemia-associated immunophenotypes 
(LAIP).20,21 These immunophenotypes are either aberrant or extremely uncommon 
within normal bone marrow and therefore allow the discrimination between the 
leukemic and normal cells. These LAIP’s in AML generally involve: a) cross-lineage 
antigen expression (i.e. the expression of typical lymphoid markers on myeloid cells), 
b) asynchronous expression of antigens (i.e. the co-expression of early markers 
such as CD34 or CD117 with antigens associated with advanced maturational 
stages of myeloid differentiation including CD15, CD56 or CD11b/c), c) antigen 
over- or underexpression (i.e. the presence of antigens such as CD13 or CD33 on 
leukemic cells at abnormally high or low levels), and d) ectopic antigen expression. 
Ectopic antigen expression in AML refers to the expression of antigens normally only 
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expressed on non-hematopoietic cells, such as expression of the NG2 antigen in a 
subset of AML with MLL gene rearrangements.22-24 Cross-lineage expression in AML 
usually concerns the expression of CD2, CD7, CD19, or terminal deoxynucleotidyl 
transferase (TdT) and can be found in up to one third of adult AML13,20,25-27 and up to 
two-third of childhood AML (Van der Velden, personal communication).
Using an appropriate panel of monoclonal antibodies, LAIP’s can be defined 
in about 80% of AML, with the majority of cases having at least two aberrant 
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Figure 2. Hypothetical scheme of myeloid differentiation. 
The expression of relevant immunologic markers is indicated for each differentiation stage; markers in 
parentheses are not always expressed. The bars represent the various types of leukemias. Abbreviations 
used: AUL = acute undifferentiated leukemia, AML = acute myeloid leukemia (M0 to M7; classification 
according to the “French-American-British” criteria); CML = chronic myeloid leukemia; NHL = non-
Hodgkin’s lymphoma. 
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Table 1. Immunophenotypic characteristics of AML.
            AML 
subtype
Marker
AML-M0a
AML 
minimally 
differentiatedb
AML-M1a
AML  
without 
maturationb
AML-M2a
AML with 
maturationb AML-M3a
AML with 
t(15;17) 
(q22;q12) 
(PML-RARA)b
CD34  ++ ++ + ±
CD117 ++ ++ ++ +
CD133 ++ + + -
HLA-DR ++  ++ + -
TdT + + + ±
CD13/33 ++ ++ ++ ++
CD65 ± + + +
MPO + / ++ + ++ ++
CD11b/c - / ± - / ± - / ± -
CD14 - - - -
CD15 ± ± ++ ±
CD36 - - - -
CD235a - - - -
CD41/CD61 - - - -
CD42 - - - -
a AML subgroups according to the French-American-Britisch (FAB) classification7
b AML subgroups according to the World Health Organization (WHO) classification10
cut-off for positivity ≥ 20% (cut-off for positivity of MPO ≥10%)9
 
-, <10% of the leukemias are positive; ±, 10-25% of the leukemias are positive; +, 25-75% 
of the leukemias are positive; ++, >75% of the leukemias are positive. The FAB and WHO 
classifications incorporate the immunophenotypic results for the recognition of AML-M0 (acute 
myeloid leukemia, minimally differentiated) and AML-M7 (acute megakaryoblastic leukemia). 
For the other AML subtypes, there is a moderate to fair correlation with specific markers. 
General introduction 15
Table 1. Immunophenotypic characteristics of AML (continued).
             AML   
        subtype
Marker
AML-M4a
Acute myelo- 
monocytic 
leukemiab
AML-
M5a/ba
Acute 
monoblastic/ 
monocytic 
leukemiab
AML-M6a
Acute 
erythroid 
leukemiab AML-M7
a
Acute 
megakaryo-
blastic 
leukemiab 
CD34 ± + / ± + +
CD117 + + + +
CD133 ± - - -
HLA-DR ++ ++ + ++
TdT + + + ±
CD13/33 ++ ++ + ++
CD65 ++ ++ ± ±
MPO ++ ++ + -
CD11b/c ++ ++ - -
CD14 + + / ++ - -
CD15 - - - -
CD36 + + ++ +
CD235a - - + -
CD41/CD61 - - - ++
CD42 - - - +
a AML subgroups according to the French-American-Britisch (FAB) classification7
b AML subgroups according to the World Health Organization (WHO) classification10
cut-off for positivity ≥ 20% (cut-off for positivity of MPO ≥10%)9
 
-, <10% of the leukemias are positive; ±, 10-25% of the leukemias are positive; +, 25-75% 
of the leukemias are positive; ++, >75% of the leukemias are positive. The FAB and WHO 
classifications incorporate the immunophenotypic results for the recognition of AML-M0 (acute 
myeloid leukemia, minimally differentiated) and AML-M7 (acute megakaryoblastic leukemia). 
For the other AML subtypes, there is a moderate to fair correlation with specific markers. 
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phenotypes.20,21,28 Examples of LAIP’s in AML samples at diagnosis are shown in 
Figure 4.
Due to their immunophenotypic heterogeneity, AML cells usually spread across 
many areas in each dot plot instead of forming a tight cluster, typically seen in acute 
lymphoblastic leukemia (ALL). Therefore, with any given marker combination, only 
a fraction of cells may appear to be phenotypically abnormal and consequently more 
than one subpopulation can be distinguished in the majority of AML.20,29 In most 
patients (>75%) two or more subpopulations co-exist. 
Figure 4. Flow cytometric examples of aberrant or unusual antigen expression patterns in four 
AML patients at diagnosis. 
(A) Lack of CD13 expression on CD34+ myeloid blast cells. 
(B) Asynchronous expression of the more mature marker CD56 on CD34+ myeloid blast cells. 
(C) Cross-lineage expression of the T-lineage marker CD7 on CD34+ myeloid blast cells. 
(D) Over-expression of CD13 on the CD34+ myeloid blast cells. 
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Figure 3. Flow cytometric immunophenotyping of whole bone marrow from a patient with an 
AML-M5 at diagnosis. 
The CD34/CD33, CD15/CD13, and HLA-DR/CD11b stainings were analyzed for the indicated 
CD45/SSC gated blast cell population. The myeloid blast cells expressed CD33, CD34 (strong 
expression), CD13 (weak expression), CD15, CD11b, HLA-DR (strong expression) and CD45 on the 
cell surface. 
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Applications of immunophenotyping in AML 
The first stratification step in recent therapeutic protocols is the discrimination 
of either AML, ALL and acute undifferentiated leukemia (AUL). For proper lineage 
assessment of the leukemic cell population immunophenotyping is of utmost 
importance. Although morphologic evaluation completed with cytochemical stainings 
can identify several subtypes of AML, for the diagnosis of the AML-M0 (characterized 
by negative cytochemical reaction for myeloperoxidase at the light microscopic 
level, but by the expression of one or more myeloid markers) and the AML-M7 
(characterized by the expression of platelet antigens such as CD41, CD42 and CD61) 
subtypes, immunophenotyping is the most powerful and rapid method (Table 1).16,30
In addition to classification into differentiation-based subtypes, detailed flow 
cytometric studies can define complex antigenic profiles that are associated with 
specific molecular defects.31 Blast cells from an AML with t(8;21) show higher levels 
of CD34 and HLA-DR, lower CD33 expression and are more frequently positive 
for CD19 and CD56 surface markers when compared to t(8;21) negative AML.32,33 
Therefore, this highly predictive expression pattern (CD34+/CD19+/CD56+) could 
serve as a screening criteria for the t(8;21). Immunophenotyping may also be 
of great value for a quick screening of acute promyelocytic leukemia (APL) with 
PML-RARA gene rearrangements. The presence of a heterogeneous expression 
of CD13, the existence of a single major blast cell population, negativity of HLA-DR, 
and a characteristic CD34/CD15 differentiation pattern show a high sensitivity and 
specificity for the prediction of PML-RARA gene rearrangements.34 AML-M4 with 
eosinophilia and inv(16) exhibit a specific CD2+ immunophenotype,35 and also the 
AML-M3 variant often co-expresses CD2.17,36
A phenotypic characterisation of AML is essential if antibody targeted therapy 
is considered as a treatment option.37 In > 85% of AML cases CD33 is expressed 
on the cell surface of the clonogenic leukemia progenitor cells. Treatment with 
a calicheamicin-conjugated anti-CD33 monoclonal antibody (gemtuzumab 
ozogamicin, Mylotarg®) has demonstrated substantial efficacy in patients with 
a CD33+ AML.38,39 Recent reports provide a basis for the development of other 
antibody targeted therapies in AML, including CD44-targeted therapy and CLL1-
targeted therapy.40-42
Finally, immunophenotyping of AML can be used to study the therapy efficacy 
by monitoring bone marrow and peripheral blood samples for the occurrence of 
minimal residual disease (MRD).43-46 
Immunophenotyping in CML
CML is a bi- or triphasic disease with an indolent chronic phase (CP), followed 
by one or both aggressive transformed stages, i.e. the accelerated phase (AP) and 
the blast crisis (BC). Flow cytometric immunophenotyping for CML patients in CP is 
of limited value. However, for patients in AP and especially for patients presenting 
in BC, flow cytometric immunophenotyping can help to identify the cell-lineage of 
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the blast cells. In about 70% of cases, the blast lineage is myeloid, while in 20-30% 
of patients, the BC is due to proliferation of lymphoblasts.47-49 Rarely, patients have 
separate populations of myeloid and lymphoid lineage simultaneously. Additionally, 
identification of LAIP’s in the blast cells can be used to monitor MRD. 
1.2 MOLECULAR GENETIC ABNORMALITIES IN MYELOID 
 LEUKEMIA
Currently, specific chromosome aberrations with fusion genes, mutated genes 
or aberrantly expressed genes are found in more than 70% of AML and more than 
95% of CML. Major specific molecular markers in AML and CML are summarized 
in Table 2.
Chromosome aberrations with fusion genes in AML
The most common reciprocal rearrangements in AML in Northwest Europe 
include t(8;21)(q22;q22) and inv16(p13q22)/t(16;16)(p13;q22), giving rise to the 
fusion genes and fusion transcripts AML1-ETO and CBFB-MYH11, respectively 
(Table 2). AML1 and CBFβ are interacting proteins forming the core binding factor 
transcription complex which is essential for normal hematopoiesis.50 Disruptions of 
the AML1/CBFβ complex is frequently implicated in leukemogenesis. AML1-ETO 
and CBFB-MYH11 fusion transcripts occur in about 10-25% of all AML (dependent 
on age) and are associated with a favorable outcome.51-53 AML1-ETO fusion gene 
transcripts are predominantly found in AML-M2.
The presence of CBFB-MYH11 fusion genes strongly correlates with AML-
M4Eo. Depending on distinct breakpoint locations, ten types of CBFB-MYH11 
fusion transcripts (A-J) are described.54,55 More than 85% of CBFB-MYH11 positive 
AML have a type A transcript; type D and E transcripts represent each nearly 5%, 
whereas all other types occur in sporadic cases. 
APL or AML-M3 accounts for 2-5% of de novo AML (higher incidences are 
reported in Southern Europe)56 and is associated with a favorable prognosis. APL is 
characterized by a chromosomal rearrangement involving the retinoic acid receptor 
alpha (RARA) gene that plays an important role in modulating myeloid differentiation. 
More than 95% of APL cases have a t(15;17)(q22;q21) with a PML-RARA fusion 
gene. While RARA breakpoints always occur within a ~15 kb fragment of intron 2, 
three breakpoint regions in the PML locus are involved in the t(15;17): intron 6 (bcr1; 
55% of cases), exon 6 (bcr2; 5%) and intron 3 (bcr3; 40%).57 Other fusion partners 
for RARA are PLZF, NPM, NuMA, and STAT5b as a result of t(11;17)(q23;q21), 
t(5;17)(q35;q21), t(11;17)(q13;q21), and t(17;17), respectively, but their frequency 
is low.58 
Chromosomal translocations involving the mixed lineage leukemia (MLL) gene 
(also called ALL-1, HRX, or TRX1) on chromosome band 11q23 are not lineage 
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Table 2. Specific molecular markers in AML and CML.
Disease category and aberration Frequency 
Children Adults
AML
Aberrations with fusion genes    
Common recurrent abnormalities
t(8;21)(q22;q22) with AML1-ETO 10-15% 6-8% a 
t(15;17)(q23;q21) with PML-RARA b 8-10% 2-5% a 
inv(16)(p13q22) and t(16;16)(p13;q22) with CBFB-MYH11 5-8% 5-7% a 
11q23 aberrations with a MLL fusionc 15-20% 3-7%
Rare recurrent abnormalities
t(6;9)(p23;q34) with DEK-CAN ~1%
t(8;16)(p11;p13) with MOZ-CBP ~1%
t(3;21)(q26;q22) with AML1-EVI1 ~1%
t(16;21)(p11;q22) with FUS-ERG ~1%
Mutations of genes
FLT3 mutations 
internal tandem duplications (ITD) 5-25%d  20-25% e
“activation loop” mutationsf ND 6-7%
RAS mutations 15-30%
AML1/RUNX1 mutations ND 8%
CEBPA mutations 6% 8-11%
NPM1 mutations 6.5% g 35% g
Abnormal expression of genes
WT1 overexpression 85-100% 85-100%
PRAME overexpression 60-65%  h 35-50%
 Ig/TCR gene rearrangements 5-10% 5-10%
CML
Aberrations with fusion genes
t(9;22)(q34;q11) with BCR-ABL (M-bcr breakpoint) >95% 
t(9;22)(q34;q11) with BCR-ABL (m-bcr breakpoint) 2-3% i
t(9;22)(q34;q11) with BCR-ABL (µ-bcr breakpoint) <2%
a Mainly concerns adult patients <60 years old. In patients >60 years old, the total frequency of AML1-ETO,
 CBFB-MYH11 and PML-RARA fusion genes is <10%.53 
b In Southern European regions, the frequency of t(15;17) with PML-RARA is essentially higher than in
 Northern European countries.56
c Seventy-one different partner chromosome regions have been detected, of which 51 partner genes are
 identified.63-65
d The occurrence of FLT3-ITD is age dependent: <1% in infant AML, 5% in children 1-10 years old and up to
 19% in children 10-18 years old.97
e The frequency of FLT3 mutations is lower in secondary AML (16%) and therapy-related AML (5-12%).82,83
 The frequency of FLT3-ITD in the elderly patients is higher.101
f  Asp835Tyr is the most common substitution.
g Percentages in primary AML (FAB non-M3 subtypes).115 There is an age dependent distribution: higher
 probabilities of NPM1 mutations in older children.116
h Data from a limited number of patients (50 children with AML).123
i   Co-expression of p190 is seen in >90% of CML with a M-bcr breakpoint.
Abbreviations: AML, acute myeloid leukemia; CML, chronic myeloid leukemia; FLT3, Fms-like tyrosine 
kinase 3; WT1, Wilms tumor; PRAME, preferentially expressed antigen of melanoma; NPM1, nucleophosmin; 
Ig, immunoglobuline; TCR, T-cell receptor; BCR, breakpoint cluster region; ND, no data yet available or 
analyzed in limited patient series.
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specific: they can be detected in AML, ALL, and mixed lineage acute leukemia. In 
~60% of infant AML, MLL gene aberrations are found.59,60 They are also frequently 
seen in childhood and adult patients with de novo AML61 or secondary AML following 
therapy containing topoisomerase II inhibitors.62 AML with MLL rearrangements 
is frequently associated with M4/M5 morphology. At present, 71 different partner 
chromosome regions have been found, of which at least 51 partner genes are 
identified.63-66 The t(6;11)(q27;q23), t(9;11)(p22;q23), t(10;11)(p12;q23) and 
t(11;19)(q23;p13.3), resulting in MLL-AF6, MLL-AF9, MLL-AF10, and MLL-ENL
fusion genes respectively, are the most common translocations in AML.67-70 
Regardless their association with other high-risk factors at presentation, MLL 
rearrangements are strongly predictive of poor clinical outcome. Although some 
reports have suggested that adult and childhood AML patients with t(9;11) carry a 
better prognosis,71-73 this is not confirmed by others.74,75
Finally, several recurrent translocations are found at low frequency (≤ 1%) in 
AML (Table 2). The t(8;16)(p11;p13) results in a fusion of the CREB-binding protein 
gene (CBP) and the MOZ gene. It is a well described entity in both de novo and 
treatment-related AML,76,77 associated with a young age at diagnosis, M4 or M5 
morphology, erythrophagocytosis, coagulopathy, and poor outcome.74 AML with 
t(6;9)(p23;q34) gives rise to the DEK-CAN fusion gene and fusion transcript. It is 
classified mostly as M2 or M4, and might show bone marrow basophilia. Patients 
with this type of leukemia are usually quite young78 and poorly respond to therapy. 
Other rare genotypic aberrations in AML are t(3;21)(q26;q22), and t(16;21)(p11;q22) 
with the molecular targets AML1-EVI1, and FUS-ERG respectively.79,80
Gene mutations in AML
FLT3 mutations are the most common genetic abnormalities in AML: they involve 
either an internal tandem duplication (ITD) in the juxtamembrane domain-coding 
sequence or a point mutation in the activation loop domain.81,82 The most common 
form of FLT3 mutation is an ITD in exon 14 and 15 (previously known as exon 11 
and exon 12), which occurs in de novo AML (~25%), secondary AML (~16%) and 
therapy-related AML (5-12%).82,83 FLT3-ITD mutations can be of variable length
-varying from 3 to up to 400 base pairs-, but they always consist of a multiplicity of three 
nucleotides, thereby retaining the reading frame.84 In about 30% of FLT3-ITD, extra 
nucleotides are randomly inserted between the duplicated stretches. FLT3-ITDs lead 
to ligand-independent autophosphorylation of the receptor, resulting in proliferation 
and inhibition of apoptosis. Point mutations of FLT3 in exon 20 (previously known as 
exon 17) occur in about 7% of AML. They predominantly involve the substitution of 
aspartic acid to tyrosine at codon 835.85,86 Other less frequent substitutions include 
Asp835Val, Asp835His, Asp835Glu, Asp835Ala, and Asp835Asn. Mutations in 
codons surrounding codon 835 (e.g. codons 836, 840, 841, and 842) are reported 
as well.87-90 Similar to ITDs, point mutations maintain the same open reading frame 
and result in a constitutively activated FLT3 protein. Some patients have both an 
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FLT3-ITD and a FLT3 point mutation, however, most patients have only one type of 
FLT3 mutation.87,91 FLT3-ITDs are significantly associated with hyperleucocytosis 
and a high bone marrow blast count. The vast majority of patients have a normal 
karyotype.82,92 However, an increased incidence (20-45%) of FLT3 aberrations in 
patients with APL, especially the M3 variant82,87,93 has been reported and FLT3-ITDs 
has been observed in 90% of patients with a DEK-CAN fusion gene.87 FLT3-ITD 
is shown to be an indicator for a bad prognosis both in adults and children.92,94-99 
Also Asp835 mutations may confer poor prognosis in AML, although their clinical 
significance needs to be confirmed.85,87 In APL patients, all studies to date failed 
to show an impact of FLT3 aberrations on relapse and disease free survival.93,100
Mutations of the N- and K-RAS genes occur in 15-30% of AML,102,103 with N-RAS 
mutations being the most common. The mutations usually involve single amino 
acid substitutions in codons 12, 13 or 61. Most RAS mutations occur as a single 
mutation in N-RAS or K-RAS, but two RAS mutations can coexist.102,104,105 Reports 
addressing the clinical significance of RAS mutations in AML are inconclusive: 
some studies demonstrate a beneficial effect,104,106 while others reached a different 
conclusion, e.g. lower complete remission in patients with RAS mutations.107 To date, 
the prognostic value of RAS mutations seems to be of minor relevance compared 
to age or karyotype. RAS and FLT3 mutations occur independently.101,107
Mutations of CEBPA, encoding the CCAAT/enhancer-binding protein-alpha, 
occur in ~6% of childhood AML and ~10% of adult AML.108,109 They are highly 
associated with M1, M2 or M4 morphology and almost exclusively reported in 
patients belonging to the intermediate cytogenetic risk-group. The presence of 
CEBPA mutations is identified as a good prognosis factor for outcome in adults,109,110 
while the prognostic relevance in pediatric AML requires further investigation.
The overall frequency of AML1 (also called RUNX1) point mutations in AML 
is ~8%.111 AML1 mutations are predominantly found in AML-M0 (16-27%);112,113 
especially biallelic mutations are tightly associated with AML-M0, while mono-
allelic AML1 mutations in AML-M0 are frequently observed in combination with 
FLT3 mutations.112 Most mutations (81%) are located in the DNA binding domain 
encoded by exons 3-5.114
Recently, NPM1 (nucleophosmin) mutations in exon 12, resulting in an aberrant 
cytoplasmic localization of the NPM1 protein, are found in 35% of adult and in 
6.5% of childhood patients with primary non-M3 AML.115,116 NPM1-mutated AMLs 
show frequently a (myelo-)monocytic morphology (M4/M5) and have a lack of the 
hematopoietic stem cell markers CD34 and CD133. The NPM1-mutations are 
strongly associated with a normal karyotype and show a high frequency of FLT3-
ITDs. Several studies showed that NPM1-mutations without FLT3-ITDs in AML 
with normal karyotype predict a favourable outcome.117-119 The stability of NPM1 
mutations between diagnosis and relapse is reported in a small patient group, 
suggesting that NPM1 mutations might be useful to monitor MRD.120 
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Abnormal expression of genes in AML
In AML, abnormal expression of genes that are not involved in chromosomal 
translocations, include overexpression of the WT1 gene (Wilms tumor) and 
overexpression of the PRAME gene (preferentially expressed antigen of melanoma). 
High levels of WT1 can be found in the majority of AML patients at diagnosis;121 the 
prognostic impact is however still uncertain. Overexpression of PRAME in AML is 
reported only in small series: high levels op PRAME are found in 35% of adult AML 
and 62% of childhood AML.122,123 It is associated mainly with AML subtypes carrying 
a relatively favorable prognosis: AML with t(8;21), and APL with t(15;17). 
Chromosome aberrations with fusion genes in CML
The hallmark of CML is the Philadelphia chromosome which results from a 
reciprocal translocation t(9;22)(q34;q11) with formation of a BCR-ABL fusion gene 
(Table 2) and hybrid protein.124,125 The latter has a constitutively active tyrosine 
kinase function which induces aberrant oncogenic signaling.126 Breakpoints in the 
ABL gene almost exclusively occur in a ~200 kb breakpoint region upstream of 
exon a2, while breakpoints in BCR are clustered in three well defined breakpoint-
cluster regions (Figure 5).127,128 The major breakpoint cluster region (M-bcr) is a 
~2.9 kb chromosomal region between exon 13 and 15. It is detected in >95% of 
CML and leads to the formation of two types of mRNA molecules (e13a2 or e14a2, 
formerly assigned as b2a2 and b3a2), both encoding a p210BCR-ABL fusion protein. 
Secondly, the rarely occurring (2-3% of cases) minor breakpoint cluster region 
(m-bcr), spanning a ~55 kb intronic sequence between the two alternative exons 1 
and 2, results in an e1a2 fusion gene transcript that encodes the p190BCR-ABL fusion 
protein. Thirdly, the micro-breakpoint cluster region (µ-bcr), a ~1 kb sequence located 
in intron 19 of the BCR gene, results in an e19a2 fusion gene transcript. This e19a2 
fusion transcript encodes a p230BCR-ABL fusion protein which is mainly found in the 
rare neutrophilic variant of CML.129,130 Table 3 shows the major molecular variants 
of BCR-ABL and its associated clinico-pathological features.131-133
Atypical BCR-ABL transcripts having junctions other than e13a2, e14a2, e1a2 
or e19a2, are found in 1-2% of CML patients. They can be assigned to 4 groups 
according to common features of the BCR and ABL breakpoints within the fusion 
gene: 1) fusion genes in which BCR breakpoints are located outside the three 
recognized breakpoint cluster regions,134,135 2) fusion genes in which the breakpoint 
occurs within exons,136 3) fusions in which ABL breakpoints are located downstream 
of exon a2 giving rise to a hybrid mRNA with an a3 junction,137 and 4) transcripts that 
contain ‘bizarre’ insertions or intervening sequences between BCR and ABL.138,139 
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1.3 IMMUNOGENOTYPIC CHARACTERISTICS OF MYELOID
  LEUKEMIA
Surface membrane-bound immunoglobuline (Ig) molecules and T-cell 
receptor (TCR) molecules represent the antigen-specific receptors of mature 
B and T lymphocytes, respectively. Although the number of different gene segments 
in the Ig and TCR encoding genes is relatively limited (~ 470), an enormous diversity 
Table 3.  Major molecular variants of BCR-ABL and associated clinico-pathological features.
BCR 
breakpoint 
region
Fusion
transcript a
BCR-ABL 
fusion 
protein
Disease association
M-bcr e13a2 (b2a2)
and/or
e14a2 (b3a2)
p210BCR-ABL >95% of typical CMLb
10-20% of Ph+ childhood precursor-B-ALL
25-45% of Ph+ adult precursor-B-ALL
<1% of T-ALL 
<1% of AML
27% of normal individuals c
m-bcr e1a2 p190BCR-ABL  d 2-3% atypical CML, often with monocytosis or        
         dysplastic features 
>90% of CML with a classical M-bcr breakpoint e 
80-90% of Ph+ childhood precursor-B-ALL
70-75% of Ph+ adult precursor-B-ALL
<1% of AML (associated with M4 or M5) 
majority (69%) of normal individuals c
µ-bcr e19a2 p230BCR-ABL neutrophilic variant of CML 
CML with marked thrombocytosis
<1% of AML 
a   All fusion transcripts also can exist as splice variants involving exon a3 (see Figure 5).
b  Approximately 20% of CML patients have both e13a2 and e14a2 transcripts due to alternative   
 splicing.131
c   Only detected with PCR-assays reaching sensitivities of 10-8 to 10-9.140,141
d   Also referred to as p185BCR-ABL.
e  e1a2 transcripts in patients with M-bcr breaks are most likely the result of alternative splicing of
  e13a2 or e14a2 transcripts.142,143
Abbreviations: BCR, breakpoint cluster region; Ph, Philadelphia chromosome; CML, chronic myeloid 
leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia. 
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ABL (9q34)
1b 1a
a2 a3
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M-
~2.9 kb
bcr m-bcr
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~200 kb
cen
cen
tel
tel
m-
~55 kb
bcr
e1a2
type
frequency
in CML
2-3 %
1767 228 401 697
1
1
2 3
3
4
4e1a3 rare
m- : p190bcr BCR-ABL
100 bp
e14a2
30913015 3195 3270 228 401 697
13
13
13
13
1211
1211
1211
1211
14
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2
2
3 4
3 4
3 4
3 4
e13a2
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e14a3 rare
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100 bp
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frequency
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e19a2
3562 3671 3810 228 401 697
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type
A
B
e19a3 1817 19 3 4
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?
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of the antigen-specific receptors is possible owing to the fact that combinations of 
gene segments are made, which are different in each lymphocyte and lymphocyte 
clone. Clonal Ig and TCR gene rearrangements are found in virtually all ALL 
patients, and they can also be seen in a subset of AML patients. 
Ig and TCR gene rearrangements
During early B- and T-cell differentiation, germline V (variable), D (diversity), and 
J (joining) gene segments of the Ig and TCR genes rearrange and each lymphocyte 
thereby obtains a particular combination of V-(D-)J segments. In IGH, TCRB, and 
TCRD rearrangments one of the J gene segments is joined to one of the D gene 
segments, and subsequently a V to D-J joining occurs. In IGK, IGL, TCRA, and 
TCRG rearrangements, one of the J gene segments is directly joined to one of 
the V gene segments, resulting in a V-J joining. At the coupling sites of the gene 
segments, deletions and random insertions of nucleotides occur. An example of an 
IGH gene rearrangement is illustrated in Figure 6.
This lymphoid-specific process is mediated via the V(D)J recombinase complex, 
including the recombination activating gene products (RAG1 and RAG2),144,145 which 
recognize specific recombination signals sequences (RSS). The RSS consists of a 
palindromic heptamer and nonamer sequence, separated by spacer regions of 12 
or 23 base pairs. The RSS borders the 3’ side of V gene segments, both sides of D 
gene segments and the 5’ side of J gene segments.146 TdT plays an important role 
during this Ig and TCR gene rearrangements by random insertion of nucleotides at 
the junction side of the V-(D-)J gene segments.147 
Although Ig and TCR molecules are only expressed by B and T lymphocytes, 
respectively, rearrangements of IG and TCR genes are not lineage restricted.148 
In precursor-B-ALL high frequencies of TCR gene rearrangements are found and 
cross-lineage IG gene rearrangements occur at low frequency in T-ALL.149,150 
Also AML show cross-lineage Ig and TCR gene rearrangements in approximately 
10% of cases (Table 2). IGH and IGK gene rearrangements are found in 10% 
and 3% of cases, respectively.151,152 The IGH gene rearrangements mainly concern 
incomplete DH-JH joinings (>90%) with frequent usage of the more downstream DH 
gene segments (>90%) and the JH4 and JH6 gene segments.152 So far only one AML 
case has been reported having a rearranged Ig lambda locus.153 TCRD, TCRB, and 
TCRG gene rearrangements are found in 9%, 7%, and 5% of AML patients,151,152,154 
Figure 5.
A) Schematic diagram of the exon/intron structure of the BCR and ABL genes, involved in 
t(9;22)(q34;q11). The centromere (cen) and telomere (tel) orientation, exon numbering, and relevant 
breakpoint regions are indicated. The old nomenclature of the BCR and ABL exons is indicated. 
B) Schematic diagram of the three BCR-ABL transcripts (p190, p210 and p230) found in CML. The 
numbers under the fusion gene transcript refer to the first (5’) nucleotide of the involved gene, except 
when the last (3’) nucleotide of the upstream gene is indicated. The e19a3 junction is included as a 
theoretical possibility, however, no cases have been reported yet. 
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Figure 6.
A. Schematic diagram of human IGH gene rearrangement. In this example DH3 is first joined to JH4, 
followed by VH3 to DH3-JH4, thereby deleting all intervening sequences. This rearranged gene complex 
can be transcribed into precursor mRNA, which will be transformed into mature mRNA by splicing out all 
non-coding intervening sequences. Finally, the transcript will be translated into an IgH chain. 
B. Schematic diagram of the junctional regions of the joined VH3, DH3, and JH4 gene segments. The at 
random insertion and deletion of nucleotides at the junction sites of V, D, and J gene segments make 
the junctional regions into ‘fingerprint-like’ sequences, which are probably different in each lymphocyte. 
Germline and inserted nucleotides are indicated by capital letters and small letters, respectively. 
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respectively. This frequencies are in concordance with the physiological hierarchy 
of TCR gene rearrangements during T cell differentiation. Studies on AML-M0 cases 
show higher incidences (22%) of IGH/TCR gene rearrangements.113 However, 
no prognostic significance can be linked to the presence of clonal Ig/TCR gene 
rearrangements in AML.155-157 The occurrence of Ig/TCR gene rearrangements 
in AML and its immunophenotypic characteristics has been investigated. Some 
studies reported significant associations between positivity for B cell-associated 
markers and the presence of Ig/TCR gene rearrangements,152 others correlated 
the expression of T cell markers or TdT with the occurrence Ig/TCR gene 
rearrangements.153,154,158,159 
Small series report on the occurrence of Ig/TCR gene rearrangements in 
CML and show close similarities between the genotypic features of B-lymphoid 
BC CML and precursor-B-ALL.160,161 Also in myeloid lineage BC CML, Ig/TCR gene 
rearrangements are reported.162 Finally, in CP CML IGH gene rearrangements can 
be detected from seven months prior to the development of lymphoid BC.163,164 
2. MODERN THERAPY OF MYELOID LEUKEMIA
2.1 STANDARD TREATMENT MODALITIES IN MYELOID 
 LEUKEMIA 
Acute myeloid leukemia
The initial treatment of newly diagnosed AML consists of a remission induction 
regimen to achieve two goals: firstly, the reduction of the malignant BM blast 
percentage to ≤ 5%, and/or the elimination of overt extramedullary disease, and 
secondly, the restoration of normal hematopoiesis. Having achieved this, the 
therapeutic goal is to prevent relapse. Strategies to improve leukemia-free and 
overall survival, include consolidation therapy, maintenance therapy or stem cell 
transplantation (SCT). 
Anthracyclines and cytarabine are cornerstones of modern AML therapy. 
Pediatric AML induction is based on the standard “7+3” induction regimen 
(i.e. 7 days cytarabine and 3 days anthracyclines), and the adding of a third agent 
such as 6-thioguanine or etoposide.165-167 These schemes induce a remission in 
approximately 85% of pediatric patients. In adult AML, modern remission induction 
schedules are also based on anthracyclines given at 3 days and cytarabine given 
over 7 to 10 days, possible combined with a third drug.168 These schedules induce 
complete remission in about 75-80% of younger patients (<60 years) and 50-55% 
of older patients.169 
Post-remission therapies are based on high-dose cytarabine with or without 
autologous or allogeneic SCT.170,171 Several pediatric cooperative groups addressing 
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the role of autologous SCT in post-remission therapy, failed to show a benefit of 
autologous SCT over chemotherapy alone.172 The optimal number of cycles of 
intensification chemotherapy in children is not known166,171,173,174 nor is the role of 
ALL-like maintenance therapy.175 In adults, post-remission chemotherapy is 
nowadays limited in duration (2 or 3 consolidation courses), but made more 
intensive.176,177
In contrast to children and younger adults, the outcome results of elderly 
patients with AML has not improved substantially during the last decades. Older 
adults with AML have a dismal long-term outcome with a 5-year survival of less than 
5 to 8%.178,179 Treatment in the elderly AML patients is more difficult by their limited 
ability to tolerate intensive chemotherapy. No standard therapy is available for 
patients aged ≥ 80 years of age. For patients aged 61-79 years, induction therapy 
might be similar to the standard therapy in younger AML patients, however, for 
post-remission therapy so far no standard strategy exists. 
Eight to 10% of younger AML patients have resistant disease and 10% will die 
due to treatment toxicities.180 The overall relapse risk for younger AML patients 
achieving complete remission is 45-50%, but primarily depends on important risk 
factors such as cytogenetics, age and response of the BM to the first course of 
chemotherapy.181,182 
In patients with refractory or relapsed disease, reinduction regimens typically 
use high-dose cytarabine, as well as mitoxantrone, etoposide, or fludarabine.183,184 
For consolidation, patients preferably undergo allogeneic SCT with either a related 
or unrelated donor.185 Despite the risks associated with allogeneic SCT, between 
20-50% of patients can be salvaged.186,187 The salvage rates are significantly 
affected by the duration of the first complete remission (CR1), with shorter CR1 
(<6 months or while on therapy) being associated with lower salvages rates.188 
It is well accepted to consider APL as a separate entity, requiring a specific 
therapeutic approach involving all-trans-retinoic acid (ATRA). This is discussed in 
paragraph 2.2. 
The trend of dose intensification has largely explored the therapeutic potential 
of conventional drugs with toxicities precluding further dose escalation. Therefore, 
the focus is shifting now to the development of less toxic alternative strategies 
selectively targeting the leukemic cells. 
Chronic myeloid leukemia
The treatment goal in CML is the elimination of the Philadelphia (Ph) positive 
clone and the restoration of Ph-negative hematopoiesis. Treatment decisions 
in CML patients primarily are based on the patient’s age and the phase of the 
disease.
The conventional chemotherapeutic agents busulfan and hydroxyurea (HU) 
control the elevated white blood count and the disease-related symptoms in 
a majority of CML, without a demonstrable effect on the natural history of the 
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disease: they fail to induce a cytogenetic remission, nor do they delay the onset 
of the acceleration phase (AP) or blast crisis (BC). Consequently, their effects are 
primarily palliative.189
In contrast, interferon (IFN) in monotherapy or in combination with subcutaneous 
Ara-C, can induce complete hematologic (22-87%) and major cytogenetic responses 
(10-46%) in patients with chronic phase (CP) CML.190 In patients with advanced 
disease, IFN demonstrated less activity.191 However, IFN is not curative and 
10-25% of patients discontinue their therapy because of intolerance.192,193
To date allogeneic SCT is the only treatment modality with an established 
curative potential.194-196 The most significant determinants of transplantation 
outcome are the patient’s age, the phase and duration of the disease. Disease-
free survival (DFS) with matched-related allogeneic SCT are 40-80% in CP phase, 
15-40% in AC phase, and 5-20% in BC. In CP CML, patients <30-40 years have 
a DFS of 60-80%, while in patients >45 years of age a 5-year DFS of 25% is 
reported.197 Unfortunately, allogeneic SCT is only an option for 25-40% of patients 
and it carries substantial risks of treatment related morbidity and mortality. The 
probability of SCT-related death ranges from 20-40%,198 with a higher mortality risk 
for transplants from unrelated or non-HLA-matched donors. However, in younger 
patients outcomes may be similar in molecularly matched unrelated SCT compared 
to related SCT.199,200 Nonablative preparative regimens (mini-transplants or reduced 
intensity transplants) have attempted to expand the indications of allogeneic SCT 
to older patients and to reduce transplant related mortality and complications. Early 
results demonstrate a reduced morbidity and mortality,201 but a higher incidence 
of persistent or recurrent disease, which could be approached with post-SCT 
regimens such as donor lymphocyte infusions.202,203 For patients without a donor, 
until recently IFN/Ara-C was considered the gold standard treatment, although 
elderly CML patients often were excluded or treated with IFN at reduced dosages 
due to the higher drug toxicity. 
2.2 TARGETED TREATMENT MODALITIES 
A problem with standard chemotherapeutical agents is their toxicity towards 
normal cells. Therefore, therapeutic strategies that deliver the cytotoxic agent 
preferentially to the tumor are developed. These targeted therapies include 
monoclonal antibodies, e.g. gemtuzumab ozogamicin, and agents targeting the 
molecular basis of the disease, e.g. all-trans-retinoic acid and tyrosine kinase 
inhibitors which will further be discussed. In addition, other agents such as 
farnesyltransferase and histone deacetylase inhibitors, proteasome inhibitors and 
antiangiogenesis agents have recently been tested. 
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All-trans-retinoic acid (ATRA)
APL cells harbor the t(15;17), resulting in the PML-RARA fusion gene transcript 
and protein, which is leukemogenic. APL cells are sensitive to all-trans-retinoic acid 
(ATRA) which binds to PML-RARA and inhibits its anti-differentiation transcriptional 
activity.204, 205 
ATRA used as a single agent induces remission in the majority of patients 
with APL, however, disease recurrence uniformly occurs within 3 to 4 months 
without additional therapy.204 Multiple trials have demonstrated a benefit for 
ATRA in combination with chemotherapy206,207 with recent evidence suggesting 
that anthracyclines play a more important role than cytosine arabinoside.208,209 
ATRA may also have a role in maintenance therapy after successful consolidation, 
although studies are ongoing to evaluate if this prolongs event free survival, 
especially in patients with a high initial leukocyt count (≥ 10.000/µL).206,210
Patients who relapse after ATRA plus chemotherapy can be induced into a 
second remission with ATRA or arsenic trioxide (ATO). The likelihood of a second 
response is considerable, particularly if several months have passed since the last 
administration of this agent. After remission re-induction, intensive chemotherapy for 
consolidation is needed to produce durable molecular remissions. Administration of 
ATO in relapsed APL results in a remission induction rate of ~85% and a molecular 
remission of approximately 70%, particularly after two cycles of treatment.211-213 APL 
patients in ≥ second molecular remission are usually further consolidated using 
SCT.214
The introduction of ATRA, has changed the clinical course of APL from an often 
fatal disease to one of the most curable subtypes of AML.206,215,216 However, clinical 
ATRA-resistance in APL (reviewed by Gallagher217) may hamper the response 
rates. Primary resistance of APL to ATRA as a single agent or in combination 
with chemotherapy, is rare both in de novo APL and in APL at first relapse from 
previous chemotherapy or in cases initially refractory to chemotherapy. By contrast, 
secondary acquired ATRA resistance is very common especially in patients treated 
continuously with oral ATRA as a single agent. Acquired ATRA resistance has been 
linked to both systemic (e.g. increased catabolism) and APL cellular (e.g. decreased 
nuclear transport) elements. ATRA resistance is found in 10-30% of patients who 
relapse from a CR achieved and consolidated with ATRA-containing regimens.217 
Fortunately, ATRA resistant disease appears highly sensitive to ATO. Consequently, 
ATRA and ATO have drastically changed the clinical outcome in APL.
Gemtuzumab ozogamicin (GO)
Gemtuzumab ozogamicin (Mylotarg®, formerly know as CMA-676), is an 
immunoconjugate in which a humanized IgG4 CD33 monoclonal antibody is 
chemically linked to N-acetyl gamma calicheamicin through an acid-labile linker. 
Calicheamicin is a highly potent antitumor antibiotic (belonging to the class of 
anthracyclines) that cleaves double-stranded DNA.218 The molecular target of GO is 
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the surface CD33 antigen, which is expressed on early multilineage hematopoietic 
progenitors and myelo-monocytic precursors, but not on normal hematopoietic 
stem cells and nonhematopoietic tissues.219,220 Eighty-five to 90% of AML are 
CD33+ as defined by the presence of CD33 on more than 20-25% of the leukemic 
cells. GO binds CD33 with high affinity and the antibody-antigen complex is rapidly 
internalized, finally leading to cell death. Figure 7 is a schematic representation of 
the mechanism of action of GO. 
In elderly CD33+ AML patients in first relapse and who were not considered 
candidates for other cytotoxic chemotherapy, GO resulted in an overall second 
remission of 30%, when administered as a single agent at a dose of 9 mg/m2 as 
two infusions 14 days apart.221,222 Based on these results, GO received an US FDA 
approval for treatment of relapsed AML patients over 60 years of age. 
Several groups have evaluated the potential of GO in different situations of AML. 
Reports from small patient series suggest activity of GO as a single agent223,224 or 
in combination regimens225,226 as front line therapy in the elderly. There is some 
clinical experience in children with relapsed or refractory AML treated with GO 
on compassionate use;227,228 results demonstrated that GO has clinical activity in 
these children showing 40-55% responders with a blast reduction in the BM to 
≤ 5%. However, complete remission required additional intensive therapy, such as 
allogeneic SCT. Recent studies suggested that GO as a single agent is effective 
for patients with molecularly relapsed APL,229,230 while GO combined with all-trans-
retinoic acid appears active in untreated APL.231 A feasibility study in younger 
AML patients showed that the simultaneous administration of GO with intensive 
chemotherapy as first line treatment induced a remission in 91% of patients.232 
Potential mechanisms of GO resistance and treatment failure include the 
escape by CD33-negative leukemic cells, drug efflux via permeability glycoprotein 
or multidrug resistance protein 1,233,234 anti-apoptotic effects of Bcl-2 or Bcl-XL, and 
high circulating CD33 antigen burden leading to compromised drug delivery to 
BM.235
Imatinib mesylate (IM)
The discovery of the BCR-ABL-mediated pathogenesis of CML provided the 
rationale for the design of inhibitory agents that target BCR-ABL kinase activity. In 
1998, imatinib mesylate (Gleevec®, Glivec®, formerly STI571), a selective inhibitor 
of ABL and its derivative BCR-ABL tyrosine kinase, was introduced to the clinic for 
the treatment of CML.236 Imatinib (IM) binds the kinase domain of BCR-ABL thereby 
inhibiting its activity and selectively eradicating the leukemic cells with a low toxicity 
profile. Figure 8 is a schematic representation of the mechanism of action of IM. 
IM is effective as a single agent for the treatment of patients in all stages of 
CML, whether newly diagnosed or previously treated. However, most encouraging 
results are seen in CP CML.237-241 The International Randomized Study of 
Interferon and STI571 (IRIS) showed superior outcomes for newly diagnosed 
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CP CML; complete hematologic and major cytogenetic response rates of 95% and 
85% respectively at 18 months, and major molecular response rates of ≥3 log at 
12 months in 39%.240,241 An update at 30 months showed that for patients who 
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C
D
E
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Figure 7. Mechanism of action of gemtuzumab ozogamicin (Mylotarg®).
(A) Gemtuzumab is a humanized CD33 murine monoclonal antibody linked to the antitumor antibiotic 
calicheamicin. After binding of gemtuzumab to surface CD33-antigens on normal and leukemic cells (B), 
the CD33-antigen/gemtuzumab complexes are rapidly internalized (C). Upon internalization of these 
complexes, newly produced CD33-antigens are rapidly expressed on the cell surface and subsequently 
can bind gemtuzumab (D). The rate of renewed CD33-antigen expression appears to be related to the 
degree of CD33 saturation and internalization, and to the activation status of the cell. The internalization 
is followed by hydrolysis of the acid-labile linker in the intracellular endosomes and lysosomes, the 
degradation of the antibody part of gemtuzumab, and finally by the activation of the calicheamicin γ1 
derivate (D). The active calicheamicin enters and accumulates in the nucleus, binds to the minor groove 
of DNA and causes double-stranded DNA breaks (E). This results in the induction of cell death and 
apoptosis (F).
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achieve a complete cytogenetic remission (CCyR) and a reduction in BCR-ABL 
transcript levels of ≥3 log at 12 months, the probability of remaining progression 
free was 100% compared to 93% for patients with < 3 log reduction in BCR-ABL 
transcript levels and 82% for patients who were not in CCyR at 12 months.242 Data 
on long-term disease-free survival and overall survival are awaited as follow-up 
continues. Small studies also have shown a significant activity of IM against CML 
in relapse after allogeneic or autologous SCT.243,244 Because IM monotherapy has 
shown to be significantly more effective and better tolerated than IFN/Ara-C, it has 
been approved as first-line treatment for patients with a new diagnosis of CML. The 
recommended starting dosages are 400 mg for CP CML and 600 mg for AP/BC 
CML.245,246 
Although IM is unquestionably effective in the treatment of CML, some patients 
may ultimately relapse with resistant disease. A minority of patients in CP and a 
substantial proportion in advanced disease phases are either initially refractory to 
IM treatment or lose IM sensitivity over time and experience relapse.247,248 Clinical 
resistance is primarily mediated by reactivation of BCR-ABL kinase activity within 
the leukemic cells by either point mutations within the kinase domain of BCR-ABL 
Figure 8. Mechanism of action of imatinib mesylate (Gleevec®). 
Imatinib mesylate (IM) competes with adenosine triphosphate (ATP) for occupancy of its specific binding 
pocket within the kinase domain of the BCR-ABL protein. When the binding pocket is occupied by 
ATP, BCR-ABL can catalyse the phosphorylation of tyrosine residues on substrate proteins (left). IM is 
structural similar to ATP and can bind to the ATP-binding pocket within the BCR-ABL (right). Because 
IM lacks the essential phosphate groups that are normally provided by ATP, phosporylation of tyrosine 
residues on substrate proteins cannot take place. Substrate proteins with unphosphorylated tyrosine 
residues fail to adopt the necessary conformation for binding to effector molecules. Consequently, 
downstream activation of signal transduction pathways crucial for CML leukemogenesis are inhibited. 
P
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or, to a lesser extend, by amplification of the BCR-ABL genomic locus.249-251 Point 
mutations within the tyrosine kinase binding site can prevent IM from binding by 
interrupting critical contact points between IM and the protein, or by precluding 
access of IM to its binding site. Usually a single point mutation is detected, but 
occasional patients carry more than one BCR-ABL point mutation.252,253 The 
incidence of BCR-ABL mutations increases with CML disease progression.254,255 
To date, approximately 30 different point mutations that encode for distinct single 
amino-acid substitutions in the BCR-ABL kinase domain have been identified 
in the CML cells from relapsed patients resistant to IM.253 In vitro studies have 
demonstrated that some mutants (e.g. T315I) have 1 to 2 log higher 50% inhibitory 
concentration (IC50) values for IM compared to wild-type BCR-ABL, whereas others 
have slightly higher IC50 values.256,257 Another major IM resistance mutation which 
also enhances the activity of BCR-ABL kinase is E255K.258
Clinical management to avoid or overcome IM resistance might include dose 
escalation (depending on the type of the mutation), cessation or temporary 
interruption of IM therapy, and upfront or second-line combination therapy. 
Recently, second-generation molecular targeted therapies, including AMN107 and 
BMS354825, have been designed and tested in phase I trials for patients with IM 
resistant CML.259-263 Both agents showed an increased potency with sensitivities 
against all BCR-ABL point mutations except for T315I mutation. Currently phase 
II studies are being started. Recently, a new non-ATP-competitive inhibitor of 
BCR-ABL showed in vitro activity against all IM resistant mutants, including T315I 
mutations.264,265 Both the introduction of IM and the development of second-
generation molecular targeted therapies represent a big step forward in the clinical 
management of CML patients. 
3. MINIMAL RESIDUAL DISEASE DIAGNOSTICS FOR
  EVALUATION OF TREATMENT
Modern treatment protocols for AML induce a complete remission,175,266,267 
cytomorphologically defined as the presence of less than 5% blast cells in the bone 
marrow (BM), in a high proportion of leukemia patients (50-80%, depending on the 
age). However, many patients ultimately relapse, implying that current treatment 
protocols are not capable of killing all clonogenic malignant cells in these patients. 
To trace low frequencies of malignant cells, so called minimal residual disease 
(MRD), more sensitive techniques are required (Figure 9). MRD techniques should 
reach sensitivities of at least 10-3 (one leukemic cells in 1000 normal cells), but 
sensitivities of 10-4 to 10-6 are preferred. 
Several large scale studies have shown that monitoring of MRD in malignant 
disease predicts clinical outcome. In both childhood and adult ALL, detection of 
MRD can be used to evaluate early treatment response and to improve stratification.268-271
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 In APL and CML, MRD information obtained at specific time points enables 
effective early treatment intervention.272-274 Also in AML, different risk groups can be 
identified based on the MRD levels at specific therapeutic time points.275-277 MRD 
information leads not only to the identification of patients at high risk of relapse, but 
may also be a first step towards reduction of treatment intensity in patients who 
might currently be over-treated.
3.1 TECHNIQUES FOR MRD DETECTION
During the past decades, several methods for MRD detection have been 
developed and evaluated, including conventional cytogenetics, fluorescent in situ 
hybridization, Southern blot analysis, immunophenotyping, and polymerase chain 
reaction (PCR). Most of these techniques are not suitable for clinical MRD detection 
due to limited sensitivity, limited specificity, or limited applicability. 
At this moment, three quantitative techniques reaching sensitivities of 10-3 to 
10-6 are widely used for detection of MRD in leukemia patients; (1) multiparameter 
flow cytometric immunophenotyping, based on the occurrence of leukemia-
associated aberrant, unusual, or ectopic phenotypes, (2) PCR analysis of junctional 
Figure 9.
Diagram of the relative frequencies of leukemic cells in peripheral blood or bone marrow of patients with 
acute myeloid leukemia, during and after therapy, and during development of relapse. The detection limit 
of cytomorphology, flow cytometric immunophenotyping and PCR techniques are indicated. I: induction, 
C: consolidation, Tx: transplantation.
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regions of rearranged Ig and/or TCR genes, and (3) PCR analysis of fusion gene 
transcripts associated with chromosome aberrations. In addition, PCR analysis of 
FLT3 mutations and aberrantly expressed genes (e.g. WT1) have recently been 
evaluated as PCR MRD-markers in AML. The choice of the technique primarily 
depends on the applicability of the technique and the required sensitivity (Table 4). 
Table 5 summarizes the advantages and disadvantages of the different MRD 
techniques. 
MRD detection by flow cytometric immunophenotyping
Acute leukemias can be regarded as malignant counterparts of cells in immature 
stages of hematopoiesis. Consequently, the presence of normal hematopoietic cells 
may limit the immunophenotypic detection of leukemic cells. Despite this inherent 
limitation, immunophenotypic MRD detection is still possible because leukemia 
associated phenotypes (LAIP’s) can be identified in the vast majority of AML patients 
(>80%).20,21,28 
It should be noted that the immunophenotype of the leukemic cells may be 
heterogeneous and that several subpopulations can be present at diagnosis.29,278 As 
relapses can occur by a less represented subpopulation, all leukemic subpopulations 
should be monitored for reliable MRD analysis.279
A possible pitfall of immunophenotypic MRD detection in acute leukemia is the 
occurrence of immunophenotypic shifts during the course of the disease, which 
Table 4. Sensitivity and applicability of MRD-targets in myeloid malignancies.
PCR analysis Immunophenotyping
Ig/TCR gene 
rearrangements
Fusion 
genes
FLT3-
ITD
WT1 LAIP
Sensitivity 10-4-10-5 10-4-10-6 10-4-10-5 10-3-10-4 10-3-10-4
Applicability
AML children 5-10% 20-40% 5-25% 85-100% 75-85%
AML adults 5-10% 10-20%a 20-25% 85-100% 75-85%
APL ND >95% 20-45% ND >95%c
CML ND >95% <2% ND b 75-85% (myeloid BC) 
60-98% (B-lymphoid BC)
90-95% (T-lymphoid BC)
a Mainly concerns adults <60 years of age. Lower frequencies are reported in elderly AML patients 
  (>60 years of age).50
b WT1 expression in blast crisis (BC) is higher than in chronic phase.
c APL with a PML-RARA gene rearrangement have a specific phenotypic pattern.34
ND: no data yet available or only analyzed in a limited number of patients.
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Table 5. Advantages and disadvantages of MRD techniques.
MRD technique Advantages Disadvantages
Flow cytometric 
immunophenotyping
− single cell analysis − immunophenotypic shift
− cell viability can be determined − presence of subpopulations in AML
− information on normal cells − background of normal cells
− relatively easy and cheap − limited sensitivity (10-3 – 10-4)
− rapid (1-2 days)
− relatively patient-specific
− applicable for most patients
PCR analysis
 fusion genes  
     (mRNA level)
− stable target (related to oncogenesis) − instability of RNA
− relatively easy − not patient but tumor specific
− rapid (1-3 days) − risk of contamination
− no (or very low <10-6) background in 
   normal cells
− variable expression levels (may be
   affected by therapy)
− suitable for monitoring uniform 
   patient groups
− useful in only a subset of AML 
   patients (5-30%)
− sensitive (10-4 – 10-6)
 fusion genes   
    (DNA level)
− patient specific − labor intensive identification of exact
   breakpoints, except for some 
   translocations with small breakpoint 
   regions, eg. µ-bcr rearrangements 
   (e19a2 junction) 
− low risk of contamination
− high stability of DNA
− stable target (related to oncogenesis)
− no (or very low <10-6) background in 
   normal cells
− useful in only a subset of AML 
   patients (5-30%)
− suitable for monitoring uniform 
   patient groups
− sensitive (10-4 – 10-6)
 Ig/TCR gene
     rearrangements
     (DNA level)
− patient specific − background of normal cells
− low risk of contamination − high complexity 
− DNA amount per cell is relatively 
   constant
− labor intensive and time consuming at 
   diagnosis
− rapid during follow-up − relatively expensive
− high stability of DNA − loss of target due to clonal evolution 
   (ongoing/secondary rearrangements
   and oligoclonality) − sensitive (10-4 – 10-5)
− useful in only a minority of AML 
   patients (<10%)
 mutated genes: 
     FLT3-ITD 
     (DNA level)
− related to oncogenesis − target may not be stable
− patient specific − useful in subset of patients only 
   (10-25%)− can be identified with limited set of 
   primers
− high stability of DNA
− DNA amount per cell is relatively 
   constant
− no background in normal cells
 mutated genes: 
     FLT3-ITD 
     (mRNA level)
− related to oncogenesis − instability of RNA
− patient specific − target may not be stable
− no background in normal cells − useful in subset of patients only 
   (10-25%)
 aberrant 
     expressed 
     genes: WT1 
     (mRNA level)
− easily identified − instability of RNA
− applicable for most patients − not tumor specific
− background expression in normal  
   cells
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may concern up to 90% of childhood and adult AML.279-283 These shifts include a 
gain or loss of myeloid antigens (CD13 and CD33), changes in expression of 
cross-lineage markers (CD2, CD7, CD19, and CD56) or changes in the progenitor-
associated antigens (CD34 and CD117). However, at least one leukemia-specific 
marker combination is retained by the leukemic cells at relapse in virtually all AML 
patients.280 This implies that preferably at least two marker combinations per patient 
should be used for immunophenotypic MRD monitoring. Some studies reported that 
AML tends to relapse with a less differentiated phenotype than observed at diagnosis; 
they suggested that antibody panels used for MRD monitoring should not only be 
restricted to the immunophenotypes detected at diagnosis, but also should include 
markers of lineage immaturity.279,284
MRD detection by PCR analysis of fusion genes associated with chromosome 
aberrations 
Almost all CML and 20-30% of AML patients have characteristic tumor-specific 
chromosome aberrations with the formation of fusion genes. These fusion genes 
are generally monitored at the RNA level, while monitoring at the DNA level is only 
sporadically done.
At the RNA level, the fusion genes are transcribed into fusion gene transcripts, 
which are similar in individual patients despite distinct breakpoints at the DNA 
level. After reverse transcription into cDNA, the fusion gene transcripts are used 
as targets for quantitative MRD-PCR analysis. Primer and probe sets for real-time 
quantitative PCR (RQ-PCR) based detection of the most common fusion gene 
transcripts as well as control gene transcripts, have been designed.285,286 Generally, 
sensitivities of at least 10-4 can be obtained using these RQ-PCR approaches. 
Low levels of fusion gene transcripts can be present in healthy individuals; for 
instance, BCR-ABL e13a2/e14a2 and BCR-ABL e1a2 transcripts are found in 
27% and 69% of normal individuals, respectively.140,141 Although the prevalence of 
BCR-ABL carrying leukocytes in the blood of healthy individuals is extremely low, 
probably less than 1 to 10 per 108 leukocytes, the presence of these fusion gene 
transcripts may hamper MRD detection, if the sensitivity of the RQ-PCR assay is 
extremely high. 
Because of the high sensitivity of PCR techniques, cross-contamination of RT-
PCR products between patient samples can be a pitfall in RT-PCR-mediated MRD 
studies employing fusion gene transcripts. Such cross-contamination is difficult 
to recognize, since fusion-gene RT-PCR products are leukemia-specific but not 
patient-specific. Furthermore, RNA is rather instable and differential stability of 
fusion gene transcripts and control gene transcripts may result in unreliable MRD 
data.287-289 An additional (theoretical) disadvantage of applying RNA targets is that 
the fusion gene transcription process might be affected by the cytotoxic treatment, 
potentially resulting in transcript levels that differ per treatment phase.
MRD-PCR analysis of chromosome aberrations with fusion genes can also 
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been performed at the DNA level. Advantages of this approach include the patient 
specificity of breakpoint fusions at the DNA level, the low degradation rate of DNA, 
the easy quantification (as only one target per cell is present), and the stability 
throughout the disease course. However, the fusion genes frequently found in AML 
and CML have DNA breakpoints which are often scattered over large regions up to 
200 kb and which are different in each patient. This implies that the identification of 
these breakpoint fusion sites is labor intensive, requiring special techniques (e.g. 
long-distance PCR, long-distance inverse PCR or ligation-mediated PCR). For small 
breakpoint regions (e.g. the µ-bcr), DNA targets can relatively easy be identified 
and potentially be used as patient-specific targets for monitoring of MRD.290 
MRD detection by PCR analysis of Ig and TCR gene rearrangements 
The junctional regions of rearranged Ig and TCR genes can be considered as 
“fingerprint-like” sequences, which are most probably different in each lymphocyte and 
thus also in each lymphoid malignancy.291 Therefore, junctional regions can be used 
as leukemia-specific targets for MRD-PCR analysis. After confirming the clonality 
of the rearrangement and sequencing, junctional region-specific oligonucleotides 
can be designed and subsequently be tested for sensitivity and specificity using 
RQ-PCR analysis.292 For this purpose, germline primers and probes have been 
designed during the last years for IGH, IGK-Kde, TCRG, TCRD, TCRB, and Vδ2-
Jα rearrangements. These primer-probe sets in combination with junctional region-
specific primers can generally reach sensitivities of 10-4.292 However, the sensitivity 
is dependent on the involved gene segments, size and sequence of the junctional 
region, and the background of comparable rearrangements in normal cells.292 
Ig/TCR gene rearrangements might be prone to subclone formation, as shown 
in precursor-B-ALL. The problem of oligoclonality at diagnosis is the uncertainty 
which clone is going to emerge at relapse and should be monitored with MRD-PCR 
techniques. Moreover, secondary and ongoing Ig/TCR gene rearrangements might 
occur in the time period between diagnosis and relapse, resulting in the loss of 
leukemia-specific MRD targets. The design of primers around the relatively stable 
D-J region may prevent false-negative PCR results. In precursor-B-ALL, monoclonal 
MRD-PCR targets are characterized by a high stability (85-90% of all targets retained 
at relapse), whereas oligoclonal MRD-PCR targets are frequently lost (only 40% 
preserved at relapse).293 So far, no data are available on the possible clonal evolution 
of Ig/TCR gene rearrangements in AML during therapy or at the time of relapse. 
MRD detection by PCR analysis of other genetic aberrations 
MRD detection via leukemia-specific fusion genes is only available in a minority 
of patients. However, the use of other genetic aberrations (e.g. FLT3-ITD or the 
overexpression of WT1) as molecular markers for MRD monitoring may potentially 
cover a large fraction of patients. 
The detection of FLT3-ITD can be done both at the DNA and the RNA level. 
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Advantages of using FLT3-ITD as MRD-PCR targets are its patient specificity and 
the (theoretical) absence of background amplification in normal cells (in practice, 
some amplification in normal cells may be seen due to the limited specificity of the 
assay). Several studies reported on the instability of this marker during the course 
of the disease; in ~12% of patients gains or losses of FLT3-ITD at relapse are 
reported.294-299 Consequently, FLT3-ITD should be regarded with caution with respect 
to its usefulness as MRD-PCR target. 
WT1 may represent a molecular marker for MRD monitoring in the majority of 
patients, including the fusion gene transcript-negative AML patients. Aberrant WT1 
expression levels can easily be identified.300-302 However, WT1 expression is not 
patient-specific and expression of WT1 in normal cells, which is dependent on the 
sample type (BM versus PB), may hamper a sensitive detection.303-305
3.2.  CLINICAL RELEVANCE OF MRD DETECTION
For several categories of hematological malignancies, it has been shown that 
detection of MRD correlates with clinical outcome and that MRD information is 
important for clinical decision-making (Table 6). 
Acute myeloid leukemia
A few large-scale studies evaluating the clinical relevance of MRD monitoring 
in AML have been performed. Studies in childhood AML, using flow cytometric 
immunophenotyping with cut-off levels between 0.1 and 0.5%, showed that patients 
with occult leukemia after induction therapy were significantly more likely to relapse 
Table 6. Clinical applicability of MRD detection in myeloid malignancies.
Type of MRD application
Early response to 
front-line treatment
Continuous 
monitoring for 
therapy titration
MRD assessment 
before SCT
MRD assessment 
after SCT
APL ++ ++ + +
AML ++ - + +
CML + +* + ++
++ :  value of MRD detection proven by prospective studies
+ :  potentially clinically relevant but not yet proven by large prospective studies 
- :  MRD detection has no additional value as compared with conventional cytomorphological   
  techniques
SCT :  stem cell transplantation
* monitoring of treatment protocols which include imatinib
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than those lacking detectable MRD.276,306,307 Flow cytometric MRD studies in adult 
AML also have shown the clinical relevance of MRD, although the time point 
(after induction or at the end of consolidation) at which prognostic information was 
obtained differed between the reported studies.275,277,308-311 Of importance are the 
studies by San Miguel et al., who defined different risk groups for AML patients in 
morphological remission according to the MRD level in BM after induction therapy. 
For an appropriate recognition of the true low-risk patients a sensitivity of 10-4 was 
required.275,277 Such sensitivities cannot be obtained using a standard antibody 
panel but need patient-tailored labelings, depending on the LAIP’s identified at 
diagnosis. However, in about 10-25% of patients no aberrant immunophenotype 
can be identified using the currently available technologies.44,275
MRD analysis in childhood and adult AML by PCR analysis of fusion gene 
transcripts has only been reported in relatively small patient series and generally 
showed that monitoring of MRD may be helpful in the recognition of patients at high 
risk of relapse and patients in a curable state.312-323 
 Acute promyelocytic leukemia
Particularly in APL, the clinical utility of frequent PCR-monitoring was confirmed 
in large prospective studies. After completing induction therapy including ATRA and 
chemotherapy, detectable PML-RARA transcripts were found in approximately 50% 
of patients.225,324,325 No correlation was found between the PCR status at the time of 
morphological remission and the risk of relapse. By contrast, detection of MRD after 
the end of consolidation was strongly associated with subsequent overt hematological 
relapse, whereas the achievement of a PCR-negative status was associated with 
prolonged survival.326 Early detection of molecular relapse, which usually precedes 
hematological relapse at a median time of 2-3 months, has been defined as a condition 
requiring early administration of salvage therapy; patients treated at the time point of 
molecular relapse had a significantly better 2-year event-free survival than patients 
treated with the same salvage therapy at the time of hematological relapse.327,328 
A number of small studies have highlighted the role of molecular monitoring in the 
context of hematopoietic stem cell transplantation (SCT) in APL. The pre-transplant 
status was a relevant indicator of subsequent outcome for patients undergoing 
autologous SCT,329 while in patients undergoing an allogeneic SCT, PCR-positivity 
pre-transplant may convert to PCR-negativity after transplantation. Evidence to date 
suggest that patients with PML-RARA transcripts still detectable 3 months after SCT 
are destined to relapse in the absence of intervention,329,330 while PCR-negativity has 
been consistently documented in BM derived from patients in long-term remission 
following autologous and allogeneic SCT.330  
Chronic myeloid leukemia
For CML patients, much experience has been gained in measuring the BCR-
ABL transcript levels in PB after conventional allogeneic SCT. The significance of 
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identifying BCR-ABL transcripts within the first 6 months after transplantation remains 
controversial. In one series such transcript numbers had no clinical relevance,331 
whereas in the Hammersmith experience, the absence of or presence of only low 
levels of residual disease early after SCT (at 3 to 5 months) was significantly correlated 
with a low risk of relapse at 3 years.332 The finding of persisting BCR-ABL negativity 
from 6 months to 5 years after SCT predicted a low risk for subsequent relapse.333 
The BCR-ABL transcript levels were also informative after reduced-intensity SCT;334 
early increase of BCR-ABL transcripts correlated significantly with the probability 
of hematological relapse. In spite of the yet relatively short-term experiences, MRD 
information also seems of clinical importance in imatinib-treated CML patients. The 
IRIS trial investigated imatinib as primary therapy in CP CML patients: results showed 
that patients with a CCyR and a reduction in BCR-ABL transcript numbers of at least 
3 log by 12 months of therapy, had a significantly superior progression-free survival 
as compared to those who achieved lesser degrees of molecular response or those 
who failed to achieve CCyR.240,241 Longer follow-up should determine whether imatinib 
can induce prolonged progression-free survival and improved overall survival.
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Fusion genes and junctional regions of 
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Fusion genes result from chromosome aberrations such as translocations, 
inversions or deletions. In most leukemias the fusion genes are transcribed into 
fusion gene transcripts which are frequently similar between individual patients 
despite distinct breakpoints at the DNA level (Figure 1). After reverse transcription 
into cDNA, the fusion gene transcripts are used as polymerase chain reaction 
(PCR) targets for quantitative analysis of minimal residual disease (MRD). Primer 
and probe sets for real-time quantitative PCR (RQ-PCR) detection of the most 
common fusion gene transcripts as well as control gene transcripts have been 
designed (Figure 1) and reach sensitivities of at least 10-4.1,2 
Junctional regions of rearranged immunoglobulin (Ig) and T-cell receptor (TCR) 
genes represent unique ‘fingerprint-like’ sequences, which are assumed to be 
different in each lymphoid cell and lymphoid malignancy.3 Therefore, junctional 
regions of Ig and TCR genes can be used as patient-specific targets for MRD-PCR 
analysis. After confirming clonality and sequencing of the rearrangement, junctional 
region-specific oligonucleotides can be designed. Germline primer and probes for 
RQ-PCR analysis have been designed for IGH, IGK-Kde, TCRG, TCRD, TCRB, 
and Vδ2-Jα rearrangements. These primer-probe sets in combination with junctional 
region-specific primers can generally reach sensitivities of 10-4.4 
RQ-PCR allows accurate quantification of PCR products during the exponential 
phase of the PCR amplification. During and after each subsequent PCR cycle, 
fluorescent signals are detected, and quantitative data can be obtained in a 
short period of time without the need of post-PCR processing. One principle of 
RQ-PCR detection is based on the use of hydrolysis probes which exploit the 
5’→3’ exonuclease activity of the Thermus aquaticus (Taq) polymerase to detect 
and quantify specific PCR products (Figure 2).5 The hydrolysis probe (also referred 
as TaqMan probe) is conjugated with a reporter and a quencher fluorochrome, and 
should be positioned within the target sequence. As long as the probe is intact and 
both fluorochromes are in each other’s close vicinity, the fluorescence emitted by the 
reporter fluorochrome will be ‘absorbed’ by the quencher fluorochrome. However, 
upon amplification of the target sequence, the hydrolysis probe is initially displaced 
from the DNA strand by the Taq polymerase and subsequently hydrolysed by the 
5’→3’ exonuclease activity of the Taq polymerase. This results in the separation of 
the reporter and quencher fluorochrome and consequently, the fluorescence of the 
reporter fluorochrome becomes detectable. During each consecutive PCR cycle 
the amount of fluorescent signal will further increase because of the exponential 
accumulation of free reporter fluorochromes. Based on the background fluorescence 
intensity, a cut-off level can be determined for specific fluorescence. This threshold 
is used to calculate the cycle threshold (CT) of each sample (Figure 3A). To calculate 
the amount of template for each patient sample, a standard curve prepared from a 
dilution series from a diagnostic sample or a plasmid for both the target and control 
gene, can be used (Figure 3B). The target gene amount is subsequently divided by 
the control gene amount to obtain a normalized target value. 
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Figure 1. 
(A) Schematic diagram of the exon/intron structure of the MYH11 gene, which is involved in the 
inv(16)(p13q22). The centromere (cen) and telomere (tel) orientation, exon numbering, and the 
breakpoint region are indicated. 
(B) Schematic diagram of the 3 most frequent types of CBFB-MYH11 fusion transcripts (type A, D and 
E) covered by the RQ-PCR primers and probe set of the Europe Against Cancer program.1 The relative 
frequency of each particular transcript appears on the right side of the diagram. The different types of 
transcripts are mainly caused by breakpoints in different introns of the MYH11 gene. The numbers under 
the fusion gene transcript refer to the first (5’) nucleotide of the involved gene, except when the last (3’) 
nucleotide of the upstream gene is indicated. The number under the primers and probe refers to their 
5’ nucleotide position in the normal gene transcript. ENF = European network forward primer, ENPr = 
European network TaqMan probe, ENR = European network reverse primer.
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In this part of the thesis, PCR-based MRD-targets in myeloid leukemia were 
studied. Previous studies using Southern blot analysis had shown the occurrence 
of cross-lineage Ig/TCR gene rearrangements in AML.6 For RQ-PCR MRD studies, 
the precise sequence of the junctional region of the rearranged Ig/TCR genes 
needs to be known. Therefore, we performed a precise characterization of the type 
of Ig/TCR gene rearrangements that occur in AML (see Chapter 2.2). Secondly, we 
Figure 2. Principle of RQ-PCR detection using the 
hydrolysis probe technique. 
(A) During the annealing phase, the double-dye 
oligonucleotide probe hybridizes to the complementary 
nucleotide sequence of the template during the PCR 
reaction. 
(B) The probe is degraded during the extension phase by 
the DNA Taq polymerase enzyme, resulting in a fluorescent 
signal in the PCR tube detected by the machine. 
(C) End of PCR cycle. R: reporter dye, Q: quencher dye.
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Figure 3.
(A) Amplification plot of several 10-fold dilutions of a diagnostic leukemia sample. The samples 
were diluted in normal mononuclear cell (MNC) RNA. Based on the background fluorescence intensity 
detected during the first three to 15 PCR cycles, a threshold is determined. The CT is defined as the 
PCR cycle at which the fluorescent signal exceeds the threshold for the first time. The CT value is 
directly proportional to the amount of target sequence present at the beginning of the reaction. The 
deltaRn corresponds to the increase in fluorescence intensity when the plateau phase is reached.
(B) Standard curve prepared from the data in (A). The slope of the standard curve is close to the 
theoretical slope of -3.32 for a PCR reaction with maximum efficiency. Unknown samples can be plotted 
in the standard curve. Based on their CT value, the amount of template can be calculated. 
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investigated whether Ig/TCR gene rearrangements and chromosome aberrations 
with fusion gene transcripts are complementary targets for PCR-based MRD studies 
in AML (see Chapter 2.2). Additionally, we developed a RQ-PCR for the analysis of 
RAG1 and RAG2 gene expression levels as a potential tool for the selection of AML 
samples with Ig/TCR gene rearrangements (see Chapter 2.2). 
Similar to rearranged Ig and TCR genes, fusion genes of chromosome 
aberrations at the DNA level are different in each patient, thereby representing 
patient-specific targets for PCR-based MRD monitoring. We focussed on the 
identification of genomic BCR-ABL e19a2 fusions (see Chapter 2.4).
Finally, as difference in stability over-time between fusion gene transcripts and 
control gene transcripts may result in an over- or underestimation of the MRD levels, 
we investigated the stability over-time of the fusion gene as well as the control gene 
transcripts (see Chapter 2.3). 
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ABSTRACT
PCR-based monitoring of minimal residual disease (MRD) in acute leukemias 
can be achieved via detection of fusion gene transcripts of chromosome aberrations 
or detection of immunoglobulin (Ig) and T cell receptor (TCR) gene rearrangements. 
We wished to assess whether both PCR targets are complementary in acute 
myeloid leukemia (AML). 
We investigated 105 consecutive AML cases for the presence of fusion 
gene transcripts by reverse transcriptase polymerase chain reaction (RT-PCR): 
AML1-ETO associated with t(8;21), CBFB-MYH11 with inv(16), PML-RARA with 
t(15;17), BCR-ABL with t(9;22), and MLL-AF4 with t(4;11). In 17 out of 105 AML 
cases (16%), fusion gene transcripts were found. Ninety-five of these AML patients 
(13 with fusion gene transcripts) were also investigated for the presence of IGH, 
IGK, TCR, and TCRD rearrangements by Southern blot and/or PCR-heteroduplex 
analysis and sequencing. In nine out of 95 patients (9.5%) such rearrangements 
were found. Combined data revealed that only one patient with a fusion gene 
transcript had a coexistent Ig/TCR rearrangement. The nine AML patients with
Ig/TCR rearrangements, as well as five additional AML patients from a previous 
study were investigated in more detail, revealing that Ig/TCR rearrangements in 
AML are immature and unusual. The presence of Ig/TCR rearrangements in AML 
did not correlate with RAG gene expression levels as determined by real-time 
quantitative PCR.
In conclusion, fusion gene transcripts and Ig/TCR rearrangements are infrequent, 
but complementary MRD-PCR targets in AML. 
INTRODUCTION
Over the past decade, advances in therapeutic approaches have improved the 
outcome for patients with acute myeloid leukemia (AML). About 75% of patients 
under 65 years and about 50% of elderly patients achieve a complete remission, 
cytomorphologically defined as the presence of less than 5% blast cells in the 
bone marrow (BM). However, many patients relapse, implying that treatment 
does not kill all AML cells and that surviving cells remain undetected by the use of 
cytomorphology. To trace low frequencies of remaining leukemic cells, i.e. ‘minimal 
residual disease’ (MRD), more sensitive methods are required. MRD techniques 
should reach sensitivities of at least 10-3 (one leukemic cell in 1000 normal cells), 
but sensitivities of 10-4 to 10-6 are preferred.1 Flow cytometric immunophenotyping 
and polymerase chain reaction (PCR) techniques are able to detect such low 
frequencies of leukemic cells. Detection of MRD by flow cytometry is based on 
the presence of aberrant phenotypic features of the AML cells that allow them 
to be distinguished from normal cells.2 Monitoring of MRD by PCR techniques is 
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based on the detection of clone-specific sequences, such as junctional regions 
of immunoglobulin (Ig) and T cell receptor (TCR) genes or on the detection of 
leukemia-specific breakpoint fusion gene transcripts of chromosome aberrations. 
Junctional regions of Ig and TCR gene rearrangements are the result of 
recombination of different variable (V), diversity (D), and joining (J) gene segments 
with deletions and random insertions of nucleotides at the coupling sites of the 
gene segments. This lymphoid-specific process is mediated via V(D)J recombinase 
activity, wherein the recombination activating gene products (RAG1 and RAG2) 
play a crucial role. Clonal patient-specific Ig and TCR gene rearrangements can be 
identified in the vast majority of pediatric and adult patients with acute lymphoblastic 
leukemia (ALL).3,4 Cross-lineage Ig and TCR gene rearrangements have been 
reported in AML patients as well. Results from the literature reveal that Ig heavy 
chain (IGH) gene rearrangements occur in 4 to 18% of AML patients, whereas 
Ig kappa light chain (IGK) gene rearrangements occur in 1 to 5% only.5-10 So far, 
only one AML case has been reported having rearrangements of the Ig lambda 
(IGL) locus.10 Rearrangements of the TCR gamma (TCRG) and TCR delta (TCRD) 
genes have both been found in 4 to 14% of cases.9-12
Several types of PCR-detectable chromosome aberrations are relatively
frequently found in AML: t(8;21)(q22;q22) occurs in 6-8% of adult AML and 
10-14% of childhood AML and can especially be found in the AML-M2 subtype; 
inv(16)(p13;q22) occurs in 5-7% and is closely associated with the AML-M4Eo 
subtype; t(15;17)(q22;q21) is found in 5-10% of AML and is exclusively found in 
acute promyelocytic leukemia (AML-M3); about 5% of de novo AML have 11q23 
abnormalities involving the MLL gene, such as t(4;11)(q21;q23) and t(9;11)
(p22;q23).13-15 However, t(9;22)(q34;q11) is rarely found in AML.15 Chromosome 
aberrations can be used for risk group classification: 11q23 aberrations are 
associated with poor prognosis, whereas t(8;21), t(15;17) and inv(16) are associated 
with relatively good prognosis.16,17
Since previous studies mainly focused on the detection of either chromosome 
aberrations or Ig/TCR gene rearrangements, we now investigated the occurrence of 
both types of MRD-PCR targets in a large group of 105 consecutive AML patients. 
The aim of the here presented study was two-fold: (1) precise characterization of the 
type of Ig/TCR gene rearrangements that occur in AML patients; and (2) analysis 
of whether Ig/TCR gene rearrangements and chromosome aberrations with fusion 
gene transcripts are complementary PCR targets for MRD studies. Additionally, we 
developed a “real-time” quantitative polymerase chain reaction (RQ-PCR) using 
TaqMan technology for the analysis of RAG1 and RAG2 gene expression levels in 
AML patients, as a potential tool for selection of AML samples with Ig/TCR gene 
rearrangements. 
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MATERIALS AND METHODS
Patients and cell samples
Peripheral blood (PB) or BM samples from 105 consecutive AML patients (81 adults and 24 children) 
were obtained at initial diagnosis. The diagnosis of AML was based on cytomorphology, cytochemistry, 
and flow cytometric immunophenotyping. Myeloid blast crises of chronic myeloid leukemia were 
excluded from the study. Patients were classified according to the revised French-American-British 
(FAB) criteria.18 Mononuclear cells (MNC) were isolated by Ficoll-Paque centrifugation (density: 
1.077 g/cm3; Pharmacia, Uppsala, Sweden) and stored in liquid nitrogen.
Additional molecular analysis was performed on five previously described AML patients with 
Southern blot-detectable Ig/TCR gene rearrangements of which DNA was still available.9 Three other 
patients from this previous study could not be further investigated due to lack of DNA.
Reverse transcriptase polymerase chain reaction (RT-PCR)
Total RNA was prepared from cryopreserved MNC by phenol-chloroform extraction.19 RT-PCR 
was performed on all 105 AML patients as previously described.15 Samples were investigated for 
the presence of six fusion gene transcripts associated with well-defined chromosome aberrations: 
AML1-ETO, CBFB-MYH11, PML-RARA, BCR-ABL p190 and p210 and MLL-AF4. Quality of RNA was 
checked by amplification of ABL gene transcripts. A single PCR was performed in a volume of 50 μl 
using 2 μl of cDNA. The sequences of the primers used for PCR amplification were developed during the 
BIOMED-1 Concerted Action.15 PCR conditions comprised: initial denaturation at 95°C for 30 s, followed 
by 35 cycles of 30 s at 94°C, 60 s at 65°C and 60 s at 72°C using a Perkin Elmer 9600 thermal cycler 
(Applied Biosystems, Foster City, CA, USA). Appropriate positive and negative controls were used in 
all experiments.15
Southern blot analysis of Ig/TCR gene rearrangements
Screening for IGH, IGK, and TCRD gene rearrangements was done by Southern blot analysis. DNA 
was isolated from frozen MNC fractions using the QIAamp Blood Kit (Qiagen, Chatsworth, CA, USA).20 
Fifteen μg of DNA was digested with BglII (Gibco Ltd. Paisley, Scotland), size-separated in 0.7% agarose 
gels, and transferred by vacuum blot to Nytran-13N nylon membranes (Schleicher and Schuell, Dassel, 
Germany), as described.21 The membranes were hybridized with 32P-random oligonucleotide-labeled 
probes. The IGH gene configuration was analyzed with the IGHJ6 probe (DAKO Corp, Carpinteria, CA, 
USA),22 IGK gene rearrangements were analyzed with the IGKJ5 and IGKDE probes (DAKO),23 and the 
TCRD gene configuration was analyzed with the TCRDJ1, TCRDJ3 and TCRDV2 probes (DAKO).24
Appropriate analysis of TCRG gene rearrangements can not be performed on BglII restricted DNA.25 
Because of limited availability of DNA, an additional digest with EcoRI (Gibco) was only performed in 
patients who showed clonal TCRG gene rearrangements by PCR heteroduplex analysis (see below). 
The TCRG gene configuration in these patients was analyzed with the TCRGJ13 probe (DAKO).25
PCR heteroduplex analysis of Ig/TCR gene rearrangements
Only patients who showed rearrangements and/or deletions of IGH, IGK, and/or TCRD genes 
on Southern blot were further investigated by PCR heteroduplex analysis for these genes. Southern 
blotting for detection of TCRG gene rearrangements was performed in a limited number of patients, 
but PCR heteroduplex analysis was performed in all patients. All relevant PCR analyses were also 
performed on the five AML samples from a previous Southern blot study, which showed Ig/TCR gene 
rearrangements.9 PCR was essentially performed as described previously.26 Briefly, in each 50 μl PCR 
reaction, 50 ng DNA sample, 6.25 pmol of the 5’ and 3’ oligonucleotide primers and 1 U AmpliTaq 
Gold polymerase (Applied Biosystems) were used. The sequences of the oligonucleotides used for 
amplification of IGH, IGK, TCRG, and TCRD gene rearrangements were described elsewhere.26,27 PCR 
conditions comprised: initial 10 min at 94ºC, followed by 35 cycles of 45 s at 92ºC, 90 s at 60ºC and 
2 min at 72ºC using a Perkin-Elmer 480 thermal cycler (Applied Biosystems). A final extension step of 
10 min at 72ºC was performed after the last cycle. Appropriate positive and negative controls were used 
in all experiments.26
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To confirm clonality of the PCR-amplified rearrangements, heteroduplex analysis was performed 
on positive PCR products.28 PCR products were denaturated at 94ºC for 5 min and subsequent 
cooled at 4ºC for 60 min to induce duplex formation. The duplexes were immediately loaded on a 6% 
non-denaturating polyacrylamide gel in 0.5 x Tris-boric acid-EDTA (TBE) buffer, run at room temperature 
and visualized by ethidium bromide staining. A 100-bp DNA ladder (Promega Corp, Madison, WI, USA) 
was used as size marker.
Sequence analysis of Ig and TCR gene rearrangements
PCR products found to be clonal by heteroduplex analysis were directly sequenced, except for 
cases in which heteroduplex PCR analysis showed more than two clonal bands. In such cases, homo- 
or heteroduplex bands were excised from the polyacrylamide gel and eluted as described before.27 The 
eluted PCR products were sequenced directly. Sequencing was performed using the BigDye terminator 
cycle sequencing kit with AmpliTaq DNA polymerase on an ABI PRISM 377 automated sequencer 
(Applied Biosystems). Briefly, 50 to 200 ng of PCR product, 3.2 pmol primer and 5 μl BigDye terminator 
mix were used in a 15 μl reaction volume. The cycling protocol was 96ºC for 30 s, followed by 60ºC for 
4 min for a total of 25 cycles. All rearrangements were sequenced in two directions from two independent 
PCR products.
Interpretation of sequence data
V, D and J gene segments in TCRG and TCRD rearrangements were identified as described 
previously.29 The Ig sequences were analyzed with the DNAPLOT software (Müller, H.H. Althaus, 
University of Cologne, Germany) by searching for homology with all known human germline sequences 
obtained from the VBASE directory of human Ig genes (http://www.mrc-cpe.cam.ac.uk/imt-doc/) and 
IMGT (http://imgt.cnusc.fr:8104/). Most sequences were additionally analyzed using BLAST sequence 
similarity searching tool (National Center for Biotechnology Information: http://www.ncbi.nlm.nih.gov/
BLAST/).
Real-time quantitative PCR (RQ-PCR) of RAG gene expression levels
Based on germline RNA sequences of the human RAG1 and RAG2 genes, primers and 
TaqMan probes were designed using Primer-Express software (Applied Biosytems) according to the 
manufacturer’s guidelines. RAG1: forward primer 5’-TGAGTAATATCAACCAAATTGCAGACA-3’, 
reverse primer 5’-GGATCTCACCCGGAACAGC-3’, TaqMan probe 5’-CCCCAGATGAAATTCAGCAC
CCACATATTAA-3’; RAG2: forward primer 5’-GTTTAGCGGCAAAGATTCAGAGA-3’, reverse primer 
5’-GTCCATCAAAATTCATCAGTGAGAA-3’, TaqMan probe 5’-CAAAAATCTACGTACCATCAGAAACTA
TGTCTCTGCA-3’ (Applied Biosystems). 
Fifty µl reaction mixtures contained Universal Master Mix 2x (Applied Biosystems), 900 mM primers, 
200 mM probe and approximately 100 ng of RNA (6 µl cDNA). RQ-PCR experiments were performed 
in duplicate and consisted of 2 min at 50ºC, 10 min at 95ºC, followed by 50 cycles of 15 s at 95ºC and 
1 min at 60ºC. Real-time detection of obtained PCR products was based on TaqMan technology using 
the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). Non-template controls (NTC) 
and thymocyte DNA were used as negative controls in each RAG1/RAG2 RQ-PCR experiment. In 
all cases, thymocyte DNA did not result in any amplification, indicating that RAG1 and RAG2 mRNA 
was specifically detected by our RQ-PCR method. A standard curve was established using a dilution 
series of thymocyte RNA (10-1 to 10-6) in cell line RNA (HL-60). As HL-60 cells do not express RAG1 or 
RAG2, HL-60 cDNA was taken as a control in each experiment and was always negative. To correct 
for differences in the amount of total RNA added to a reaction, the copy number was normalized to 
the GAPDH housekeeping gene (Applied Biosystems kit). The GAPDH assay was confirmed to be 
RNA specific, as thymocyte DNA included in each experiment was always negative. RQ-PCR data of 
RAG1 and RAG2 were subsequently corrected for the tumor load of the sample as determined by flow 
cytometric immunophenotyping.
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Statistical analysis 
A χ2 or Fisher’s exact test on a 2 x 2 table was performed for comparison of patient and disease 
characteristics (age, sex, FAB subtype and immunophenotype) between AML patients with Ig/TCR gene 
rearrangements vs patients without Ig/TCR gene rearrangements. A P value of <0.05 was regarded to 
be statistically significant.
A linear mixed model has been used to analyze differences in RAG gene expression as a function of 
the type of RAG gene (RAG1 and RAG2), sample origin (BM or PB) and patient group (AML-germline, 
AML-rearranged and ALL). To model the correlation between the repeated measures per subject, a 
Kronecker product of two unstructured covariance matrices (one for sample origin, and one for the type 
of RAG gene) was used. The alpha-level 0.05 was used. All analyses were performed with the SAS-
procedure PROC MIXED (version 8.1).
RESULTS
Detection of fusion gene transcripts in AML patients
Of 105 AML patients, 17 harboured chromosome aberrations (16%) 
(4/24 pediatric patients and 13/81 adults) as detected by RT-PCR analysis. Six 
patients (four children and two adults) had an AML1-ETO fusion gene transcript 
(5.7%): four concerned AML-M2, one AML-M4 and one AML-M1. CBFB-MYH11 
fusion gene transcripts were detected in six cases (5.7%); all six concerned the 
predominant type A fusion gene transcript.15 Five of these six leukemias were 
classified as an AML-M4Eo and one as AML-M5. Three cases with PML-RARA 
fusion gene transcripts were found (2.9%): all these patients had an AML-M3 
morphology. In two adult AML patients (1.9%), a BCR-ABL fusion gene transcript 
was identified: one encoded the 210 kDa fusion protein and one the smaller 190 
kDa BCR-ABL protein. They corresponded with an AML-M0 and an AML-M4, 
respectively. An MLL-AF4 fusion gene transcript was not found in this series. In 
the additional series of five AML patients from our previous study,9 no fusion gene 
transcripts were detected by RT-PCR.
Detection of Ig/TCR rearrangements in AML
Ninety-five AML patients (74 adults and 21 children) were subjected to Southern 
blot analysis of the IGH, IGK and TCRD gene loci. Ten patients could not be studied 
because of insufficient amounts of DNA; coincidently, four of these 10 patients 
contained a fusion gene transcript. This is in contrast to only 13 of the 95 patients 
(14%), which were studied for Ig/TCR gene rearrangements.
 IGH gene rearrangements were detected by Southern blotting in 5/95 AML 
patients (5%): two children and three adults (Figure 1). Monoallelic IGH gene 
rearrangements were found in three out of five patients (P-26, A-16, and A-34) and 
biallelic rearrangements were observed in case P-08. Southern blot analysis of 
patient A-62 showed three rearranged bands of different densities, suggesting the 
formation of subclones. Detailed PCR heteroduplex analysis of the IGH locus in 
the five patients with IGH gene rearrangements on Southern blot, detected seven 
clonal homoduplexes: one complete VH-JH rearrangement (patient P-08) and six 
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incomplete DH-JH rearrangements (Table 1). Sequence analysis revealed that the 
complete rearrangement concerned a VH6-DH1-JH3b joining. In the incomplete 
rearrangements, the DH3-22 gene segment was used preferentially (3/6 cases). 
The other three DH segments used in the incomplete rearrangements were DH1-26, 
DH2-2 and DH3-16. Except for one (DH2-2), all identified DH gene segments belong 
to the more downstream part of the DH region. One Southern blot detectable IGH 
rearrangement (in P-08) could not be identified by PCR analysis with the primer set 
used (Table 1).
 IGK gene rearrangements were found in only one patient (P-08): hybridization 
with the IGKJ5 probe showed a deletion, whereas hybridization with the IGKDE 
probe revealed a rearranged band. All other AML patients displayed the IGK locus in 
Figure 1. Southern blot analysis of the IGH gene in three pediatric and four adult AML patients. 
Control DNA and DNA from the seven AML patients were digested with BglII, size separated and blotted 
on to nylon membrane filters, which were hybridized with the 32P labeled IGHJ6 probe. The IGH gene 
was rearranged in five out of the seven patients presented and a germline configuration was present in 
two patients (P-20 and A-38). Rearrangement of the IGH gene locus on one allele was found in three 
patients (A-16, A-34 and P-26) and on both alleles in one patient (P-08). In patient A-62, more than two 
rearranged IGH gene bands of different density were visible, suggesting the presence of subclones. 
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Table 1.  Junctional regions of the clonal Ig and TCR gene rearrangements in (A) 9/95 consecutive 
de novo AML patients with cross-lineage rearrangements and (B) five selected AML
patients from a previous study.9
Gene locus Patient code Rearrangement Junctional regiona
IGH b P-08 VH6-1-DH1-JH3b 0/TCT/-6/DH1/-2/GGCGATTGC/-1            A
Not identified
P-26 DH3-16-JH4b -6/CTTGGATC/-4
A-16 DH3-22-JH4b 0/0/-8
A-34 DH3-22-JH4b -10/CAC/-6
A-62 DH1-26-JH4b -4/GGGTTG/-6
DH2-2-JH6c -11/TCCC/-6
DH3-22-JH4b -3/CCCC/-4
IGK P-08 Vk3-20-Kdec 0/GGGAGGGAGAT/0/Jk3-intron-
RSSJk4/0/AGGCCGG/-3
TCRD P-08 Vδ2-Dδ3-Jδ1 -5/CCATT/0/Dδ3/0/CCCGATGT/0
P-20d Dδ2-Dδ3 0/GGGGTG/-1
P-24 Biallelic deletion not applicable
TCRG e P-08 Vγ9-Jγ2.3 (subclone) -2/CACCAAAGGAGGGGGT/-3
A-25 Vγ10-Jγ2.3 (subclone) -8/GATTAAGGGGGGG/-11
Vγ9-Jγ2.3 (subclone) 0/CCT/-14
A-38 Vγ9-Jγ2.3 (subclone) 0/CGGG/-12
IGH b RM DH2-21-JH NAf                                                             B
PM DH4-23 -JH4b 0/GGTGGAAGG/-10  
DH7-27-JH6b -10/CGCGGGCT/-23 
BM DH7-27-JH5b -2/0/-3 
JC Not identified  
TCRD RS Vδ2-Dδ3 -7/CCCGTCC/-1 
PM Dδ2-Jδ1 -1/AATACTGGGGGGCCCAGGGG/-3 
Dδ2-Jδ1 -1/CCCGGTACTTAAAAATAGG/0 
TCRG PM Vγ8-J+γ2.3 -3/GGAAGG/-5 
Vγ11-Jγ2.1 -7/GGG/-5 
RS Vγ11-Jγ2.3 -7/CTAGGGGA/-5  
a Given are the numbers of deleted nucleotides from the germline sequence of the involved gene
  segments and the sequence of the N-regions.
b The most recent nomenclature was used to designate IGH gene segments.36
c Complex IGK gene rearrangement: The Vk3-20 gene segment was coupled to Jk3, followed by the 
 intronic sequence till the RSS of Jk4. The Jk4 gene segment itself was absent, the RSS of Jk4 was
 followed by another junctional region and Kde. 
d This is the only AML patient who also had a fusion gene transcript.
e The four TCRG gene rearrangements were only detectable by PCR, not by Southern blotting, implying 
 that they were derived from small subclones. 
f NA, sequence information not available.
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germline configuration. PCR heteroduplex analysis of patient P-08 showed a VκIII-
Kde rearrangement. The size of this PCR product appeared to be approximately 
800 bp on agarose instead of the expected 429 bp (Figure 2). Sequence analysis 
revealed a complex rearrangement in which the Vκ3.20 gene segment was coupled to 
the Jκ3, followed by the intronic sequence until the RSS of Jκ4. The Jκ4 gene segment 
Figure 2. PCR heteroduplex analysis of cross-lineage rearrangements in AML. 
Samples containing PCR products were subjected to heteroduplex PCR analysis, separated in a 6% 
polyacrylamide gel and visualized by ethidium bromide staining. (A) Clonal Vδ2-Jδ1 and Dδ2-Dδ3 
homoduplexes were seen in patient P-08 and P-20, respectively. The VκIII-Kde combination showed 
a large clonal product in P-08. Analysis with VγII family-specific primers in combination with Jγ1.3/2.3 
primers shows homoduplexes in three patients. (B) Using DH3 primers in combination with JH consensus 
primers, clonal PCR products were found in patients A-16, A-34 and A-62.
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itself was absent, yet another junctional region, followed by Kde was found (Table 1). 
So, this seemingly VκIII-Kde rearrangement is in fact a Jκ4-Kde rearrangement.
Analysis of the TCRD gene configuration in the 95 samples demonstrated 
rearrangements and/or deletions of this locus in three pediatric cases (P-08, 
P-20 and P-24). By PCR heteroduplex analysis, clonal TCRD PCR products were 
found in two patients: in patient P-08, the rearrangement consisted of a complete 
Vδ2-Dδ3-Jδ1 joining, whereas in patient P-20 an incomplete Dδ2-Dδ3 rearrangement 
was identified. In patient P-24 both TCRD alleles were deleted. TCRG gene 
rearrangements were generally not analyzed by Southern blotting, due to limited 
availability of DNA. Hence PCR heteroduplex analysis of TCRG was performed in 
all 95 AML patients (74 adults and 21 children). Four monoclonal rearrangements 
were found in three patients (A-25, A-38 and P-08). Subsequent direct sequence 
analysis of PCR products elucidated that in these four rearrangements the VγII 
(Vγ9) or VγIII (Vγ10) gene segment was joined to the Jγ2.3 gene segment. By 
Southern blotting, no rearranged bands of TCRG gene locus could however be 
detected in these three patients, indicating that all four clonal PCR products were 
probably derived from small subclones. The junctional regions of all identified Ig 
and TCR gene rearrangements showed deletions as well as insertions (Table 1).
Taking the Southern blot and PCR heteroduplex analysis data together, major 
cross-lineage IGH, IGK and/or TCRD gene rearrangements occurred in only 
6/95 AML patients (Table 1). In only one patient (P-20) a fusion gene transcript 
(AML1-ETO) associated with a chromosome aberration was also found. Therefore, 
at least one reliable PCR target was available for MRD detection in 18 out of 95 
AML patients (19%).
Identification of Ig/TCR gene rearrangements in an additional series of five 
AML patients
In our previous study,9 8/54 (15%) patients were shown to have Ig/TCR gene 
rearrangements by Southern blot analysis. Five of them were studied here by PCR 
heteroduplex analysis. 
PCR-heteroduplex analysis of the IGH locus resulted in a total of four 
monoclonal DH-JH products in three out of four patients with Southern blot detected 
rearrangements. The DH family gene segments used included DH2, DH4 and DH7. 
Additional sequencing showed that the DH gene segments belonged to the most 
downstream part of the DH region. The rearranged allele detected by Southern blot 
analysis in patient JC, could not be identified with the used primer combinations 
(Table 1).
For the TCRD gene locus, a Vδ2-Dδ3 rearrangement was detected in patient 
RS by Southern blot analysis and confirmed by PCR heteroduplex analysis in 
this study. The other rearranged allele in this patient could not be identified. In 
patient PM, Southern blot analysis showed one rearranged allele. Using the 
Dδ2-Jδ1 primer combination, two heteroduplexes and co-migrating homoduplexes 
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were found by PCR heteroduplex analysis. Sequence analysis allowed us to identify 
both heteroduplexes (Table 1).
Biallelic rearrangements of the TCRG locus were found in two patients 
of the previous study.9 PCR heteroduplex analysis allowed us to identify a 
VγI-Jγ2.3 and a VγIV-Jγ2.1 joining in patient PM, whereas only one of the two 
TCRG gene rearrangements found by Southern blot could be identified in patient RS 
(VγIV-Jγ2.3) (Table 1).
Association of Ig/TCR gene rearrangements with patient and disease 
characteristics
AML patients with Ig/TCR gene rearrangements and patients without Ig/TCR 
gene rearrangements were compared for their patient and disease characteristics 
(age, sex, FAB subtype and immunophenotype). Cytogenetic findings could 
not be included, since these data were incompletely. Results showed that two 
associations were statistically significant. Firstly, in the patient group of 16 to 
60 years, the frequency of Ig/TCR gene rearrangements (2%) was significantly 
lower (P = 0.041) as compared to the other patient groups (<5 year, 5-15 years and 
>60 years). A second significant association was observed between the expression 
of B cell associated markers (CD19 and/or CD20) and the presence of Ig/TCR gene 
rearrangements (P = 0.014). All other immunophenotypic parameters, including 
expression of T cell-associated markers (CD2/CD4/CD5/CD7) and TdT, were not 
significantly related to the presence or absence of Ig/TCR gene rearrangements. 
Finally, no significant correlation was found between sex or FAB subtype and the 
occurrence Ig/TCR gene rearrangements. 
Analysis of RAG1 and RAG2 expression levels
BM and/or PB of seven AML patients with Ig and/or TCR rearrangements could 
be analyzed for the level of RAG1 and RAG2 transcripts, in order to investigate 
whether the occurrence of Ig/TCR gene rearrangements in AML was related to 
RAG expression levels. Results were compared with the expression levels in nine 
AML patients without Ig/TCR gene rearrangements. ALL patients with monoclonal 
(n=10) or oligoclonal (n=10) rearrangements were used as positive control groups. 
Results showed that the RAG1 expression was significantly lower than the RAG2 
expression in all four groups (P < 0.05). However, the RAG1 and RAG2 expression 
levels were not significantly different between the AML patients with rearranged 
Ig/TCR genes and the AML patients with germline genes. Furthermore, the RAG1 
and RAG2 expression levels were significantly lower in AML with rearranged 
Ig/TCR genes than in ALL with monoclonal rearrangements and ALL with oligoclonal 
rearrangements (P <0.0001). RAG1 and RAG2 expression levels did not differ 
significantly between the two latter control groups. Finally, the expression levels of 
RAG1 and RAG2 were not significantly different between BM and PB samples of 
the AML patients (Figure 3).
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DISCUSSION
In our study, 105 consecutive AML patients were investigated by RT-PCR for 
the presence of fusion gene transcripts, which were identified in 17 AML patients 
(16%), including four of the 24 children (16.5%). This percentage in childhood AML 
is rather low compared with the frequencies published by other groups,30 which 
may be caused by the relatively small number of children analyzed. In agreement 
with the findings of Raimondi et al.,30 we found that t(8;21) is the most common 
aberration in pediatric patients. In the adult AML patients, we identified 13 fusion 
gene transcripts (16%). Although in adult AML the frequency of the investigated 
fusion gene transcripts is considered to be 20-25%, age-related differences can be 
observed. In AML patients above 60 years of age at diagnosis, the total frequency 
of detectable fusion genes is <10%.31 In our study, 27 of the 81 adults belonged to 
this older age group and only one of them (4%) contained a fusion gene transcript 
(inv(16)) as detected by RT-PCR; this might partly explain the lower overall 
percentage in this study. Consequently, the frequency of fusion transcripts in the 
AML patients below 60 years was 22% (12/54). Two adult AML patients contained 
BCR-ABL transcripts, which is a remarkable finding because in most AML reports 
the frequency of t(9;22) is <1%.15
Figure 3. RAG1 and RAG2 gene mRNA levels in AML and ALL as assessed by RQ-PCR. 
BM (circles) and/or PB (triangles) samples of AML with or without rearranged Ig/TCR genes were 
analyzed for their levels of RAG1 and RAG2 transcripts. Monoclonal and oligoclonal ALL were used as 
positive controls. 
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Cross-lineage Ig/TCR gene rearrangements were investigated in 95 out of the 
105 AML patients. Southern blot analysis of the IGH, IGK and TCRD genes showed 
that clonal rearrangements were found in five, one and three cases, respectively, 
corresponding to seven different patients. These frequencies are somewhat lower 
than those found by other groups (Table 2).9-12 In our previous study, we found 
IGH, IGK and TCRD gene rearrangements in 13%, 2%, and 4% of the patients, 
respectively. In six of the seven cases of our new patient series, we could identify 
the rearrangements with PCR heteroduplex analysis. Sequence analysis of these 
rearrangements showed that most junctional regions were comparable to what can 
be found in ALL. Hence, these Ig/TCR gene rearrangements are potentially suitable 
as PCR targets for MRD analysis.
Previous studies indicate that about 5% of AML cases have TCRG gene 
rearrangements as detected by Southern blot analysis.9,10 In our series, 95 AML 
patients were prescreened by PCR heteroduplex for this target: four clonal 
rearrangements were identified in a total of three patients. However, no rearranged 
bands could be found by subsequent Southern blot analysis, probably because 
the clonal PCR products derived from a small leukemic subclone. We therefore 
assume that these TCRG gene rearrangements are not useful as PCR-MRD 
targets in AML. 
To get more insight into the type of Ig/TCR gene rearrangements that occur 
in AML, we additionally performed PCR heteroduplex analysis in five AML 
patients, who were shown to contain IGH (n=4), TCRD (n=2), and/or TCRG 
(n=2) rearrangements by Southern blot analysis.9 Looking at the IGH locus of both 
patient groups, 10 of the 11 gene rearrangements were incomplete DH-JH joinings 
(Table 1). Only one concerned a complete VH-DH-JH recombination, involving 
the most downstream VH6-1 gene segment. Virtually all used DH gene segments 
(10/11; 91%) belonged to the more downstream DH segments. Analysis of the JH 
gene segment usage showed a more frequent usage of the JH4 and JH6 gene 
segments, which is also the case in normal lymphocytes and B cell malignancies. The 
predominance of incomplete DH-JH rearrangements together with the frequent usage 
Table 2. Frequency of Ig and TCR gene rearrangements in AML.
Referencesa IGH genes IGK genes TCRD genes
Fontenay et al.12 10/57  (17%) NT 8/57  (14%)
Adriaansen et al.9 7/54  (13%) 1/54  (2%) 2/54  (4%)
Sanchez et al.10 16/160  (10%) 8/160  (5%) 21/160  (13%)
Schmidt et al.11 NT NT 9/100  (9%)
This study 5/95  (5%) 1/95  (1%) 3/95  (3%)
TOTAL 38/366  (10.4%) 10/309  (3.2%) 43/466  (9.3%)
a Only reports on large patient series (n>50) were used for this table. 
NT Not tested.
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of the more downstream DH gene segments fits with immature rearrangements as 
also found in T-ALL.27 The only IGK rearrangement identified comprised a complex 
IGK gene rearrangement, which is rare in B cell malignancies (AW Langerak, 
unpublished results), and has never described in normal cells before. This complex 
rearrangement can only be explained by a multistep process.32 Irrespective of the 
subclonal origin of the four TCRG gene rearrangements in the random series of 
95 AML patients, it is remarkable that the total of seven TCRG rearrangements 
all included one of the four most downstream Vγ gene segments. Finally, the 
frequency of TCRD gene rearrangements is in line with previous reports.33,34 Two 
TCRD rearrangements concerned the immature incomplete Vδ2-Dδ3 and Dδ2-Dδ3 
rearrangements; in one patient biallelic Dδ2-Jδ1 rearrangements were detected 
and another patient contained a complete Vδ2-Dδ3-Jδ1 rearrangement. This is in 
contrast to precursor-B-ALL, where TCRD gene rearrangements generally do not 
concern Jδ1 segments. Thus, the TCRD gene rearrangements in AML are rather 
heterogeneous. 
Overall results show that only in one patient (P-20), a PCR-detectable chromosome 
aberration coexisted with an Ig/TCR gene rearrangement. Therefore, cross-lineage 
Ig/TCR gene rearrangements in AML might be useful as supplementary MRD-PCR 
targets in addition to leukemia-specific chromosome aberrations. 
As the frequency of PCR-detectable Ig/TCR rearrangements in AML appeared 
to be low (<10%), we aimed to analyze whether their presence can be predicted by 
relatively high expression levels of RAG1 and RAG2 transcripts, enzymes involved 
in the rearrangement processes. Our results obtained by RQ-PCR analysis showed 
that the expression levels of both RAG1 and RAG2 mRNA were comparable 
between AML patients with and without Ig/TCR gene rearrangements. Although 
these genes must have been expressed in an earlier phase of AML development, 
they might have been downregulated at time of diagnosis. Apparently, RAG1 and 
RAG2 mRNA levels are not a straightforward tool for the prediction of Ig/TCR gene 
rearrangements in AML (Figure 3). 
We also checked for associations between Ig/TCR gene rearrangements and 
patient and disease characteristics, such as immunophenotype, especially B 
and T cell-associated markers. Our results showed that the frequency of Ig/TCR 
gene rearrangements (2%) in the patient group of 16 to 60 years was significantly 
lower as compared to other age groups. Another interesting finding was the 
significant association between positivity for B cell-associated markers (CD19 
and/or CD20) and the presence of Ig/TCR gene rearrangements. Importantly, no 
significant association between TdT expression and the presence of Ig/TCR gene 
rearrangements was seen, although most Ig/TCR rearranged AML did have inserted 
nucleotides at their junctional region. Most probably, Ig/TCR gene rearrangements 
represent early post-oncogenic events, whereas the enzymatic activity of V(D)J 
recombinase (RAG1 and RAG2) and TdT is already downregulated at the time of 
diagnosis. 
PCR targets for detection of MRD in AML 89
In conclusion, this study shows that fusion gene transcripts and Ig/TCR gene 
rearrangements are generally complementary, but relatively infrequent PCR targets 
for MRD detection in AML. Investigation of Ig/TCR gene rearrangements in AML 
patients is probably not realistic in a routine setting, because this provides only a 
limited number of additional MRD-PCR targets, and its presence cannot be predicted 
by RAG mRNA expression. Previous studies on Ig/TCR gene rearrangements used 
Southern blot analysis and might have given an overestimation of the number of 
MRD-PCR targets, since not all rearrangements found by Southern blotting can be 
identified by PCR. 
In this study, only approximately 20% of the AML patients had a reliable 
MRD-PCR target (16% with chromosome aberrations and 6% with PCR-identified 
Ig/TCR gene rearrangements). Consequently, the detection of MRD in the majority 
of AML patients needs another reliable and sensitive technique. Multi-parameter 
flow cytometric immunophenotyping is the best suited alternative, since 70 to 80% 
of AML patients show an aberrant or infrequent immunophenotype at diagnosis.1,35
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ABSTRACT
Quantification of minimal residual disease (MRD) using fusion gene transcripts 
provides prognostic information. As shipment of freshly collected samples to the 
PCR laboratory may take considerable time, the assessment of the over time 
transcript stability is crucial for reliable MRD studies. Differences in stability over 
time of fusion gene transcripts and control gene transcripts may result in an over- or 
underestimation of the MRD levels. We evaluated in diagnostic samples and MRD 
settings, the stability over time of the control gene transcripts in normal and leukemic 
cells, peripheral blood (PB) and bone marrow (BM) samples, and different types 
of leukemia, as well as the stability of fusion gene transcripts over time. Results 
indicated that transcripts are rapidly degraded ex vivo and that the degradation 
can differ between transcript type, between PB and BM, and between patients. Our 
results indicate the need for processing the samples on the day of sampling, or 
better, to collect the samples in tubes with an RNA stabilisator. 
INTRODUCTION
During the last decade, several studies have shown that quantification of 
minimal residual disease (MRD) provides prognostic information that can be used 
for treatment decisions in individual patients. In acute lymphoblastic leukemia (ALL), 
MRD information obtained at early time points during therapy allows the recognition 
of high risk and low risk patients, who may benefit from treatment intensification 
or treatment reduction, respectively. In acute promyelocytic leukemia (APL) and 
chronic myeloid leukemia (CML), MRD information at specific time-points enables 
effective early treatment intervention.1
Quantitative MRD data with sensitivities of at least 10-4 can be obtained by real-
time quantitative PCR (RQ-PCR) analysis using fusion gene transcripts associated 
with chromosomal abnormalities as MRD-PCR targets.2 For this purpose, primer 
and probe sets have recently been developed within the Europe Against Cancer 
(EAC) program.3 In addition, three control gene transcripts (abelson (ABL), b2-
microglobine (B2M) and glucuronidase (GUS)) were selected based on their 
suitability for MRD studies in leukemic patients.4
Shipment of freshly collected patient samples to the MRD-PCR laboratories 
may take considerable time. Especially in multi-center studies it may take 1-3 days 
before the patient sample can be processed. During this period, the quality of the 
RNA present in the sample may deteriorate;5 this can be due to induction of cell 
death with subsequent degradation of RNA, or to cellular changes resulting in 
altered stability or altered expression of transcripts. So far, only few studies have 
addressed the stability of fusion gene transcripts and control gene transcripts in 
patient samples.6-7
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Differential stability over time of fusion gene transcripts and control gene 
transcripts may result in over- or underestimation of MRD levels. Therefore, 
careful assessment of the transcript stability is crucial for reliable MRD studies. 
We determined whether the stability of the control gene transcripts differed (1) 
between normal and leukemic cells, (2) between bone marrow (BM) and peripheral 
blood (PB) samples, and (3) between different leukemia (ALL, AML, and CML). 
Furthermore, we investigated the stability of fusion gene transcripts over time and 
evaluated whether this stability was comparable to the stability of control gene 
transcripts. 
MATERIALS AND METHODS
Three different sample protocols were used in this study: protocol 1 (whole BM and/or PB obtained 
at diagnosis or relapse; n=29), protocol 2 (mononuclear cells (MNC) obtained at diagnosis or relapse, 
diluted (20x) in MNC of a healthy control to mimic an MRD setting; n=9), and protocol 3 (whole BM 
and/or PB samples obtained during follow-up; n=26). In all three protocols, the cell sample was divided 
into five identical tubes. Tube 0 was processed immediately, whereas tube 1, 2, 3, and 4 were kept at 
room temperature and processed at day 1, 2, 3, and 4 after sample collection, respectively. On the day 
of processing, MNC were separated by Ficoll density centrifugation (protocol 1 and 3 only) and RNA 
was isolated from 2 x 106 MNC. cDNA and RQ-PCR reactions were performed according to the EAC 
protocol.3
Because the control gene transcripts were the topic of our study, their absolute copy numbers could 
not be used to correct for the quantity and quality of the RNA. Therefore, ratios between copy numbers 
of the different control genes were used to determine whether they showed comparable degradation 
rates. Statistical analysis (mixed model with type of sample protocol (1/2/3), sample type (BM/PB), 
leukemia type (ALL/AML/CML), and time (0/1/2/3/4 days) as variables) showed that for none of the 
three ratios (ABL/B2M, ABL/GUS, and GUS/B2M) the type of protocol had a significant effect, indicating 
that the stability of the control gene transcripts is comparable between leukemic cells and normal cells, 
also during therapy. Therefore, for subsequent analyses, data from the three different sample protocols 
were combined.
We subsequently analyzed the stability of fusion gene transcripts. It should be noted that at arrival 
of the sample in the laboratory it was not known whether the newly diagnosed leukemia harbored a 
fusion gene transcript (sample protocol 1 and 2) or whether MRD was present during follow-up (sample 
protocol 3). Consequently, the number of patients that could be analyzed for individual fusion gene 
transcript was generally low (one MLL-AF4; two TEL-AML1; three BCR-ABL p190; three AML1-ETO; two 
PML-RARA; one CBFB-MYH11; 18 BCR-ABL p210). Therefore, no statistical analysis was performed 
per type of fusion gene transcript and data were analyzed independent of the type of sample protocol 
and the sample type (except for BCR-ABL p210). As the fusion gene/control gene transcript ratio in 
follow-up samples or diluted diagnostic samples is obviously lower than the ratio in diagnostic samples, 
the ratio at day 0 was set at 1 and the ratio at the subsequent days was expressed relative to day 0. 
In order to obtain data on the absolute degradation rate of gene transcripts over time, we evaluated 
the stability of the three control gene transcripts (ABL, B2M, and GUS) in PB samples obtained from 
healthy subjects, using an in vitro transcribed non-human RNA as an exogenous internal positive control 
in order to correct for variations in MNC number, RNA isolation, and cDNA synthesis. Whole PB samples 
(n=12) were divided into four tubes. From tube 1, MNC were immediately separated by Ficoll density 
centrifugation, counted, and lyzed (first step RNA isolation). Per 1 x 106 cells, 5 µl of exogenous control 
RNA (1000-fold diluted; kindly provided by Wanli Bi, Applied Biosystems, Foster City, CA, USA) were 
added, followed by completion of the RNA isolation, cDNA synthesis, and RQ-PCR analysis. Tubes 2-4 
were processed identically at day 1-3.
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RESULTS
Comparison of control gene transcript ratios between BM and PB samples 
showed significant differences (Figure 1). The ABL/B2M and GUS/B2M ratios 
differed significantly between PB and BM at day 1, day 2, and day 4, with higher 
ratios in BM (Figure 1A and B). In contrast, the ABL/GUS ratio did not differ between 
BM and PB (data not shown) and did not change significantly over time (Figure 1C). 
These effects were comparable between the three main leukemia types. Overall, 
these data indicate that (1) the stability of ABL, GUS, and B2M is comparable 
among ALL, AML, and CML cells; (2) ABL and GUS transcripts have a comparable 
degradation rate between BM and PB; and (3) B2M transcripts show a higher 
degradation rate than ABL and GUS transcripts in BM, but not in PB.
Although the mean stability of most fusion gene transcripts seemed to be 
comparable to the control genes (as reflected by a constant ratio around 1), large 
differences in stability could be observed between patients expressing the same 
fusion gene transcript. For example, the maximum and minimum fusion gene/
control gene transcript ratio (i.e. the assumed MRD level) in individual samples 
could differ up to 25-fold for AML1-ETO (at day 2), more than 100-fold for BCR-
ABL p210 normalized to B2M (day 2, 3, and 4), and up to 40-fold for BCR-ABL 
p210 normalized to ABL or GUS (day 2, 3, and 4). An example is shown in 
Figure 2 for the ratio between BCR-ABL p210 and ABL in PB samples of CML 
patients processed at five subsequent days. Apparently, the stability of the fusion 
gene transcripts can vary substantially between different patients. Consequently, 
MRD data obtained from samples that are not processed immediately after sampling 
may not accurately reflect actual fusion gene transcript levels.
Experiments to obtain data on the absolute degradation rate of gene transcripts 
over time, showed that the exogenous control normalized CT values of all three 
control gene transcripts increased with time and generally an increase of 1 CT was 
observed on consecutive days (data not shown). These results indicate that the 
absolute degradation rate is approximately 50% per day (i.e. an increase of the CT 
value with one cycle) in PB MNC.
DISCUSSION
Although our data are based on a limited and heterogeneous set of samples, 
they clearly indicate that transcripts are rapidly degraded ex vivo and that the rate 
of degradation can differ between different types of transcripts, between PB and 
BM, and between patients. As such differential degradation will result in an over- or 
underestimation of MRD levels, samples should preferably be processed on the day 
of sampling; this processing should include at least the Ficoll density centrifugation-
based separation of MNC and the cell lysis step of the RNA extraction. Even better, 
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Figure 1. Stability of control genes over time.
Whole BM or PB samples were obtained from patients with leukemia at diagnosis or during follow-up. A 
total of 64 samples was obtained from 26 AML patients (21 BM, five PB), 22 CML patients (five BM, 17 
PB), and 16 ALL patients (six BM, 10 PB; 12 precursor-B-ALL and four T-ALL patients).
(A) The ABL/B2M ratio differed significantly between BM and PB samples at day 1, 2, and 4. The ABL/
B2M ratio in BM samples at day 1, 2, 3, and 4 was also significantly higher than at day 0. These effects 
were comparable between the three types of leukemia and therefore the combined data of the three 
leukemia types are shown.
(B) The GUS/B2M ratio in all three leukemia types was significantly different between BM and PB at day 
1, 2, and 4. Because the GUS/B2M ratio was significantly lower in ALL than in AML and CML,4 only the 
GUS/B2M ratio in ALL is shown.
(C) In agreement with previous results,4 the ABL/GUS ratio was significantly higher in ALL as compared 
to AML and CML. Nevertheless, the ABL/GUS ratio did not differ between BM and PB and remained 
stable during the four day time period in all three leukemia types; consequently combined data of BM 
and PB samples are shown for each leukemia type. Symbols: *, P<0.05 relative to t=day 0; #, P<0.05 
BM vs PB (mixed model analysis).
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because changes in transcript levels can already occur within the initial 4 h,5 
samples should be collected in tubes with immediate stabilization of intracellular 
RNA, thereby preventing any degradation of control gene and/or fusion gene 
transcripts. Such reagents for stabilization of RNA have recently successfully been 
applied in a multi-center study.8
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ABSTRACT
BCR-ABL rearrangements represent the hallmark of chronic myeloid leukemia 
(CML). The breakpoints are usually clustered in the major breakpoint cluster region 
(BCR) and only sporadically, cases with breakpoints in the micro-BCR (µ-BCR) 
region are reported. In a new case of CML showing a µ-BCR-ABL rearrangement, 
we identified the DNA breakpoint sequence of the e19a2 junction using a ligation-
mediated polymerase chain reaction (LM-PCR). Two other e19a2 junctions (one 
in a previously reported AML patient and one in the AR230 cell line) were also 
identified using this LM-PCR approach. 
Breakpoints within the µ-BCR were located within a 393 bp stretch in the 
downstream part of intron 19, while ABL breakpoints were scattered over a ~24 kb 
region. At the coupling of the BCR and ABL intronic sequences, no insertions or 
duplications of sequences were found. Notably, in two out of three cases the break 
in the ABL gene was located within or near an Alu element. 
This is the first report in which the exact DNA breakpoint sequences in e19a2 
junctions are identified by LM-PCR. Such DNA sequences may potentially be used 
as patient-specific PCR targets for monitoring minimal residual disease. 
INTRODUCTION
The Philadelphia chromosome (Ph) derives from a balanced translocation 
between chromosomes 9 and 22, and results in a BCR-ABL fusion gene. In the 
vast majority of Ph+ leukemias, breakpoints in the ABL gene are distributed over 
a ~200 kb breakpoint region between exons 1b and a2, while breakpoints in the 
BCR gene are clustered in three well-defined regions.1 The major breakpoint 
cluster region (M-BCR) is a ~2.9 kb chromosomal region between exons 13 and 
15.1 The breakpoint can be detected in more than 95% of chronic myeloid leukemia 
(CML) and can lead to two types of mRNA molecules (e13a2 or e14a2, formerly 
assigned as b2a2 and b3a2), both encoding a p210BCR-ABL fusion protein. The minor 
breakpoint cluster region (m-BCR) spans a ~55 kb intronic sequence between 
the two alternative exons 1 and 2. The corresponding e1a2 fusion gene transcript 
encodes the p190BCR-ABL fusion protein and is frequently associated with Ph+ acute 
lymphoblastic leukemia. The micro-breakpoint cluster region (µ-BCR) spans a 
~1 kb sequence which is located in intron 19 of the BCR gene. The corresponding 
fusion gene transcript e19a2 results in a 230 kDa protein. The e19a2 fusion gene 
was initially described to be associated with neutrophilic-CML (N-CML), a mild Ph+ 
myeloproliferative disease with only rarely progression, but in later reports e19a2 
fusion gene transcripts were also found in classical CML and in acute myeloid 
leukemia (AML).2,3 
Here, we report in a new case of CML with an e19a2 transcript the fusion at 
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the DNA level between BCR and ABL genes by using ligation-mediated PCR (LM-
PCR). Additionally, the genomic µ-BCR-ABL breakpoints in an e19a2-positive AML 
and the AR230 cell line were identified.
PATIENTS, MATERIALS AND METHODS
Clinical course
In January 1999, a 69-year-old female was referred to the hospital with a leucocytosis of 130 x 
109/l and immature granulocyte precursors. A bone marrow (BM) aspirate showed an increased 
cellularity with a myeloid/erythroid ratio of 10. Cytogenetic analysis revealed three pathological clones: 
46,XX,t(9;22)(9q34;22q11)[10]/47,XX,idem,+der(22)t(9;22)[2]/46,XX,der(9)t(9;22),idic(22)(22pter→
22q11:9q34:9q34:22q11→22pter)[2], supporting the diagnosis of CML in acceleration. An e19a2 fusion 
gene was identified by RT-PCR analysis using a BCR exon 19 primer (Table 1) and two previously 
described ABL exon a3 primers.1 She was treated with hydroxyurea (HU) and showed a hematologic 
response. In May 2002, her BM showed 11% blasts. Gleevec® was started, but soon discontinued 
because of side effects. HU was restarted, but in December 2002 the patient deceased due to disease 
progression.
Ligation-mediated polymerase chain reaction and sequencing
To determine the DNA breakpoint region of the µ-BCR-ABL rearrangement in this CML as well as 
in a previously reported e19a2-positive AML and the e19a2-positive AR230 cell line, an LM-PCR was 
performed.3-5 DNA (1 µg) was digested with 30 U blunt end restriction enzymes (DraI, PvuII, HincII, 
and StuI). To both ends of the restriction fragments, 25 µM of adaptor DNA was ligated.5 The ligation 
Table 1. Sequences (5’–3’ sequence) of the primers used in this study.
Primers used for RT-PCR analysis
  BCR-e19 TTC GGA GTC AAG ATT GCT GTG
  ABL-a3 (B and E3’) see BIOMED-1 report (ref. 1)
Primers used for first round LM-PCR
  BCR-LM1 GGA GGT GGG CAT CTA CCG
  AP1 see Przybylski et al. (ref. 5)
Primers used for second round LM-PCR
  BCR-LM2 CGG ACA TCC AGG CAC TGA A
  AP2 see Przybylski et al. (ref. 5)
Primers used for sequencing
  µBCR-sCML CCT TCC TGC TAT CAG ACG AC
  µBCR-sAML CTT CTT TGG GGC ACA CAC
  µBCR-sAR230 CCA GGA CCC CTA GAA TGC
Primers used for confirmation PCR
  µBCR-cCML GGG ATG GTG GGA GAC TCA
  µBCR-cAML CCA GGA CCC CTA GAA TGC
  µBCR-cAR230 GCA GGG GTG GTT GCT ATG
  ABL-cCML GGC CCT TTC ATT CAA CG 
  ABL-cAML CCC GAC CAG TGG ATG ATG
  ABL-cAR230 TTC TGG AAT GGC TGG TAA AC
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products were subjected to two PCRs, essentially performed as described before.5 Briefly, a 50 µl 
reaction contained 1 µl of ligation products, 10 pmol of AP1 primer and BCR-LM1 primer (Table 1), 10 
mM dNTP (Amersham Biosciences Corp., Piscataway, New Jersey, USA), 2U rTth (Applied Biosystems, 
Foster City, CA, USA), and 1.5 mM Mg(OAc)2. Subsequently, a second round PCR was performed 
using 1 µl of the first-round PCR product and 10 pmol of the internal AP2 and BCR-LM2 primers 
(Table 1). Specific primers (Table 1) were used for direct sequencing of the gel-extracted bands (Zymoclean 
gel DNA recovery kit, Zymo Research, CA, USA). The presence of µ-BCR-ABL rearrangements was 
confirmed by PCR analysis performed on undigested genomic DNA using µ-BCR- and ABL-specific 
primers (Table 1). 
RESULTS
DNA was digested with DraI, PvuII, HincII, and StuI restriction enzymes: ten 
restriction sites were found in the germline BCR sequence between exons 18 and 
21 (Figure 1A). The first-round LM-PCR identified germline PCR products of 253, 
1992, 1679, and 1317 bp in DraI, PvuII, Hinc II, and StuI digests, respectively, 
while the second-round LM-PCR gave germline PCR products of 206, 1945, 1632, 
and 1270 bp, respectively. In the AR230 cell line, an additional non-germline PCR 
product of 1014 bp was identified after the second PCR of HincII digested and 
amplified DNA, while nested LM-PCR of the CML patient and the AML patient 
revealed additional PCR products of 1469 and 1086 bp, respectively, in PvuII 
digested DNA (Figure 1B). Direct sequencing of the gel-extracted bands identified 
all three genomic µ-BCR-ABL fusion sites (Table 2). At the fusion site of BCR and 
ABL intronic sequences, no insertions or duplications of nucleotides were found. 
The three µ-BCR breaks occurred in a 393 bp stretch of intron 19. In the 
CML patient, almost the entire sequence of intron 19 was preserved, with only 
six nucleotides deleted. The BCR breakpoint in AR230 was also located in the 
Figure 1.
(A) Schematic representation of the BCR gene. In total, 10 restriction sites of DraI (D), PvuII (P), HincII 
(H), and StuI (S) in the BCR gene between exons 18 and 21 are shown. The bold arrows show the 
location of the µ-BCR DNA breakpoints in the AML patient, the CML patient, and the AR230 cell line 
(Genbank accession code: U07000).
(B) Agarose gel electroforesis of amplified DNA after nested LM-PCR. Results of germline controls (gc), 
the AML patient, the CML patient, and the AR230 cell line are shown. Germline bands of 1945 and 1632 
bp were found in PvuII and HincII digested DNA, respectively. Additional bands (encircled) differing in 
size from the germline control were seen in PvuII digested DNA of the AML patient (1086 bp) and the 
CML patient (1469 bp), and in HincII digested DNA of the AR230 cell line (1014 bp). *100 bp ladder; 
** λ/PstI DNA ladder.
(C) Schematic representation of the ABL gene showing the approximate location of the breakpoint 
regions in the first intron of the ABL gene. A, B and C indicate breakpoint regions, respectively, 30 kb ± 5, 
100 kb ± 13, and 135 kb ± 8 downstream from exon 1b, involved in M-BCR rearrangements.8 D indicates 
the ABL breakpoint region involved in the three µ-BCR rearrangements, which is located 162 ± 12 kb 
downstream from exon 1b. The bold arrows show the precise location of the ABL DNA breakpoints in the 
AR230 cell line, the CML patient and the AML patient (Genbank accession code: U07563).
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downstream part of intron 19, while in the AML patient, the break occurred more 
towards the middle of intron 19 (Figure 1A). 
Breakpoints in the ABL gene were distributed over ~24 kb at the 3’end of the 
first ABL intron (Figure 1C). In the CML patient, the ABL breakpoint occurred within 
an Alu element, and in the AR230 cell line Alu repeats were located within 400 bp 
at both sides of the breakpoint. No repeats were found in the µ-BCR breakpoint 
region. 
DISCUSSION
This is the first study in which LM-PCR was used to identify the exact DNA 
breakpoints in the ABL and BCR genes in e19a2 junctions. The low incidence of 
e19a2 junctions may partly be caused by the relatively short length of intron 19 
(~1 kb) as compared with m-BCR (~55 kb) and M-BCR (~2.9 kb). Currently, primary 
factors that determine the preferential breakage sites in the BCR and ABL genes 
are unknown. It has been proposed that high densities of repetitive DNA, such as 
Alu elements, could provide hot spots for homologous recombination and mediate 
chromosomal translocation. The characterization of genomic DNA breakpoints in 
CML with BCR-ABL translocations has been reported.6,7 In some cases, the BCR 
gene preferentially recombined with Alu elements; however, no unique pattern 
explained all DNA breaks. In our study, the µ-BCR recombined with regions close 
to or within Alu elements of the ABL gene in two out of three cases. 
Conflicting data are reported with regard to the breakpoint sites in the ABL gene 
in CML. Nonrandom chromosomal breakpoints within the first intron of ABL have 
been suggested, with three breakpoint cluster regions downstream from exon 1b.8 
However, others reported equally dispersed breaks over intron 1b without any 
clustering.9 The ABL breaks in our three e19a2 junctions were scattered over a 
~24 kb region at the 3’ part of intron 1b. During transcription exon 1a is probably 
spliced out, resulting in the BCR exon 19/ABL exon a2 mRNA junction. 
Transcription of the p230 BCR-ABL gene in the great majority of patients with 
N-CML is extremely low: the level of p230BCR-ABL transcripts in untreated N-CML 
patients was similar to the level of p210 BCR-ABL transcripts in typical CML patients in 
cytogenetic remission after interferon-α treatment.10 This low transcription level of 
Table 2.  µ-BCR-ABL DNA breakpoint sequences for the three e19a2 junctions amplified 
by LM-PCR. 
µ-BCR-ABL
CML CCGCTGCATTTCCGTGCTCTCATCCTGCCGGGCGCGATGG 
AML TGTAAGCACCAATGGCCAATTAATGACATCCTGGCCGAGAA
AR230 TGGGAGGAGTCAGATGAGCTGTATGGCCCAGTCAAGTTGAC
The BCR sequence is underlined. Overlapping sequences of BCR and ABL genes are depicted bold. 
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the p230 BCR-ABL gene in most patients may hamper the use of RT-PCR at diagnosis 
and particularly during follow-up, which can be overcome by using genomic DNA 
breakpoint fusion sites as PCR targets. However, because the DNA breakpoint 
fusion regions, particularly of the ABL gene, are scattered over large regions and 
differ in each patient, special methods are needed for identification of these DNA 
breakpoint fusion sites. In our study, we used an LM-PCR to identify the e19a2 
fusion at the DNA level. 
Patient-specific DNA breakpoint fusion sites may be attractive PCR targets for 
monitoring of minimal residual disease (MRD) by real-time quantitative PCR using 
an allele-specific reverse primer positioned at the breakpoint area of the fusion 
genes, in combination with a µ-BCR-specific forward primer and probe. DNA targets 
for disease monitoring have several advantages over RNA targets, including low 
degradation rate, easy quantification (as only one target per cell is present), and 
stability throughout the disease course.
In conclusion, using LM-PCR, we identified DNA sequences of three e19a2 
junctions which may potentially be used as patient-specific DNA targets for 
monitoring of MRD. Although Alu elements might be involved in some µ-BCR-ABL 
rearrangements, further studies on a larger series of e19a2-positive leukemias are 
needed to better understand the mechanisms by which µ-BCR-ABL DNA breaks 
are mediated. 
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CHAPTER 3.1
Clinical applications of molecular and flow cytometric
diagnostics in detecting minimal residual disease and 
evaluating therapy efficacy in myeloid leukemia
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1. CLASSICAL APPLICATIONS
MRD studies in myeloid leukemia using molecular as well as flow cytometric 
approaches have shown that monitoring of residual disease may help to assess the 
efficacy of treatment and enables the identification of particularly patients at high 
risk of relapse.1-3 
The treatment effectiveness of new therapeutics (e.g. imatinib mesylate (IM)) 
targeting the molecular base of the disease, can accurately be monitored by 
real-time PCR. In Chapter 3.4 is shown how the currently available molecular 
techniques can provide inside into treatment effectiveness of IM in advanced CML 
after allogeneic bone marrow transplantation. 
The kinetics of tumor load reduction during therapy as well as the increase of 
tumor cells at the time of relapse can be monitored by RQ-PCR analysis of fusion 
gene transcripts both in bone marrow (BM) and in peripheral blood (PB) samples. 
Comparing the RQ-PCR results of paired PB-BM samples is essential to evaluate 
the possibility of safely replacing BM by PB for PCR-MRD monitoring in clinical 
settings. As the regular collection of BM aspirates is a rather traumatic experience, 
especially in children, it would be beneficial if BM sampling could be replaced by PB 
sampling. In Chapter 3.3 we focused on paired samples of CBFB-MYH11 positive 
AML. 
2. SPECIFIC APPLICATIONS 
In addition to the “classical” clinical applications of molecular and flow cytometric 
techniques for MRD detection and evaluating therapy efficacy in myeloid leukemia, 
both techniques can be applied for other purposes as well (Table 1). In Chapter 
3.2 is shown how several molecular and flow cytometric techniques can be used to 
confirm or exclude the common origin of two phenotypically different malignancies 
in the same patient. 
Flow cytometric assessment of the expression of certain antigens (e.g. CD33) 
on leukemic blast cells is currently used to guide therapeutic options with antibody 
targeted therapy (e.g. gemtuzumab ozogamicin (GO)). Only 30% of CD33+ 
AML patients enter a complete remission using GO; several mechanisms of GO 
resistance and treatment failure have been proposed. We investigated whether a 
high circulating CD33-antigen burden compromises the drug delivery to the BM, 
thereby limiting the efficacy of GO treatment in AML patients (Chapter 3.5).
Early diagnosis of AML in monozygotic twins and evaluation of Guthrie 
cards
The concordance of acute leukemia in infant or childhood monozygote twins 
has been recognized to be extraordinarily high.4 The likely explanation is blood 
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chimerism: initiation of leukemia in one twin in utero, is followed by a spread to the 
co-twin by the vascular anastomoses that commonly exist within monochorionic 
placenta.5 The intraplacental “metastasis” is endorsed by the demonstration of 
the presence of clonotypic sequences in archived Guthrie cards of both twins.6 
Clonal markers used in twin leukemia studies have been fusion genes and/or 
Ig/TCR gene rearrangements.7-9 As concordant AML can develop at different 
ages10,11, using molecular or flow cytometric techniques, it is possible to detect or 
exclude the presence of the AML clone in the unaffected monozygotic twin. 
Guthrie cards have also been used to demonstrate the prenatal origin in infant 
and childhood acute leukemia. Recently in pediatric AML, MRD-PCR analyses of 
Guthrie cards of childhood AML1-ETO + AML patients showed the presence of the 
AML1-ETO fusion genes at birth in a substantial number of patients.12
Evaluation of MRD in autologous stem cell products to guide purging 
decisions in AML
A major drawback of the reinfusion of autologous BM or peripheral blood stem 
cell (PBSC) products is its possible contamination with residual malignant cells. 
The presence of MRD in the graft may contribute to relapse.13 Studies showed 
that AML patients, who were autografted in first remission with purged stem cells, 
had a lower relapse rate and a longer leukemia-free survival compared to patients 
receiving unpurged transplants.14 A major limitation of applying purging concerns 
the high toxicity of the purging procedure for normal progenitors/stem cells, with the 
Table 1.  Clinical applications of molecular and flow cytometric techniques for MRD detection
and evaluating therapy efficacy in AML.
Classical applications 
- identification of AML patients at high risk of relapse based on the MRD-levels at specific time points
     during therapy
- evaluation of the treatment effectiveness in CML after allogeneic bone marrow transplantation and 
     recognition of early relapse to guide therapeutic interventions (e.g. donor lymphocyte infusions)
- early detection of molecular relapse in APL to guide therapeutic interventions
Specific applications
- evaluation of Guthrie cards to demonstrate the prenatal origin in infant and childhood AML
- evaluation of Guthrie cards and blood samples of monozygotic twins in case of AML diagnosis
     (early diagnosis in the second twin and investigation of clonal relationship between the AML cells 
     in both twins)
- assessment of CD33 expression on leukemic blast cells to guide therapeutic options with antibody 
     targeted therapy
- evaluation of autologous stem cell products to guide purging decisions
- detection of bone marrow involvement during ‘isolated’ extramedullary AML (skin, CNS or testicular 
     infiltration) 
- assessment of a common origin of two phenotypically different malignancies in the same patient
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potential danger of increased morbidity and/or toxicity. However, the MRD frequency 
in PBSC products is predictive for duration of relapse free survival.15 Using flow 
cytometric immunophenotyping, it becomes feasible to measure the MRD burden 
in the PBSC products based on leukemia-associated phenotypes established at 
AML diagnosis. A recent study proposed an MRD-based model that could be used 
to guide the decision whether or not to purge PBSC products.16
Evaluation of bone marrow involvement during “isolated” extramedullary 
AML 
Extramedullary manifestations of AML include skin and gingival infiltrates, 
involvement of central nervous system (CNS), and testicular infiltration. Skin 
infiltration in AML patients usually occurs at presentation with BM disease. However, 
skin disease can precede BM infiltration up to 6 months (aleukemic leukemia 
cutis)17,18 and skin infiltration may be a first sign of relapse, even if the skin was not 
involved at initial diagnosis. 
Testicular infiltration in AML is rare and occurs predominantly in myelomonocytic 
or monoblastic leukemia. Cases of AML mimicking a primary testicular neoplasm 
have been reported.19 The majority of patients subsequently progress to overt AML, 
but testicular infiltration can precede an overt AML with a median duration of 10.5 
months.20 Testicular relapses of AML can occur simultaneous with a BM relapse in 
1-2% of patients,21 but also “isolated” testicular relapses in the absence of systemic 
relapse have been reported; most of these patients experienced however BM 
relapse within 2 months after the recognition of the testicular relapse.21 A testicular 
biopsy showing infiltration of the testicular tissue with malignant cells of myeloid 
origin should be considered as a harbinger of systemic leukemia. 
Both flow cytometric and molecular techniques can be used to recognize 
sub-microscopic BM involvement in cases of primary or relapsed “isolated” 
extramedullary AML.
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ABSTRACT
We describe a case of a 38-year old male with inv(16)(p13q22) positive acute 
myeloid leukemia (AML) with eosinophilia, relapsing after a molecular remission 
of almost three years. Remarkably, the leukemia at relapse was identified as a 
precursor-B-cell acute lymphoblastic leukemia (B-ALL) by cytology and 
immunophenotyping, but was inv(16)(p13q22) positive as revealed by interphase 
FISH, FICTION analysis, and real-time quantitative PCR. Analysis of immunoglobulin 
and T-cell receptor genes showed a bi-allelic DH2-JH rearrangement at relapse, but 
not at diagnosis. These findings indicate a myeloid to lymphoid lineage switch from 
an inv(16)(p13q22) positive leukemia and show that IGH gene rearrangements can 
occur in the presence of CBFB-MYH11 fusion transcripts.
INTRODUCTION
Lineage switch is a rare event in acute leukemia at relapse, and usually concerns 
a therapy-related switch from ALL to AML late in the disease course.1 Conversion 
of AML to ALL has only been reported in five cases, with a rather short time from 
diagnosis to conversion and without stable genotypic aberrations.2 Here, we report 
clinical and laboratory features of an adult patient with inv(16)(p13q22) positive 
AML with eosinophilia, who relapsed with inv(16)(p13q22) positive precursor-B-
ALL.
MATERIALS AND METHODS
Case report
A 38-year old man was admitted to the hospital in February 1998 with a history of fatigue. Laboratory 
studies revealed a hemoglobin of 4.87 g/dl, a white blood count of 14.8 x 109/l with 41% blasts, and 
a platelet count of 31 x 109/l. A bone marrow (BM) aspirate contained 68% blasts and 15% aberrant 
eosinophils (Figure 1). Based on morphology and cytochemical stainings, it was classified as an 
AML-M4Eo according to the French-American-British classification. Cytogenetic analysis showed 
46,XY,inv(16)(p13q22) and real-time quantitative PCR (RQ-PCR) analysis confirmed a CBFB-MYH11 
type A fusion gene transcript. With intensive chemotherapy according to an AML treatment protocol, he 
achieved molecular remission. After a molecular BM relapse in August 1999, he underwent an allogeneic 
stem cell transplantation (SCT) and remained in molecular remission for almost three years. In August 
2002, RQ-PCR became positive again for the CBFB-MYH11 type A fusion gene transcript, with a BM 
relapse of a precursor-B-ALL (CD10+CD19+) four months later. Cytogenetic analysis was not done. A 
CBFB-MYH11 fusion gene was found by RQ-PCR analysis. Re-induction therapy and donor lymphocyte 
infusions were given, but in May 2003 the patient relapsed again with inv(16)(p13q22) positive B-ALL. 
He deceased in July 2003 because of multiple organ failure within two weeks after a second allogeneic 
SCT. 
BM and PB samples obtained at diagnosis, during follow-up and relapse were used for flow 
cytometric and molecular investigations. 
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Flow cytometric immunophenotyping 
Lysed whole blood or BM was stained using directly conjugated monoclonal antibodies. The 
specificity and source of the antibodies are summarized in Table 1. At diagnosis, measurements were 
performed on a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA) by double labelling 
and blast cells were gated by their FSC-SSC characteristics. At relapse, cells were analysed on a 
FACSCalibur (Becton Dickinson) and gated by their CD45-SSC characteristics.
Real-time quantitative polymerase chain reaction
BM and PB samples were analysed by RQ-PCR. RNA was isolated from frozen mononuclear cells 
using the QIAamp Blood Kit (Qiagen, USA). The cDNA synthesis (40 µl) was performed using 200 
units of M-MLV Reverse Transcriptase (GIBCO BRL), 25 µM Random Hexamers (Amersham Pharmacia 
Biotech, USA) and 2 µg RNA. A 25 µl RQ-PCR reaction mixture contained TaqMan Universal PCR 
Master Mix 2x (Applied Biosystems, Foster City, CA, USA), 300 nM primers, 200 nM TaqMan probes 
and 5 µl of cDNA. Primer-probe sets were published elsewhere.3-4 Detection of PCR products was based 
on TaqMan technology using the ABI PRISM 7900 Sequence Detection System (Applied Biosystems). 
Standard curves were established using serial dilutions of CBFB-MYH11 type A or β-glucuronidase 
(GUS) plasmids (Ipsogen, Marseille, France). The copy numbers of the CBFB-MYH11 fusion gene 
transcript were normalized to GUS. 
Analysis of immunoglobulin and T-cell receptor gene rearrangements
DNA was isolated from frozen mononuclear cells and PCR analysis of IGH, IGK-Kde, TCRG, 
and TCRD gene rearrangements was performed as described previously.5 For detection of Vδ2-Jα 
rearrangements, 7 multiplex tubes, each containing one Vδ2 primer and 8 to 10 Jα primers, were used. 
TCRB rearrangements were analysed using BIOMED-2 primers.6-7 The obtained PCR products were 
subjected to heteroduplex analysis and clonal rearrangements were subsequently sequenced using the 
Big Dye-terminator cycle sequencing kit and an ABI 377 automated sequencer (Applied Biosystems) as 
described previously.8-9 
Chimerism studies
Short tandem repeats (STR) and the amelogenin locus were amplified using the AmpFLSTR SGM 
and Profiler PlusTM PCR Amplification Kits (Applied Biosystems, Lennik, Belgium), according to the 
diagnosis relapse
Figure 1.
Morphological features (May Grünwald Giemsa staining) at presentation and relapse. At diagnosis (left), 
the BM contained 68% blasts and 15% aberrant eosinophils. The relapse (right) BM showed 49% blast 
cells and 0.5% eosinophils.
Chapter 3.2120
manufacturer’s instructions. The PCR products were analysed on the ABI 3100 genetic analyser. For 
informative STRs, the height of the donor-derived allele was divided by the sum of the heights of donor 
and receptor alleles. The percentage donor chimerism is the average of this value for all informative 
STRs, multiplied by 100.
FISH and FICTION analysis
FISH (fluorescence in situ hybridization) was done on a relapse BM smear using the LSI CBFB 
dual color break apart probe for the region 16q22, as described by the manufacturer (Vysis Abbott 
Laboratories, IL, USA). 200 interphase nuclei were scored. FICTION (fluorescence immunophenotyping 
and interphase cytogenetics as a tool for the investigation of neoplasms) using anti-CD10 (clone:W8E7, 
Becton Dickinson) and the LSI CBFB dual color break apart probe for the region 16q22 was done on a 
follow-up BM smear as described elsewere.10
RESULTS
At diagnosis, flow cytometric analysis showed CD13+CD33+MPO+ myeloblasts 
co-expressing CD19 and with partial expression of TdT (Table 1, Figure 2), 
cytogenetic analysis showed 46,XY,inv(16)(p13q22) and RQ-PCR confirmed a 
CBFB-MYH11 type A fusion transcript (Figure 3). 
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Figure 2.
Immunophenotypical features at presentation and relapse. Upper plots: diagnostic BM sample showing 
CD13+CD33+CD34+CD19+ myeloblasts. Lower plots: triple labelling of the relapse BM sample showing 
CD13-CD33-CD34+CD19+ B-lymphoblasts. 
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Table 1.
Diagnosis Relapse (59 months)
Cytomorphology AML-M4Eo (FAB) Acute leukemia
Percentage of blasts in BM 68 (67% on ANC) 49 (36% on ANC)
Percentage of eosinophils in BM 15 0.5
Cytochemistry
Peroxidase positive negative
Immunophenotype 
Percentage of blast cells on ANC 51 10 
                                               (% positivity within the gated blast cell population)
CD34 (8G12)a 70 92
CD117  (95C3)b 48 0
TdT (HT-6)c 48 84
HLA-DR (L243)a 98 ND
CD13 (L138)a 58 14
CD15 (MMA)a 61 4
CD33 (P67.6)a 87 0
CD65 (VIM2)d 85 ND
MPO (MPO-7)e 80 0
CD10 (HI10a)a 0 87 (strong)
CD19 (4G7)a 80 87
CD20 (L27)a 0 25
CD24 (ALB9)b 1 64
CD2 (S5.2)a 0 ND
Immunogenotype
Karyotype 46,XY,inv(16)(p13q22) ND
RT-PCR CBFB-MYH11, type A + CBFB-MYH11, type A + 
MLL-AF4 -
BCR-ABL -
FISH (probe: CBFB) ND split signal in 15% 
IGH gene no rearrangement detected DH2.2-JH6b (-2/12/-9)
DH2.15-JH5b (-8/5/-4)
IGK gene no rearrangement detected no rearrangement detected
TCRD, TCRG, TCRB gene no rearrangement detected no rearrangement detected
DNA profile 100% receptor 100% receptor
ANC: all nucleated cells, ND: not done
a Beckton Dickinson, San Jose, CA, USA; b Immunotech/Coulter, Marseille, France; c IKT diagnostics,
Uithoorn, The Netherlands; d Caltag, San Francisco, CA, USA; e DAKO, Glostrup, Denmark.
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At relapse, immunophenotypic analysis revealed a CD10+CD19+ 
precursor-B-ALL with 10% leukemic B-lymphoblasts and without leukemic 
myeloblasts (Table 1, Figure 2). High levels of CBFB-MYH11 type A fusion transcripts 
were found by RQ-PCR (Figure 3), while MLL-AF4 and BCR-ABL were not 
present. Chimerism studies identified a 100% recipient DNA profile. FISH analysis 
showed a split signal in 15% of 200 nuclei (Figure 4). Additional FICTION analysis 
identified CD10 positive mononuclear cells displaying a split signal indicative of 
inv(16)(p13q22) (Figure 4). CD10 negative cells had normal hybridisation signals. 
Split signals were detected exclusively in the CD10 positive cells. 
PCR heteroduplex analyses of IGH, IGK-Kde, TCRG, TCRB, and TCRD gene 
rearrangements, was performed on diagnostic and relapse samples. No Ig/TCR 
gene rearrangements were found at diagnosis, but bi-allelic DH2-JH rearrangements 
were found at relapse (Table 1). Two patient specific DH2-JH RQ-PCR assays were 
developed and reached a sensitivity of 10-4/10-5. RQ-PCR on the diagnostic AML 
showed no specific DH2-JH products.
DISCUSSION
Conversions from AML to ALL are extremely rare, with only three pediatric and 
two adult cases reported.2 In these cases, the interval between diagnosis and 
conversion was rather short (range: 10-13 months), in contrast to our patient where 
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Figure 3.
RQ-PCR analysis of CBFB-MYH11 transcripts at presentation and relapse. The normalized copy numbers 
of the CBFB-MYH11 type A fusion transcripts are shown as a function of time. ◊ represent CBFB-MYH11 
fusion transcripts in PB, ■ represent CBFB-MYH11 fusion transcripts in BM. MR: molecular relapse. 
HR: hematological-morphological relapse. SCT: stem cell transplantation.     
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the interval between AML and ALL was 59 months. Moreover, the clonal relationship 
between diagnosis and relapse was not reported in these published patients. 
The present patient is exceptional because he developed a precursor-B-ALL that 
was clonally related to his previous AML, as demonstrated most convincingly by 
FICTION analysis. To our knowledge, this is the first patient with CBFB-MYH11-
positive precursor-B-ALL. It has to be assumed that the malignant clone withstood 
chemotherapy and allogeneic transplantation, but stayed under the detection limit 
(10-5) of our current RQ-PCR assay during almost three years.
Sixteen cases of donor cell leukemia (DCL) after transplantation for leukemia 
have been reported, including one case with a t(9;22)(q34;q11) in recipient and 
donor leukemia.11 A longer interval between transplantation and relapse seems to 
favour the possibility that relapse originates from donor cells. In our case, molecular 
studies excluded the possibility of DCL.12
The AML cells present at diagnosis were CD19 positive, a marker frequently 
correlated with the presence of t(8;21)(q22;q22). Previous studies showed a 
significant association between positivity for B-cell markers and the presence 
of Ig/TCR rearrangements in AML.9 However, no Ig/TCR gene rearrangements 
were found in the AML at diagnosis, whereas bi-allelic incomplete IGH gene 
rearrangements were observed in the precursor-B-ALL at relapse. Probably, 
relapse
+
CD10  cells
–
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Figure 4.
(Left) FISH analysis on a relapse BM smear. On the normal chromosome 16, the green and red signal 
are colocalized yielding a yellow signal. Arrows show split signals indicative of inv(16)(p13q22). 
(Right) FICTION analysis on a follow-up bone marrow smear of May 2003 with 7% residual leukemic 
B-lymphoblast. CD10 positive (intense blue staining) mononuclear cells (lymphoblasts) show split 
signals (arrows) indicative of inv(16)(p13q22). CD10 negative cells (a neutrophil band form is shown) 
have normal hybridisation signals. Split signals were detected exclusively in the CD10 positive cells. 
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activation of recombination activating gene products and TdT was induced when 
the leukemic cells switched from myeloid to B-cell lineage, resulting in the IGH 
gene rearrangements. The presence of CBFB-MYH11 fusion transcripts apparently 
did not block these rearrangements. However, the sole presence of incomplete 
IGH gene rearrangements in the precursor-B-ALL reflects a very immature 
immunogenotype and is found <1% of primary precursor-B-ALL, suggesting that 
the original myeloid origin and/or the presence of CBFB-MYH11 fusion transcripts 
might affect the Ig/TCR gene rearrangement process.13
The presented patient is exceptional because he developed a clonally related 
precursor-B-ALL after AML. Apparently, smouldering malignant cells can be 
present during many years and these cells might have the potential of changing 
their immunophenotype. Alternatively, the CBFB-MYH11 aberration might have 
occurred as a first hit, with separate second hits resulting in the AML-M4Eo at 
first presentation and the precursor-B-ALL at second presentation. However, the 
precise mechanisms to fully explain our findings await further insights.
ACKNOWLEDGEMENTS 
We are grateful to Prof. Dr. N. Blanckaert for his continuous support and to 
J. De Roover, M. Stul, P.G. Hart and B. Emanuel for their technical assistance. 
This work was supported by grant G-9.0224.99 from the Fonds voor Wetenschappelijk 
Onderzoek (FWO) Vlaanderen. P. Vandenberghe is a Clinical Investigator of the 
FWO Vlaanderen.
REFERENCES
1. Stass S, Mirro J, Melvin S, Pui CH, Murphy SB, Williams D. Lineage switch in acute leukemia. Blood 
1984; 64: 701-706.
2. Lounici A, Cony-Makhoul P, Dubus P, Lacombe F, Merlio JP, Reiffers J. Lineage switch from acute 
myeloid leukemia to acute lymphoblastic leukemia: report of an adult case and review of the 
literature. Am J Hematol 2000; 65: 319-321.
3. Gabert J, Beillard E, Van der Velden VHJ, Bi W, Grimwade D, Pallisgaard N, Barbany G, 
 Cazzaniga G, Cayuela JM, Cave H, Pane F, Aerts JL, De Micheli D, Thirion X, Pradel V, 
 Gonzalez M, Viehmann S, Malec M, Saglio G, Van Dongen JJM. Standardization and quality control 
studies of “real-time” quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) of 
fusion gene transcripts for minimal residual disease detection in leukemia - A Europe Against Cancer 
Program. Leukemia 2003; 12: 2318-2357.
4. Beillard E, Pallisgaard N, Van der Velden VHJ, Bi W, Dee R, Van der Schoot E, Delabesse E, 
Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, Van Dongen JJM, Hokland P, Gabert J. 
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic 
patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) 
- a Europe against cancer program. Leukemia 2003; 12: 2474-2486.
Lineage switch from an inv(16) positive leukemia 125
5. Pongers-Willemse MJ, Seriu T, Stolz F, d’Aniello E, Gameiro P, Pisa P, Gonzalez M, 
 Bartram CR, Panzer-Grumayer ER, Biondi A, San Miguel JF, Van Dongen JJM. Primers and 
Protocols for Standardized Detection of Minimal Residual Disease in Acute Lymphoblastic Leukemia 
Using Immunoglobulin and T Cell Receptor Gene Rearrangements and TAL1 Deletions as PCR 
targets: Report of the BIOMED-1 CONCERTED ACTION: Investigation of Minimal Residual Disease 
in Acute Leukemia. Leukemia 1999; 13: 110-118.
6. Droese J, Langerak AW, Groenen PJ, Bruggemann M, Neumann P, Wolvers-Tettero IL, 
 Van Altena MC, Kneba M, Van Dongen JJM. Validation of BIOMED-2 multiplex PCR tubes for 
detection of TCRB gene rearrangements in T-cell malignancies. Leukemia 2004; 9: 1531-1538.
7. Van Dongen JJM, Langerak AW, Brüggemann M, Evans PA, Hummel M, Lavender L, 
 Delabesse E, Davi F, Schuuring E, Garcia-Sanz R, Van Krieken JH, Droese J, Gonzalez D, 
 Bastard C, White HE, Spaargaren M, Gonzalez M, Parreira A, Smith Jl, Morgan GJ, Kneba M, 
Macintyre EA. Design and standardization of PCR primers and protocols for detection of clonal 
immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations. Report of 
the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003; 17: 2257-2317.
8. Langerak AW, Szczepanski T, Van der Burg M, Wolvers-Tettero IL, Van Dongen JJM. Heteroduplex 
PCR analysis of rearranged T cell receptor genes for clonality assessment in suspect T cell 
proliferations. Leukemia 1997; 12: 2192-2199.
9. Boeckx N, Willemse MJ, Szczepanski T, Van der Velden VHJ, Langerak AW, Vandekerckhove P, 
Van Dongen JJM. Fusion gene transcripts and Ig/TCR gene rearrangements are complementary but 
infrequent targets for PCR-based detection of minimal residual disease in acute myeloid leukemia. 
Leukemia 2002; 16: 368-375.
10. Martin-Subero JI, Chudoba I, Harder L, Gesk S, Grote W, Novo FJ, Calasanz MJ, Siebert R. 
Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and 
genetic single cell analyses. Am J Pathol 2002; 161: 413-420.
11. Cooley LD, Sears DA, Udden MM, Harrison WR, Baker KR. Donor cell leukemia: report of a 
case occurring 11 years after allogeneic bone marrow transplantation and review of the literature. 
 Am J Hematol 2000; 63: 46-53.
12. Spinelli O, Giussani U, Borleri G, Lazzari M, Michelato A, Dotti G, Barbui T, Rambaldi A. Need for an 
accurate molecular diagnosis to assess the donor origin of leukemia relapse after allogeneic stem 
cell transplantation. Haematologica 2000; 85: 1153-1157.
13. Van der Velden VHJ, Szczepanski T, Wijkhuijs AJM, Hart PG, Hoogeveen PG, Hop WCJ, 
 Van Wering ER, Van Dongen JJM. Age-related patterns of immunoglobulin and T-cell receptor 
gene rearrangements in precursor-B-ALL: implications for detection of minimal residual disease. 
Leukemia 2003; 17: 1834-1844.

CHAPTER 3.3
Quantification of CBFB-MYH11 fusion gene levels in 
paired peripheral blood and bone marrow samples by 
real-time PCR
Nancy Boeckx1,2, Jan De Roover2, Vincent H.J. van der Velden3, 
Johan Maertens4, Anne Uyttebroeck5, Peter Vandenberghe2,6, 
Jacques J.M. van Dongen3
1Department of Laboratory Medicine, Laboratory of Hematology, 
University Hospital Gasthuisberg, Leuven, Belgium
2Center for Molecular Diagnostics, University Hospital Gasthuisberg, Leuven, Belgium
3Department of Immunology, Erasmus MC, Rotterdam, The Netherlands
4Department of Internal Medicine, Hematology, 
University Hospital Gasthuisberg, Leuven, Belgium
5Department of Pediatrics, University Hospital Gasthuisberg, Leuven, Belgium
6Department of Human Genetics, KU Leuven, Leuven, Belgium
Adapted from letter. Leukemia 2005; 19: 1988-1990.
Chapter 3.3128
ABSTRACT
The inv(16)(p13q22) chromosomal rearrangement is characterized by the 
presence of the CBFB-MYH11 fusion gene transcript that can be used to monitor 
minimal residual disease (MRD). In this study, we evaluated the possibility to 
safely replace bone marrow (BM) sampling by peripheral blood (PB) sampling for 
MRD monitoring in CBFB-MYH11+ acute myeloid leukemia (AML). Therefore, we 
analyzed by real-time quantitative PCR the CBFB-MYH11 transcripts in 128 PB 
and 67 BM samples, including 64 paired PB-BM samples from 10 different AML 
patients. Results showed a moderate correlation (rs = 0.82) between the MRD 
levels in the follow-up PB-BM pairs; generally higher MRD levels were found in 
the BM samples than in the PB samples (ranges: 0.8 to 100 fold). Nevertheless, 
monitoring of CBFB-MYH11 transcript levels in PB did have predictive value: firstly, 
MRD negative PB samples after the second course predicted a favorable prognosis 
with a long term remission. Secondly, MRD levels in the PB predicted the disease 
reoccurrence 2.5 to 4 months prior to the cytological BM relapse. Although further 
studies are needed, our preliminary data show that CBFB-MYH11+ AML can be 
monitored through the regular evaluation of PB at regular time points, thereby 
avoiding the multiple invasive BM punctures.
INTRODUCTION
Inv(16)(p13q22) and the related translocation t(16;16)(p13;q22) generate a 
CBFB-MYH11 fusion gene transcript and are commonly found in acute myeloid 
leukemia (AML) M4Eo.1 This recurrent chromosomal anomaly is considered a 
good risk marker, associated with a high complete remission rate and a long-term 
disease free survival.2 Nevertheless, a considerable proportion of patients suffer 
from relapse. Analysis of minimal residual disease (MRD) may allow recognition of 
patients at high risk of relapse and/or may detect an upcoming relapse. Buonamici 
et al 3 used real-time quantitative PCR (RQ-PCR) analysis and suggested the 
existence of cut-off points in CBFB-MYH11+ AML beneath which durable remission 
is likely or above which relapse is probable. Schnittger et al 4 proposed a risk 
stratification score for CBFB-MYH11+ AML based on the quantification of fusion 
gene transcripts at diagnosis and after consolidation. So far, most MRD studies 
in CBFB-MYH11+ AML patients mainly used bone marrow (BM) samples. To 
evaluate the possibility to safely replace BM by peripheral blood (PB) for PCR-
MRD monitoring in clinical settings, comparing RQ-PCR results of paired PB-BM 
samples is essential. For specific subtypes of AML, such as the t(8;21) positive AML 
with AML1-ETO transcripts, the possibility of MRD monitoring through quantitative 
analysis of PB has been reported.5,6 Gallagher et al 7 reported on the prognostic value 
of RQ-PCR of PML-RARA transcripts and showed that paired PB-BM samples had 
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comparable MRD levels. They suggested that RQ-PCR for PML-RARA performed 
on PB at frequent follow-up points may improve predictive accuracy for relapse or 
continuing complete remission. Whether MRD monitoring of PB is of prognostic 
relevance in CBFB-MYH11+ AML patients is however still unknown.
PATIENTS AND METHODS
In this study, we quantified by RQ-PCR the CBFB-MYH11 transcripts in 128 PB and 67 BM samples, 
including 64 paired PB-BM samples taken on the same day, from 10 different CBFB-MYH11+ AML 
patients. Patients’ characteristics, type of breakpoint, cytogenetic data, treatment and clinical outcome 
are summarized in Table 1. RQ-PCR was performed as described before.8 Results were expressed as 
normalized copy numbers (NCN): (numbers of CBFB-MYH11 transcripts / numbers of β-glucuronidase 
(GUS) transcripts) x 104. CBFB-MYH11 negative samples with less than 1000 transcripts of GUS were 
excluded from further analyses; this concerned 4 PB samples, two of which had a corresponding BM 
sample. At least 3 PB and 2 BM samples were analyzed per patient with a mean of 13 PB and 6 BM 
samples. The median follow-up was 27.5 months (range: 1.5 - 66 months). The number of samples and 
the timing of sampling was not uniform among patients due to the retrospective nature of our study. 
RESULTS AND DISCUSSION
CBFB-MYH11 transcript levels in 8 diagnostic paired PB-BM samples showed 
no significant difference between both sample types (Figure 1). Out of 54 paired 
PB-BM samples obtained during follow-up, 16 pairs were MRD-negative in both 
BM and PB, while in 27 pairs MRD was detected in both BM and PB. In the 
remaining 11 paired follow-up samples MRD was detected only in BM, but not 
in the corresponding PB. MRD levels in the 54 follow-up PB-BM pairs showed a 
moderate correlation (Spearman correlation, rs = 0.82): MRD levels in BM were 
generally higher than in PB, with a variable ratio between the MRD level in the BM 
sample and the corresponding PB sample, ranging from 0.8 up to almost 100 fold 
(Figure 1). This variable range implies that no straightforward relationship exists 
between MRD levels in paired PB and BM samples of CBFB-MYH11+ AML patients 
during follow-up. The generally higher MRD levels in BM are in line with the fact that 
AML has its origin in BM.
Although CBFB-MYH11 transcript levels in follow-up PB did not precisely 
reflect MRD levels in the corresponding BM samples, monitoring of CBFB-MYH11 
transcripts in PB did have clinical and predictive value, as illustrated by the 
evolution and outcome of our 10 patients. Induction therapy resulted in a mean 
transcript reduction of 3.2 and 3.9 log in BM and PB respectively. The second 
cycle induced a mean tumor load reduction of 0.7 log in BM and 1.0 log in PB. 
After this second course, there were no molecular remissions in the BM samples. 
However, the molecular results of 8 patients with PB follow-up samples available 
after the second course, were as follows: 3 patients showed a molecular remission 
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and stayed in long term remission, while 5 patients had residual disease. In the 5 
patients with MRD positivity in their PB after the second course, 4 relapses were 
seen (Figure 2): two patients suffered from an early BM relapse (patient 3 and 5), 
one patient had a combined BM-CNS relapse (patient 8), and one patient had a 
seemingly isolated CNS relapse (patient 7). In addition, a late BM relapse was 
Table 1. Clinical, molecular and karyotypic characteristics.
Patient Sex Age at 
diagnosis
(years)
Type of 
transcript
Karyotype Therapy OS/DFS 
(months)
Clinical outcome
1 M 48 A 46,XY,inv(16)
(p13q22)[10]
chemo a, M-Allo 66 / 59 deceased in 2nd 
BM relapse
2 F 55 A 46,XX,inv(16)
(p13q22)[11]
chemo, NM-Allo 48+ / 47+ 1st CR 
3 M 17 A 46,XY,inv(16)
(p13q22)[10]
chemo, NM-Allo 45+ / 9 2nd CR after BM 
relapse
4 M 49 A 47,XY,+8,inv(16)
(p13q22)[3] 
47,XY,idem,del(7)
(q32)[4] 
47,XY, idem,-17,
+22[2]
chemo 35+ / 34+ 1st CR 
5 F 51 A 46,XX,inv(16)
(p13q22)[10]
chemo, NM-Allo 31+ / 10 2nd CR after BM 
relapse 
6 M 11 A 46,XY,t(16;16)
(p13;q22)[21]
chemo 1.5  deceased in 1st 
CR (treatment 
toxicity)
7 F 8 A 46,XX,inv(16)
(p13q22)[7] 
46,XX,add(7)
(q22),inv(16)
(p13q22)[4]
chemo, intrathecal 
chemo, Allo 
24 / 18 deceased in 
2nd CR after 
CNS relapse 
(transplant 
related)
8 M 67 D 46,XY,inv(16)
(p13q22)[9] 
47,XY,inv(16)
(p13q22),+22[2]
chemo, Mylotarg b, 
intrathecal chemo, 
cranial radiation  
20+ / 13 2nd CR after 
BM and CNS 
relapse 
9 F 68 A 46,XX,inv(16)
(p13q22)[6] 
47,XX,+8,inv(16)
(p13q22)[8]
chemo, Zarnestra c 11+ / 10+ 1st CR
10 F 31 A ND chemo 9+ / 8+ 1st CR
a  All patients were treated with standard induction regimens comprising combinations of idarubincine, 
 Ara-C, mitoxantrone, etoposide, and amsacrine. After achieving complete remission, consolidation
  courses consisted of the same drugs used for induction. OS, overall survival; DFS, disease free 
 survival; CR, complete remission; M-Allo, myelo-ablative allogeneic transplant; NM-Allo, non-myelo-
 ablative allogeneic transplant; ND, no data.
b  3 cycles of gemtuzumab ozogamicin (at relapse).
c  farnesyl transferase inhibitor (post-consolidation).
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seen in patient 1 from who no molecular PB data were available after the second 
course (Figure 2). Thus, obtaining a molecular remission in PB after the second 
course may identify patients at low risk of relapse. In contrast to Schnittger et al 4
no correlation was found between the diagnostic BM or PB transcript levels and 
clinical outcome, nor between BM or PB tumor load reduction after induction or 
second course and clinical outcome, which might be due to the limited number of 
patients in our study. 
In addition to providing prognostic information, MRD analysis may also be used 
for early detection of a (molecular) relapse. Indeed, all patients with a cytological 
BM relapse (patient 1, 3, 5, and 8), showed a significant (≥1 log) increase of 
CBFB-MYH11 transcripts in their PB 2.5 to 4 months before cytological relapse (Figure 
2). The patient who experienced an isolated CNS relapse (patient 7) after a molecular 
remission of 13 months in BM and PB, showed at the time of the CNS relapse low 
transcript levels in the BM; one month later, also the PB became positive (Figure 2). 
In conclusion, our results show that there is no straight correlation between 
MRD levels in PB samples and the corresponding BM samples during 
follow-up in CBFB-MYH11+ AML. Nevertheless, monitoring of CBFB-MYH11 
Figure 1. 
Correlation of normalized copy numbers (NCN) x 104 between 62 paired PB and BM samples from 
10 CBFB-MYH11+ AML patients. × represent paired diagnostic samples (n=8); ● represent paired 
cytological relapse samples (n=3); ○ represent paired follow-up samples in cytological remission (n=51); 
neg, MRD negative. 
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transcript levels in PB can have potential clinical value. Firstly, CBFB-MYH11-
negative PB samples after the second course might predict a favorable prognosis 
with long term remission. Secondly, CBFB-MYH11 levels in follow-up PB samples 
can predict disease reoccurrence 2.5 to 4 months prior to cytological BM relapse 
(Figure 2). Although analysis of BM could predict these relapses in some patients 
up to 2 months earlier, we believe that in practice a time frame of at least 2.5 
months should be enough to adjust therapy in order to prevent the occurrence of 
a cytological relapse. Treatment intervention at the time of molecular relapse may 
result in better clinical outcome than treatment at the time of overt clinical relapse. 
This approach was proven to be successful for PML-RARA-positive patients.9 Also 
for CML after allogeneic transplantation, it has been proven that patients benefit 
from early intervention with donor lymphocyte infusions at the time of cytogenetic 
relapse.10 Based on our preliminary data, we propose that patients with a 
Figure 2. Evolution of MRD levels in 5 patients with a cytological BM and/or CNS relapse. 
MRD levels are expressed as the ratio (CBFB-MYH11 transcripts/GUS transcripts) x 104. ▲represent 
PB samples; ○ represent BM samples; MR, molecular relapse as defined by a ≥1 log increase of NCN; 
CyR, cytological BM relapse; the time between MR and CyR is indicated in months.
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CBFB-MYH11+ AML can be monitored through regular evaluation of their PB at set 
points, thereby avoiding multiple invasive BM punctures. Such PB examinations 
could be performed every 2 to 3 months after consolidation and BM should be 
examined in case of rising CBFB-MYH11 transcripts in PB. However, further studies 
in a large population of uniformly treated patients with the collection of paired PB-
BM samples at specific time-points are needed to determine the precise clinical 
value of PB samples for disease monitoring, as well as the optimal time interval 
between consecutive PB samples that allow a reliable early detection of molecular 
relapses in CBFB-MYH11+ AML. In addition, current therapeutic protocols should 
include treatment intervention at the time of molecular relapse, since this might 
improve patient outcome.
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ABSTRACT
A 36-year old male underwent a non-related donor hematopoietic stem cell 
(HSC) transplantation after a non-myeloablative conditioning for chronic myeloid 
leukemia (CML) in second chronic phase. The early course after the transplantation 
was unfavorable, without sufficient engraftment of the allogeneic HSC and with the 
persistence of unstable advanced CML as indicated by a Ph-positive karyotype 
with clonal progression. In addition, there were contraindications against tapering 
of immunosuppression or therapeutic immunointervention with donor lymphocyte 
infusions. Four months after the HSC transplantation, treatment with imatinib 
mesylate was initiated. The administration of imatinib mesylate allowed a complete 
engraftment of donor HSC. Under continuing treatment, the patient reached 
a complete cytogenetic remission after 3 months, and molecular remission in 
peripheral blood as well as in bone marrow, in the absence of significant side effects. 
Our data indicate that imatinib mesylate induces durable complete remission of 
advanced CML persisting after allogeneic bone marrow transplantation.
INTRODUCTION
The development of imatinib mesylate (STI-571; Glivec; Gleevec; Novartis, 
Basel, Switzerland), a rationally designed inhibitor of the BCR-ABL protein tyrosine 
kinase, has marked the beginning of a new era in the treatment of CML. In first 
chronic phase, imatinib mesylate yields complete hematological remission rates of 
98% and an unprecedented 60% rate of major or complete cytogenetic responses.1 
CML in myeloid blast crisis responds substantially less well with only 8% complete 
hematological and 7% complete cytogenetic responses, and a high frequency of 
early relapses.2 As it stands today, allogeneic stem cell transplantation remains 
the only established curative treatment for CML, with a 10-year disease-free 
survival of approximately 50% for patients in early first chronic phase and with 
a matched sibling donor. Allotransplanted patients with a molecular, cytogenetic 
or hematological relapse can often be successfully rescued by discontinuation of 
immunosuppressive therapy and/or infusion of donor lymphocytes (DLI).3 Little is 
known on the place of imatinib mesylate in the management of disease persistence 
or relapse after allogeneic stem cell transplantation for CML. Here we report a case 
of advanced CML that persisted after a failed unrelated bone marrow transplantation. 
Under treatment with imatinib mesylate, stable complete donor chimerism in the 
peripheral blood, improved graft function and a complete molecular response were 
achieved.
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PATIENT, METHODS AND RESULTS
Chimerism studies
Short tandem repeats (STR) and the amelogenin locus were amplified using the AmpFLSTR SGM 
and Profiler PlusTM PCR Amplification Kits (Applied Biosystems, Lennik, Belgium), according to the 
manufacturer’s instructions. The PCR products were analysed on the ABI 3100 genetic analyser. For 
informative STRs, the height of the donor-derived allele was divided by the sum of the heights of donor 
and receptor alleles. The percentage donor chimerism is the average of this value for all informative 
STRs, multiplied by 100.
Cytogenetics
Bone marrow specimens were cultured for cytogenetic analysis by established methods. Metaphases 
were R-banded. Chromosome aberrations are described according to guidelines of an International 
System for Human Cytogenetic Nomenclature.
Real-time quantitative polymerase chain reaction
RNA was isolated from peripheral blood or bone marrow mononuclear cells using the QIAamp 
Blood Kit (Qiagen, USA). cDNA synthesis (40 µl) was performed using 2 µg RNA, 200 units of M-MLV 
reverse transcriptase (Gibco BRL) and 25 µM random hexamers (Amersham Pharmacia Biotech, USA). 
The 25 µl RQ-PCR reaction mixture contained 5 µl of cDNA, TaqMan Universal PCR Master Mix 2x 
(Applied Biosystems), 300 nM primers, 200 nM TaqMan probes as described elsewhere.4 The detection 
of the PCR products was based on TaqMan technology using the ABI PRISM 7900 Sequence Detection 
System (Applied Biosystems, Foster City, CA, USA). A standard curve was established using a serial 
dilution of BCR-ABL and β-glucuronidase plasmids (Ipsogen, Marseille, France). The copy numbers of 
the BCR-ABL fusion gene were normalized to the copy numbers of β-glucuronidase.
Clinical course and results
A 30-year old man was diagnosed with Ph-positive CML in chronic phase in December 1994. Under 
treatment with interferon-α-2b, a hematological response, but no cytogenetic response, was obtained. In 
early 2000, a myeloid blast crisis developed, and second chronic phase was reached only after intensive 
therapy with etoposide, topotecan and mitoxantrone. At this advanced disease stage, it was decided to 
perform an allogeneic bone marrow transplantation from an unrelated male donor with an immunogenic 
HLA-DRB1 subtype mismatch and an HLA-DQB1 mismatch (Recipient: DRB1*1302.DRB1*1501, 
DQB1*0602.DQB1*0604; donor: DRB1*1302.DRB1*1503, DQB1*0602.DQB1*0501). The patient now
36 years old, had poorly tolerated earlier intensive chemotherapy, therefore a non-myeloablative 
conditioning protocol was chosen, consisting of fludarabine, busulfan and antithymocyte globulin. 
Posttransplant immunosuppression included cyclosporin A and short course metotrexate. Initially, G-CSF 
supported hematological recovery was encouraging, but discontinuation of G-CSF led to a substantial 
decline of the leucocyte (Figure 1A) and platelet counts (Figure 1B). In addition, analysis of peripheral 
blood leukocyte chimerism over this time period revealed a concomitant decrease of donor chimerism 
from 25% (day 33) to less than 10% (day 84). Consecutive marrow examinations revealed hypocellular 
marrows, with a tendency to left shifting but not fulfilling cytological criteria for accelerated phase (Table 
1). Karyotypes of these marrow aspirates continued to show almost uniform Ph positivity with additional 
clonal progression (46,XY,t(9;22)(q34;q11),add(17)(p11)), and with only a minority of (donor-derived) 
Ph-negative metaphases (Figure 1C). Meanwhile, the patient had cutaneous and hepatic acute GVHD 
grade II. Therefore, neither tapering of immunosuppression nor administration of DLI were considered 
reasonable salvage options.
Imatinib mesylate (CSTI-571-0114 protocol, Novartis) was started on day 124 after transplantation, 
at an initial dose of 400 mg/day and increased to 600 mg/day 2 weeks later. Within 6 weeks, a substantial 
improvement in the platelet count was observed, followed later by a more gradual increase of erythrocyte 
and leucocyte counts. Initially, this was accompanied by peripheral blood monocytosis and an increase 
in marrow monocytes and later, marrow blasts (Figure 1 A-B and Table 1). While these findings raised 
the suspicion of leukemia progression, a rapid increase of donor chimerism in the peripheral blood 
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was found reaching 100% between days 161 and 189 (days 37 and 65 of imatinib mesylate). This 
complete donor chimerism has since remained stable at 100% (last measured on day 661) (Figure 1C). 
In addition, complete cytogenetic remission was reached in the bone marrow within 8 weeks of imatinib 
mesylate. Finally, the number of BCR-ABL transcripts in peripheral blood, as measured by RQ-PCR, 
gradually declined over time, and since day 418 (day 294 of imatinib mesylate), the patient’s peripheral 
blood has consistently tested negative on five consecutive occasions (Figure 1C). In addition, no BCR-
ABL transcripts were detectable in a bone marrow aspirate on day 686 (day 562 of imatinib mesylate), 
indicating a disease burden of less than 1/100000 cells in the peripheral blood and bone marrow (Figure 
1C). This molecular remission was confirmed with a nested RT-PCR (able to detect a 10-6 dilution of 
cDNA of a BCR-ABL positive cell line in control cDNA) on two samples from peripheral blood (days 584 
and 641) as well as a bone marrow sample (day 686) (data not shown). Except for mild facial edema, 
there have been no significant imatinib mesylate-related toxicities. Cutaneous GVHD and disturbed 
liver tests attributed to hepatic GVHD have subsided allowing discontinuation of immunosuppression 
after 5 months of imatinib mesylate. Presently, the patient is free from complaints, and has resumed 
work, as well as strenuous physical activity. The increase of central blastosis and central and peripheral 
monocytosis that were seen after imatinib initiation has eventually resolved (Figure 1 A-B and Table 1).
DISCUSSION
At present only limited experience has been reported with imatinib mesylate 
in the treatment of CML after allogeneic transplantation. There are two cases of 
patients relapsing after allogeneic transplantation for CML and in whom imatinib 
mesylate treatment induced sustained hematological and cytogenetic remission.5-6 
Others have demonstrated that the association of imatinib mesylate and DLI can 
be highly effective as a treatment for Ph-positive acute leukemia relapsing after 
BMT.7 Here, we report on the use of imatinib mesylate in a setting of persistent 
disease after allogeneic hematopoietic stem cell transplantation. There are several 
important observations. 
Figure 1. Evolution of peripheral blood counts, chimerism and disease burden after
transplantation.
(A) Leucocyte count and absolute neutrophil count. The time course of leucocyte count (WBC, black 
line) and absolute neutrophil count (ANC, gray line) is shown. 
(B) Hemoglobin level and platelet count. The time course of leucocyte count (Hb, black line) and 
platelet count (PLT, gray line) is shown. 
(C) Molecular and cytogenetic analysis of engraftment and disease burden. Peripheral blood 
leucocyte chimerism: The evolution of donor chimerism (left Y-axis) is shown over time (solid line, 
white squares). Bone marrow karyotype: Bars show the distribution of R-banded normal metaphases 
(gray), Ph-positive metaphases (black) and Ph-positive metaphases with clonal evolution (stripes), as a 
function of time. The number of metaphases analysed is given above the bar. BCR-ABL copy numbers 
in bone marrow and peripheral blood: The copy numbers of the BCR-ABL fusion gene normalized to 
those of β-glucuronidase (NCN, right Y-axis) are shown as a function of time (solid dots represent bone 
marrow, open diamonds represent peripheral blood). The dot before transplantation represents a bone 
marrow sample 18 months before transplantation. In the RT-PCRs with negative results, mRNA was 
extracted from 3-9 x 106 cells. Drop lines represent day 0 (day of transplantation) and day 124 (start of 
imatinib mesylate). 
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First, initiation of imatinib mesylate led to a rapid eradication of recipient 
hematopoiesis, as detected by chimerism analysis on peripheral blood. Second, 
despite the advanced disease stage, this was followed by a complete cytogenetic 
response achieved in the bone marrow within 2 months after initiation of therapy. 
Moreover, there was a gradual decrease of the number of BCR-ABL transcripts in 
peripheral blood, as well as in bone marrow, and a complete molecular remission 
(as verified with RQ-PCR and nested RT-PCR) was reached in peripheral blood 
as well as the bone marrow. This status of molecular remission in the peripheral 
blood has now been confirmed several times over a period spanning more than 
250 days and it is hoped that it will be durable in the future. It is known that imatinib 
mesylate can induce cytogenetic remission in advanced CML. Yet, only a minority of 
patients with advanced CML enjoy complete cytogenetic responses or hematologic 
responses that are durable beyond 1 year. In addition, molecular responses to 
imatinib mesylate are rare in patients with chronic phase or more advanced CML.1,2 
Thus, while it cannot be excluded that the complete hematological, cytogenetic 
and molecular response in this patient was achieved by the sole action of imatinib 
mesylate, one could speculate that reduction of the disease burden by imatinib 
mesylate has created a window of opportunity for an alloreactive graft-versus-
leukemia effect. Of note, imatinib mesylate has been reported to augment the 
function of antigen-presenting cells; as such it may also facilitate GVH-reactivity 
and GVL-effects.8 Finally, despite low blood counts and peripheral blood donor 
chimerism at the start of imatinib, improved graft function was achieved without 
need for a second infusion of donor hematopoietic stem cells. 
In summary, this case indicates that imatinib mesylate can be highly efficient to 
treat persisting CML after allogeneic hematopoietic stem cell transplantation. The 
observations also suggest that imatinib mesylate may promote or synergize with the 
graft-versus-leukemia effect after transplantation. More data are awaited to better 
define the role of imatinib mesylate after allogeneic stem cell transplantation.
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ABSTRACT
Gemtuzumab ozogamicin (Mylotarg®) induces remission in approximately 30% 
of relapsed AML patients. We previously demonstrated that gemtuzumab infusion 
results in near-complete CD33 saturation in peripheral blood, and that saturating 
gemtuzumab levels result in continuous binding and internalization of gemtuzumab 
due to renewed CD33 expression. We now demonstrate that a high CD33-antigen 
load in peripheral blood is an independent adverse prognostic factor, likely due to 
peripheral consumption of gemtuzumab. Indeed, CD33 saturation in bone marrow 
is significantly reduced (40-90% saturation) as compared with CD33 saturation 
in corresponding peripheral blood samples (>90%). In vitro, such reduced CD33 
saturation levels were strongly related with reduced cell kill. Apparently, high CD33-
antigen loads in blood consume gemtuzumab and thereby limit its penetration into 
bone marrow. Consequently CD33 saturation in bone marrow is reduced, which 
hampers efficient cell kill. Therefore, gemtuzumab should be administered at higher 
or repeated doses, or, preferably, after reduction of the leukemic cell burden by 
classical chemotherapy.
INTRODUCTION
Gemtuzumab ozogamicin (Mylotarg®) is a humanized CD33 antibody linked 
to the anti-tumor antibiotic calicheamicin.1 In phase-II clinical trials, gemtuzumab 
administered as single agent at two doses of 9 mg/m2 two weeks apart, resulted in 
complete remission in approximately 30% of relapsed AML patients.2, 3 Gemtuzumab 
therapy was related with low toxicity, the major complication being occurrence of 
hepatic veno-occlusive disease (VOD) in a small number of patients.4 Based on 
these results, gemtuzumab was FDA-approved for treatment of relapsed AML 
patients over 60 years of age.5
We have previously shown that after intravenous infusion of gemtuzumab, near-
complete saturation (>90%) of CD33-antigens is achieved on AML blast cells present 
in peripheral blood (PB).6 In addition, gemtuzumab also binds to CD33-antigens 
expressed by monocytes and granulocytes present in PB at the time of infusion.6 
Consequently, the total amount of gemtuzumab bound to CD33-antigens in PB 
depends on the number of CD33-positive monocytes, granulocytes, and AML blast 
cells as well on the CD33 expression level of these cells (referred to as the peripheral 
CD33-antigen load). After binding of gemtuzumab to CD33-antigens, the CD33-
antigen/gemtuzumab complexes are rapidly internalized,6 followed by hydrolysis of 
the acid-labile linker and subsequent activation of the calicheamicin γ1 derivate.1 Of 
importance, upon internalization of the complexes, new CD33-antigens are rapidly 
expressed on the cell surface and subsequently can bind gemtuzumab. The rate of 
renewed CD33-antigen expression is related to the degree of CD33 saturation and 
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internalization6 and to the activation status of the cell.7 Consequently, the process 
of CD33 saturation, internalization, and new CD33-antigen expression is ongoing 
as long as saturating gemtuzumab concentrations are maintained. This continuous 
process will result in a progressive intracellular accumulation of gemtuzumab. 
Obviously, high levels of intracellularly accumulated calicheamicin are more 
toxic than low levels. Indeed, patients with less than 5% AML blasts in their PB 
after the first gemtuzumab infusion had higher maximal gemtuzumab binding levels 
on AML blast cells (i.e. stronger CD33-antigen expression) than patients with more 
than 5% AML blasts in PB after the first infusion.6 However, no relation was found 
between CD33 expression levels and clinical outcome as assessed by analysis of 
bone marrow (BM) samples.2, 3 Apparently, the gemtuzumab response in PB, but 
not in BM, is related to the CD33 expression level on AML blasts.
We hypothesized that high CD33-antigen loads in peripheral blood consume 
intravenously administered gemtuzumab, thereby limiting gemtuzumab 
concentrations in BM. As a consequence, CD33 saturation of AML blasts in 
BM might be reduced, resulting in greatly reduced intracellular accumulation of 
gemtuzumab and thereby in inefficient cell kill.
MATERIALS AND METHODS
Patients
Patients enrolled in the gemtuzumab phase-II clinical protocols 0903B1-202-EU (n=54) and 0903B1-
203-EU (n=38) were studied.2, 3, 6 In these open, single-arm multi-center phase II studies, gemtuzumab 
(Wyeth-Ayerst Laboratories, St. Davids, PA, USA) was administered as a single 2-hour intravenous 
infusion at a dose of 9 mg/m2. In general, each patient received two gemtuzumab doses with at least 14 
days between the doses. Prior to the start of each gemtuzumab treatment cycle and 3 and 6 hours after 
the start of each gemtuzumab treatment cycle, PB samples were obtained, immediately placed on ice 
(4°C) and shipped overnight at 4°C to Immunology, Erasmus MC, Rotterdam by express courier (World 
Courier, Hoofddorp, The Netherlands). 
Six patients treated with gemtuzumab on compassionate use basis were also included in this 
study. BM samples were taken prior to and 24 h after gemtuzumab infusion. The latter sample was 
immediately diluted in 200-ml ice-cold phosphate-buffered saline and kept on ice until further analysis to 
limit additional CD33 saturation due to the presence of gemtuzumab in contaminating PB. PB samples 
were taken just prior to gemtuzumab infusion and 6 and 24 h thereafter. Inclusion of additional patients 
treated with gemtuzumab as a single agent and at a dose of 9 mg/m2 was not possible, because current 
European clinical trails employ another gemtuzumab dose and/or use a combination regimen with 
chemotherapy. 
Analysis of CD33 expression, CD33 saturation, and maximal gemtuzumab binding
Analysis of CD33 expression, CD33 saturation, and maximal gemtuzumab binding was performed 
as described previously using a flow cytometric assay. 6 Briefly, to determine CD33 saturation cells were 
incubated with biotin-conjugated mouse anti-human IgG4 antibodies (Caltag Laboratories, Burlingame, 
CA, USA), followed by streptavidin-FITC (Biosource, Nivelles, Belgium) as a second step reagent. 
To detect maximal gemtuzumab binding, cells were first incubated with excess gemtuzumab (final 
concentration: 10 µg/ml), followed by successive incubation with biotin-conjugated mouse anti-human 
IgG4 antibodies and streptavidin-FITC. As a negative control, cells were incubated with streptavidin-
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FITC alone. To detect CD33 antigenic sites not occupied by gemtuzumab, cells were incubated with 
CD33-PE (clone P67.6; BD Biosciences, San Jose, CA, USA) or, as a negative control, IgG1-PE (BD 
Biosciences). All incubations were performed at 4°C. CD45-PerCP (2D1; BD Biosciences) and/or CD14-
PE (My4; Coulter Clone, Hialeah, FL, USA) antibodies were included to distinguish between various cell 
populations.
To determine the relation between gemtuzumab concentration and CD33 saturation, the AML193 
cell line or PB from healthy volunteers was incubated with various gemtuzumab concentrations (15 
minutes at 4°C), after which CD33 saturation was analyzed. 
Analysis of peripheral CD33-antigen load
Samples taken just prior to gemtuzumab infusion were subjected to routine morphological analysis 
to assess the leukocyte differential. In addition, maximal gemtuzumab binding to AML blast cells, 
monocytes and granulocytes was determined as described above. The peripheral CD33-antigen load 
was subsequently calculated as follows: (maximal gemtuzumab binding blasts x #blasts/L) + (maximal 
gemtuzumab binding monocytes x #monocytes/L) + (maximal gemtuzumab binding granulocytes x 
#granulocytes/L).
Analysis of cell kill
To determine the relationship between induction of cell kill and gemtuzumab concentration, AML193 
cells were incubated with various gemtuzumab concentrations for 24 h or 40 h, after which cell kill was 
determined by 51Cr release assay as described previously.7, 8 Because AML193 cells also can take up 
gemtuzumab via CD33-independent mechanisms (which will contribute to its final cytotoxic activity),7 
an isotype-matched calicheamicin-conjugated antibody was not included as a control. To determine 
whether free calicheamicin (e.g. due to hydrolysis of the linkers during the incubation period) could 
contribute to cell kill, pilot experiments using free calicheamicin were performed. These experiments 
showed that the maximal amount of free calicheamicin that could be present during the incubation 
period (<0.015 µg/ml at the highest gemtuzumab dose; based on less than 1% free drug in clinical grade 
gemtuzumab and an estimated increase with maximally 2-3% in 24 hours; Philip Hamann, personal 
communication) resulted in <15% cell kill in our assay.7
Statistical analysis
To determine whether the peripheral CD33-antigen load was different between patients that 
achieved complete remission (either with or without full recovery of platelets2, 3) and non-responders, a 
Mann-Whitney U test using log-transformed data was applied. Univariate analysis using age, FAB-type, 
multidrug resistance efflux, ECOG performance status, duration of CR1, and percentage BM blasts3 was 
performed using the Mann-Whitney U test. Karyotype data were unfortunately not completely available; 
inclusion of fusion gene transcript data (CBFB-MYH11, PML-RARA, AML1-ETO) was not done due to 
the very low number of patients (3 out of 92) being positive for one of these translocation-associated 
fusion gene transcripts. Multivariate analysis, including all indicated variables that were significant in the 
univariate analysis, was performed by logistic regression. In all tests, a p value of less then 0.05 was 
considered significant.
RESULTS AND DISCUSSION
High peripheral CD33-antigen load is an independent prognostic factor
To evaluate whether a high peripheral CD33-antigen load was related to clinical 
outcome, we analyzed the CD33-antigen load in PB of 92 patients enrolled in 
the European phase-II protocols. The mean peripheral CD33-antigen load was 
significantly lower in patients who achieved complete remission than in non-
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responders (mean log(peripheral CD33-antigen load)±SD: 3.67±0.85 versus 
4.58±0.97; Table 1). Further statistical analysis using age, FAB-type, multidrug 
resistance efflux, ECOG performance status, duration of CR1, and percentage BM 
blasts 3 showed that duration of CR1 and percentage BM blasts were significant 
prognostic markers as well (Table 1). However, multivariate analysis showed that 
only the log(peripheral CD33-antigen load) was an independent prognostic factor 
(Table 1). In accordance with our data, the likelihood of achieving response to 
gemtuzumab therapy was shown to be associated with lower levels of CD33-positive 
leukemic blasts in PB 3 or BM. 2 Thus, high peripheral CD33-antigen loads reduce 
treatment efficacy, probably by consuming gemtuzumab and thereby reducing the 
gemtuzumab amount available for leukemic cells in BM. This may result in reduced 
CD33 saturation on AML blast cells present in BM and subsequently in inefficient 
induction of cell kill.
CD33 saturation on AML blast cells present in BM is reduced
To investigate whether peripheral gemtuzumab consumption indeed could 
reduce the gemtuzumab amount available for leukemic cells in BM, we analyzed 
BM samples obtained 24 h after gemtuzumab infusion. As shown in Figure 1A, 
prior to gemtuzumab infusion only background saturation levels (<20%) were 
observed in PB and BM. In PB, near complete CD33 saturation was observed at 6 h 
(data not shown) and at 24 h after gemtuzumab infusion (Figure 1A). In contrast, 
CD33 saturation in BM was significantly lower and ranged from 42% to 90%. 
Apparently, penetration of gemtuzumab (given at a dose of 9 mg/m2) into BM is not 
sufficient to completely saturate CD33-antigens on AML blasts present in BM 24 h 
after gemtuzumab infusion.
Preliminary analysis showed that the degree of reduced CD33 saturation in BM 
was only partly related to the peripheral CD33-antigen load (data not shown), but 
Table 1. Results of statistical analysis for prognostic factors.
Analysis Prognostic variablea Univariate analysisb Multivariate analysisc
CR(p) vs NRd Age 0.566 n.d.
FAB 0.508 n.d.
Percentage blasts in BM 0.046 0.272
Multidrug resistance efflux 0.888 n.d.
ECOG performance status 0.600 n.d.
Duration of CR1 0.009 0.201
CD33-antigen load PB 0.001 0.014
a  For details see reference.3 
b  Mann-Whitney U test.
c  Logistic regression. 
d CR(p): patients in complete remission, with or without full recovery of platelets (n=18); NR: non-
 responders (n=74).
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Figure 1. CD33 saturation levels in BM.
A. CD33 saturation on AML blast cells in BM and PB samples obtained prior to and 24 h after gemtuzumab 
infusion in six AML patients. Before gemtuzumab infusion only background CD33 saturation levels 
(<20%) were observed in BM. For comparison, previously published CD33 saturation levels in PB prior 
to gemtuzumab infusion (mean ± SD) are shown as well. 6 Twenty-four hours after gemtuzumab infusion, 
CD33 saturation levels in PB were near-complete (mean: 92%), whereas CD33 saturation levels in BM 
were significantly lower (mean: 74%; p<0.05 by Mann-Whitney test). The horizontal bars indicate the 
mean CD33 saturation. 
B. Relation between CD33 saturation by AML blast cells in BM and CD33 expression by blast cells for 
the same patients. High CD33 expression levels were related to lower CD33 saturation, suggesting 
that also the CD33-antigen load in BM contributes to CD33 saturation in BM (Pearson Correlation: 
-0.867; p<0.05). The six patients analyzed in our study all died: five due to disease progression and 
one due to stroke. Two patients (with 61% and 80% CD33 saturation in bone marrow) showed an initial 
response after gemtuzumab infusion, characterized by a strong reduction in blast cells in peripheral 
blood (to levels <2%). Both patients however showed a fast increase in blast cells in peripheral blood 
1-2 weeks later. It can be speculated that this is due to outgrowth of AML blast cells in BM, which were 
not sufficiently saturated with gemtuzumab for efficient induction of cell kill.
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was related to the CD33 expression level of the AML blasts in BM (Figure 1B). It will 
be interesting to analyze the relationship between peripheral CD33-antigen loads 
and CD33 saturation in BM in future protocols involving gemtuzumab in more detail. 
However, it should be kept in mind that the final CD33 saturation level in BM is not 
only affected by the peripheral CD33-antigen load, but may also be dependent on 
the total CD33-antigen load in BM. 
Complete saturation is required for efficient cell kill
After binding to CD33-antigens, gemtuzumab is rapidly internalized and the 
calicheamicin derivate is intracellularly activated.1, 6 Importantly, continuous renewed 
expression of CD33 antigens on the cellular surface of myeloid cells significantly 
increases the amount of internalized gemtuzumab as long as saturating levels of 
gemtuzumab are present.6 Therefore, the reduced CD33 saturation levels observed 
in BM may result in severely reduced accumulation of gemtuzumab into the cell, 
and thereby in inefficient induction of cell kill. To evaluate whether reduced CD33 
saturation levels indeed resulted in less efficient induction of cell kill, myeloid cells 
(monocytes, granulocytes, AML193 cells) were incubated with gemtuzumab, and 
CD33 saturation and/or cell kill were determined. As shown in Figure 2, CD33 
saturation and gemtuzumab-induced cell kill were both concentration dependent. 
Of importance, the combined CD33 saturation and cell kill data indicate that 
CD33 saturation levels <90% (as found in BM) resulted in a dramatic decrease 
in cell lysis (<5%; Figure 2C). Thus, gemtuzumab concentrations resulting in 
near complete CD33 saturation levels (>90%) are required for efficient cell kill. 
In our opinion this reflects the continuous process of saturation, internalization, 
and new expression of CD33-antigens,6, 9 resulting in the progressive accumulation 
of gemtuzumab (and consequently calicheamicin) in the cell (see Figure 3A). In 
agreement with this, the steep increase in gemtuzumab-induced cell kill (from 15% 
to >45%) is observed in the gemtuzumab concentration range of 0.5 to 2.5 µg/ml; 
at these concentrations the vast majority of the gemtuzumab-induced cell kill is 
CD33-mediated.7 Additionally, at such high gemtuzumab concentrations (>1 µg/ml) 
CD33-independent uptake mechanisms (i.e. endocytosis) may occur.7 Irrespective 
whether gemtuzumab is taken up by the cell via CD33-dependent internalization 
or via CD33-independent mechanisms, our data indicate that high gemtuzumab 
concentrations (those resulting in near complete CD33 saturation) are needed for 
efficient cell kill. The reduced CD33 saturation levels in BM (Figure 1) indicate that 
the gemtuzumab concentration in BM is relatively low, and consequently cell kill will 
be reduced (Figure 2).
Implications for gemtuzumab therapy
In this report we show that a high peripheral CD33-antigen load is an independent 
adverse prognostic factor in AML patients treated with gemtuzumab. Our data 
indicate that a high peripheral CD33-antigen load consumes a large part of the 
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gemtuzumab dose (9 mg/m2), which results in reduced gemtuzumab penetration in 
BM (Figure 3B). As a consequence, CD33 saturation of AML blast cells present in 
BM is incomplete, which drastically hampers subsequent cell kill.
For efficient killing of AML blasts in BM, the effective gemtuzumab dose should 
be increased in order to reach consistently high CD33 saturation levels. This can be 
done by increasing the dose of 9 mg/m2 or by giving repeated doses at subsequent 
days,9 which may however be complicated by the increase of severe side effects, 
including VOD.4 Alternatively and preferably, gemtuzumab could be administered 
after reduction of the leukemic cell burden by classical chemotherapy. However, 
so far, in most studies applying gemtuzumab-based combination regimens, 
gemtuzumab is given prior to or simultaneously with chemotherapy.10-15 The use 
of gemtuzumab in a post-remission regimen, combined with chemotherapy, has 
recently shown to be feasible and well-tolerated but needs further investigation.16 
To further improve the intracellular accumulation of gemtuzumab, drug efflux 
modulators such as cyclosporine A may be added to the treatment regimen as 
well.13-18 A better understanding of gemtuzumab’s mechanism of action will hopefully 
contribute to the design of future treatment protocols which maximally exploit the 
potencies of gemtuzumab.
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Figure 2. Relation between CD33 saturation and gemtuzumab-induced cell kill.
A. CD33 saturation of AML193 cells in relation to gemtuzumab concentration (mean ± SD; n=3). 
For CD33 saturation levels >90% (as observed in PB), a gemtuzumab concentration of at least 0.2 µg/ml 
was needed. For CD33 saturation levels of 40-90% (as observed in BM), gemtuzumab concentrations of 
0.01-0.1 µg/ml (i.e. 2 to 20-fold lower) were needed. The dotted lines indicate the mean CD33 saturation 
level in BM (74%) or PB (92%) and the corresponding gemtuzumab concentration. Comparable data 
were obtained for granulocytes (CD33+ (low); n=3) and monocytes (CD33+ (high); n=3).
B. Lysis of AML193 cells in relation to gemtuzumab concentration (mean ± SD; n=3). Lysis was 
determined using a 51Cr release assay after incubation with various gemtuzumab concentrations for 
24 h or 40 h.7, 8 The steep increase in cell kill observed at gemtuzumab concentration ranging from 
0.1 to 2.5 µg/ml (from <5% to >45% cell kill) is assumed to be gemtuzumab-specific, because the vast 
majority of cell kill can be inhibited by addition of an excess of CD33-antibody.7 At higher gemtuzumab 
concentrations, also CD33-independent uptake of gemtuzumab may be involved.7
C. Relation between CD33 saturation and cell lysis of AML193 cells. The combined data of A and B show 
that CD33 saturation levels >90% (as observed in PB; CD33 saturation window PB) resulted in 10-50% 
lysis. CD33 saturation levels <90% as observed in BM (CD33 saturation window BM) result in <5% lysis.
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Detection of minimal residual disease (MRD) at different time-points during 
follow-up in myeloid leukemia patients provides information on the effectiveness 
of treatment and might enable the identification of risk groups. To evaluate therapy 
efficacy both flow cytometric and molecular PCR techniques can be used. In this 
thesis, we focussed on the further identification of potential PCR-based MRD 
targets, both in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) 
patients. Additionally, we showed that quantitative MRD techniques are feasible 
and applicable in AML and CML patients for clinical decision-making during and 
after treatment. 
What is the preferred method for evaluating therapy efficacy in 
myeloid leukemia? 
Acute myeloid leukemia
In AML both immunological and molecular PCR techniques are used to evaluate 
therapy efficacy. These approaches provide quantitative MRD information during 
and after therapy, and allow the early identification of patients at high risk of relapse, 
thereby providing a window for therapeutic intervention. To minimize the chance of 
false-negative results (e.g. due to clonal evolution or phenotypic shifts), it would be 
attractive to monitor MRD by measuring two entirely independent features of the 
leukemic cells. However, currently not all AML patients can be evaluated with both 
techniques, due to the absence of leukemia-associated immunophenotypes (LAPs) 
or due to the lack of a specific or stable PCR-target. In addition, both approaches 
reach different sensitivities and have their specific limitations. 
For real-time quantitative PCR (RQ-PCR) MRD analyses, standardized protocols 
for the most frequent fusion gene transcripts in AML are available, allowing to 
exchange and compare data between different centers.1 Other advantages of this 
approach are the high sensitivity (10-4/10-6) and the stability of the targets between 
diagnosis and relapse. However, we showed that the stability over-time of fusion 
gene transcripts can vary substantially between patients and that the rate of 
degradation can differ between different types of transcripts and between peripheral 
blood (PB) and bone marrow (BM), if samples are not processed immediately after 
sampling.2 Additionally, PCR-based MRD detection of chromosome aberrations 
with fusion genes is only applicable in a minority of AML patients (20-30%), which 
stresses the need for other PCR-targets. We showed that cross-lineage Ig/TCR 
gene rearrangements are generally complementary MRD-PCR targets to fusion 
genes in AML.3 These Ig/TCR gene rearrangements might be useful as additional 
MRD-PCR targets, but they are only present in a small number of AML patients 
(<10%). In addition, it mainly concerns immature rearrangements, which can 
be subject to clonal evolution during therapy or at the time of relapse. We also 
showed that the RAG1 and RAG2 mRNA levels are not a straightforward tool for 
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the prediction of Ig/TCR gene rearrangements in AML. Therefore, the identification 
and characterization of Ig/TCR gene rearrangements, as well as the development 
of patient-specific primer/probe sets, makes it probably too time consuming for their 
use in a routine diagnostic laboratory. Finally, other molecular markers including 
FLT3 mutations, WT1 expression, and MLL-PTD may be targets for PCR-based 
MRD detection in a large number of AML patients.4-7 However, contradictory data 
for their clinical use as follow-up markers are reported. These discrepancies 
may be due to different patients cohorts, the use of different primers covering 
different parts of the gene, or due the different PCR protocols. It illustrates the 
need for further standardization of these assays (e.g. within the European AML 
Network (LeukemiaNet)) in order to determine their technical feasibility and clinical 
applicability as MRD-markers in AML. In the meanwhile, the need for novel PCR-
based MRD targets in AML are eagerly awaited; gene expression profiling using 
DNA micro-arrays may play a role in their identification. 
Flow cytometric immunophenotyping in AML is based on the presence of LAPs 
and is applicable in the vast majority of AMLs (>80%).8,9 The sensitivity of flow 
cytometry for MRD detection in clinical samples usually ranges from 10-3 to 10-4. 
Although it is technically not a problem to evaluate 106 cells by flow cytometry, 
the difficulty is the recognition of small numbers of residual leukemic cells within 
the background of normal immature and maturating myelo-monocytic BM cells. 
This requires a detailed knowledge of the myelo-monocytic differentiation patterns, 
as well as insight in the specificity of LAPs, e.g. their occurrence in normal and 
regenerating BM samples. Standardization of flow cytometric MRD procedures 
including pre-analytical (e.g. selection of antibodies, sample preparation), analytical 
(e.g. number of cells analyzed) and post-analytical (e.g. identification of LAPs, 
expression of MRD data) steps are essential before MRD data obtained from 
different laboratories become comparable and interchangeable, and before MRD 
data can be implemented into treatment protocols with MRD-based therapeutic 
interventions. These harmonization processes are currently a subject of a 
Dutch-Belgian working group. 
Overall, if a LAP can be identified in addition to a PCR target, it is advisable to 
use both flow cytometry and PCR analysis for monitoring MRD. This was illustrated 
in our patient with an inv(16)+ AML relapsing as an inv(16)+ ALL; the relapse was 
only predicted by PCR analysis, while flow cytometry gave false-negative results 
due to phenotypic changes.10 
Chronic myeloid leukemia
MRD monitoring in CML patients is currently mainly done by RQ-PCR of BCR-ABL 
fusion gene transcripts. This approach is applicable in almost all CML patients and 
especially used for patients treated with imatinib or patients after transplantation.11 
A potential disadvantage of using mRNA targets for PCR analysis is the possibility of 
false-positive results due to contamination. However, the currently available closed 
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PCR systems have drastically reduced the possibility of contamination. While 
fusion transcripts are leukemia-specific targets for PCR-based MRD monitoring, 
genomic DNA breakpoint fusion sites differ in each CML thereby representing 
patient-specific targets. We identified the DNA sequences of BCR-ABL fusions, 
particularly for the p230BCR-ABL gene.12 By using an allele-specific reverse primer 
positioned at the breakpoint area of the fusion genes, in combination with a µ-BCR-
specific forward primer and probe, these patient-specific DNA breakpoint fusion 
sites may be attractive PCR targets for MRD by RQ-PCR. Although patient-specific 
DNA targets have several advantages over mRNA targets (e.g. low degradation 
rate, easy quantification, stability throughout the disease course), special methods 
are needed for their identification. For CML patients presenting in a blast crisis, flow 
cytometric immunophenotyping should be used in parallel to RQ-PCR.
What is the preferential sample type for clinical MRD monitoring 
in myeloid leukemia?
Both BM and PB samples can potentially be used for flow cytometric and 
molecular MRD monitoring in myeloid leukemia patients. Although the rather 
invasive and traumatic BM sampling procedure -especially for pediatric patients- 
might be an argument in favor of PB sampling, in clinical settings the required 
sensitivity for MRD detection will play an important role in the determination of the 
preferred sample type. 
Chronic myeloid leukemia
Studies in CML patients showed that MRD levels of BCR-ABL transcripts 
analyzed by RQ-PCR seemed comparable in PB and BM samples. In the 
imatinib era, RQ-PCR data obtained from PB samples have shown to provide 
clinical prognostic MRD information; results from the IRIS study demonstrated that 
the reduction of BCR-ABL transcript levels in PB samples can predict the probability 
of remaining progression free.13
Acute myeloid leukemia
For RQ-PCR analysis of fusion gene transcripts in AML patients, it is still not 
clear whether PB might be a reliable alternative for BM in clinical MRD settings. 
Studies that demonstrated a prognostic significance of RQ-PCR analysis of fusion 
genes in AML mainly analyzed BM samples. Quantitative data on PB samples are 
scarce. For monitoring PML-RARA fusion gene transcripts, PB was shown to be 
only slightly less effective than BM.14 Limited data comparing the transcript levels of 
AML1-ETO fusion genes during follow-up, showed that MRD levels in BM samples 
were generally higher than in the corresponding PB samples, with variable ranges 
between the two sample types.15,16 We found comparable data for CBFB-MYH11 
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positive AML patients.17 Nevertheless, results in AML with AML1-ETO, CBFB-
MYH11 and PML-RARA suggest that RQ-PCR analysis of PB samples might have 
clinical and prognostic value, especially if carried out at frequent time intervals. 
While an interval of less than 3 months has been suggested, the optimal frequency 
of MRD measurements as well as the clinical significance of detecting MRD in the 
PB and its relation to MRD detected in the BM still requires further investigation. 
Depending on the results of such studies, monitoring schedules for BM and/or PB 
samples after induction and consolidation might be adapted for each individual 
marker. If shown to be equally informative, PB could be preferred. 
What can we expect from new techniques in the clinical 
management of patients care?
 
Gene expression profiling using DNA micro-array analysis 
AML is an heterogeneous disease with distinct biological and prognostic 
groups; its accurate classification is critical for treatment and prognosis. 
In routine clinical practice, AML is currently analyzed and classified on the 
basis of its morphological and immunohistochemical characteristics, its cell 
surface marker expression, and molecular and cytogenetic abnormalities. 
So far, cytogenetics and molecular analyses provide the most important markers 
for determining prognosis and guiding therapy in AML. However, both techniques 
still provide far from complete insight into the diversity of AML, particularly for AML 
with a normal karyotype. 
Results of gene expression profiling studies using DNA micro-arrays showed 
that this approach can successfully be applied to classify a variety of hematopoietic 
malignancies, including (subsets of) AML (Table 1).18-21 The gene signatures have 
proven to be robust, showing diagnostic accuracies that in many cases exceed those 
achieved using routine diagnostic approaches. Gene expression profiling using DNA 
micro-arrays can capture much of the information assayed by the various ‘classical’ 
techniques, but importantly, gene profiling using DNA micro-arrays can broaden the 
scope of analysis, thereby filling important gaps in the diagnostic approach to AML. 
Gene expression profiling using DNA micro-arrays may: 
1) identify clinically relevant outcome predictors (prognostic and disease progression 
makers), thereby supporting accurate risk-stratification of patients;22
2) provide information about drug sensitivity, thereby predicting response to therapy 
and allowing individualized selection of effective drugs; 
3) provide insight into the critical molecular pathways that sustain the growth and 
survival of leukemic cell transformation, which might help in the development of 
targeted therapies.
A challenge for the near future will be, how to apply the micro-array technology 
and information from micro-array based experiments to clinical diagnostics. While 
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expression profiling continues to improve our understanding of hematological 
malignancies, some applications of micro-array based research might have the 
potential to enter clinical practice. Small arrays with strong predictive capabilities 
and arrays with the potential to recognize additional subgroups, might potentially 
be used in a clinical setting. It is also reasonable to expect that the discovery of 
novel diagnostic and prognostic markers by gene expression profiling will result in 
improved diagnosis and molecular tailored therapeutic plans for each individual 
patient. Future will show whether gene expression profiling will replace the ‘classical’ 
techniques or that all techniques evolve together as complementary approaches to 
improve diagnosis and therapy. 
Proteomics
Another challenging technology with potential clinical applications in leukemia 
patients involves proteomics. Proteins are functionally the most relevant components 
of biological systems and form the basis of every conceivable cellular function. 
Changes observed in the proteome between leukemia patients and healthy 
individuals can be used as a biomarker to detect disease, and as a basis for the 
development of pharmacological drugs for therapeutic intervention.
Preliminary results from proteomic studies on leukemia show that distinct protein 
profiles of acute leukemia FAB subtypes can be identified.23 It can be expected that 
proteomics might also identify additional subgroups of acute leukemia with clinical 
relevance.
Although the clinical applications of proteomics offers promises, further work is 
required to enhance the performance and reproducibility of established proteomic 
tools. Issues regarding the pre-analytical variables and analytical variability must 
be addressed to gain further progress. 
Table 1. AML-subtypes identified by gene expression profiling.
Classification into/identification of previously cytogenetically/molecular defined subgroups18-21
− t(15;17) 
− t(8;21) 
− inv(16) 
− 11q23 abnormalities 
− AML with normal karyotype 
− FLT3 mutations 
− CEBPA mutations 
− overexpression of EVI1 
Identification of new subgroups/clusters
− new good and poor outcome subgroups within AML with normal karyotype, t(8;21) and inv(16)19
− cases classified as FAB AML-M720
− novel clusters including FAB AML-M4/M518
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What can we expect from new targeted drugs in myeloid 
leukemia? 
Specific molecular targeted therapies including ATRA and imatinib mesylate 
have drastically improved the outcome of APL and CML patients, respectively.13,24 
We showed that even in patients with advanced CML persisting after allogeneic BM 
transplantation, imatinib mesylate can induce a durable complete remission.25 Also 
new developments in monoclonal antibody therapy (e.g. Mylotarg®) have improved 
outcome for AML patients.26 However, despite these (major) improvements, still many 
myeloid leukemia patients suffer from resistant disease or relapse, and especially 
the treatment of the older AML patients (age >60 years) is very disappointing with 
only modest, if any, improvement in overall survival over the past 3 to 4 decades. 
Recent advances in the understanding of the genetic basis of myeloid leukemia 
and the nature of the mutations that contribute to the phenotype, have led to 
development of an expanding group of new targeted agents. Table 2 shows some 
of the potential new (molecular) targeted agents currently undergoing evaluation 
for the treatment of AML and CML. Phase I and/or II trials showed that these agents 
have clinical activity (e.g. reduction of blast cells in BM and PB and induction of 
partial or complete remission). However, the new drugs do not induce frequent 
and/or durable remission and long-term survival when administered as single 
agents. To obtain high(er) remission rates as well as durable remission, targeting the 
multiple pathophysiological pathways in myeloid leukemia is likely to be essential. 
Therefore, future clinical trials should use the new targeted drugs in combination 
with standard chemotherapy or should combine several new agents targeting more 
than one gene mutation, in order to prevent the development of resistance to any 
particular drug.
CONCLUSIONS
Our study has contributed to the further identification of PCR-based MRD targets 
in myeloid leukemia and has shown that quantitative approaches (flow cytometry 
and molecular techniques) can be applied in routine clinical diagnostics to evaluate 
therapy efficacy and to guide therapeutic interventions in myeloid leukemia. 
Future AML protocols (e.g. HOVON protocols) aim to incorporate MRD data for 
MRD-based therapeutic interventions. It is to expect that this might improve patient 
outcome due to a more individualized risk-adapted strategy: treatment intensification 
for patients at high risk for relapse or treatment reduction for those with a low risk 
for relapse. A prior aim should be the further standardization of ‘classical’ MRD 
techniques such as flow cytometric approaches. In parallel, novel technologies 
such as gene expression profiling by DNA micro-array and proteomic analysis, 
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should focus on 1) the further identification of new MRD targets, 2) the identification 
of clinically useful risk gene expression signatures, and 3) the development of new 
targeted therapies. 
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ABBREVIATIONS
ALL acute lymphoblastic leukemia
AML acute myeloid leukemia
AP acceleration phase
APL acute promyelocytic leukemia
ATO arsenic trioxide
ATP adenosine triphosphate
ATRA all-trans-retinoic acid
AUL acute undifferentiated leukemia
BC blast crisis
BCR breakpoint cluster region
BM bone marrow
C gene segment constant gene segment
CCyR complete cytogenetic response
CD cluster of differentiation
CML chronic myeloid leukemia
CP chronic phase
CR complete remission
CR1 first complete remission
CT threshold cycle
D gene segment diversity gene segment
DFS disease free survival
DNA deoxyribonucleic acid
EAC Europe Against Cancer
FAB French-American-British
FDA Food and Drug Administration
FICTION fluorescence immunophenotyping and interphase cytogenetics
  as a tool for the investigation of neoplasms
FISH fluorescent in situ hybridization
GO gemtuzumab ozogamicin
HOVON stichting hemato oncologie voor volwassenen Nederland
HSC hematopoietic stem cell
HU hydroxyurea
IFN interferon
Ig immunoglobin
IGH immunoglobin heavy chain gene
IGK immunoglobin kappa light chain gene
IGL immunoglobin lambda light chain gene
IM imatinib mesylate
IRIS  International Randomized Study of Interferon and STI571 
ITD internal tandem duplications
Abbreviations170
J gene segment joining gene segment
Kde immunoglobin kappa deleting element
LAIP leukemia associated immunophenotype
LM-PCR ligation mediated polymerase chain reaction
MNC mononuclear cells
MPO myeloperoxidase
MRD minimal residual disease
PB peripheral blood
PCR polymerase chain reaction
Ph chromosome Philadelphia chromosome
precursor B-ALL precursor-B-cell acute lymphoblastic leukemia
RAG recombination-activating gene
RNA ribonucleic acid
RSS recombination signal sequence
RT-PCR reverse transcriptase polymerase chain reaction
RQ-PCR real-time quantitative polymerase chain reaction
SB Southern blotting
SCT stem cell transplantation
T-ALL T-cell acute lymphoblastic leukemia
TCR T-cell receptor
TCRA T-cell receptor alpha gene
TCRB T-cell receptor beta gene
TCRD T-cell receptor delta gene
TCRG T-cell receptor gamma gene
TdT terminal deoxynucleotidyl transferase
V gene segment variable gene segment
WHO World Health Organisation
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SUMMARY
Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are 
malignancies characterized by an uncontrolled proliferation of (immature) myeloid 
cells in the bone marrow (BM). During the past decades, a lot of progress has 
been made in the treatment and the understanding of the biology of AML and CML. 
Patients with myeloid leukemia are usually treated with chemotherapy, possible 
followed by stem cell transplantation. New therapeutic agents are recently available 
including monoclonal antibodies and agents targeting the molecular basis of the 
disease (see Chapter 1). Despite therapy, many patients experience relapse and 
most of them will ultimately die of disease progression. 
The response to therapy can be evaluated by a cytomorphologic examination 
of the BM. However, microscopic techniques can only detect 1 to 5% of malignant 
cells, which is not sufficiently sensitive for the identification of patients who are prone 
to relapse. Indeed, patients who reach a complete remission, cytomorphologically 
defined as the presence of less than 5% of blast cells in the BM, may ultimately 
relapse. To trace low frequencies of remaining leukemic cells, i.e. minimal residual 
disease (MRD), more sensitive methods are required. MRD techniques should 
allow the detection of one leukemic cell within the background of at least 104 normal 
cells (sensitivity of ≤10-4).
The first part of our study focussed on polymerase chain reaction (PCR) 
detectable MRD-targets. These MRD targets represent DNA and/or RNA sequences 
of the leukemic cells that are assumed to be unique for each patient or leukemia, 
as they result from 1) chromosome aberrations with the formation of fusion 
genes, or 2) immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements. 
The unique “fingerprint-like” sequences can easily be identified and characterized 
by PCR-analysis and sequencing. Moreover, “real-time quantitative PCR” (RQ-
PCR) allows not only the detection of residual leukemic cells, but also the level of 
MRD. 
In Chapter 2.2, we investigated the occurrence of “cross-lineage” Ig/TCR 
gene rearrangements in a large group of AML patients. Although the frequency of 
PCR-detectable Ig/TCR gene rearrangements appeared to be low (<10%), 
Ig/TCR gene rearrangements were complementary to the presence of fusion gene 
transcripts that were found in 16% of AML patients. This implies that “cross-lineage” 
Ig/TCR gene rearrangements are complementary MRD-PCR targets in AML patients 
and that PCR allows sensitive MRD detection in 20-25% of AML patients. Because 
Ig/TCR gene rearrangements were rather infrequent, we analyzed whether high 
expression levels of RAG transcripts (enzymes involved in the process of Ig/TCR 
gene rearrangements) correlated with the presence of the “cross-lineage” Ig/TCR 
gene rearrangements in AML. Since no correlation was found, analysis of RAG 
expression levels can not be used as a screening tool for predicting the presence 
of Ig/TCR gene rearrangements in AML.
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In Chapter 2.3, we focused on the over-time stability of fusion gene transcripts 
as MRD-PCR targets. Shipment of freshly collected samples to the PCR laboratory 
may take considerable time. During this period, the quality of the RNA present in 
the samples may deteriorate. We showed that fusion gene transcripts as well as 
control gene transcripts rapidly degrade ex vivo and that the rate of degradation 
can differ between different types of transcripts, between peripheral blood (PB) and 
BM, and between patients. As such differential degradation may result in an over- 
or underestimation of MRD levels, samples should preferably be processed on the 
day of sampling. 
In Chapter 2.4, we characterized the rare µBCR-ABL fusion gene transcript at the 
DNA level. Fusion gene transcripts are most frequently analysed at the RNA level, 
but such PCR products are leukemia-specific, not patient-specific. Consequently, a 
potential disadvantage of monitoring fusion gene transcripts at the RNA level, is the 
possibility of cross-contamination. Using a ligation-mediated PCR, we identified the 
µBCR-ABL fusion sites in three samples. The identified DNA sequences represent 
patient-specific “fingerprints” and can potentially be used as PCR targets for MRD 
monitoring. We also showed that the breakpoints were rather clustered within the 
genome. 
In the second part of our study we focused on the clinical applicability of MRD 
analyses for the evaluation of therapy-efficacy in myeloid leukemias. Both flow 
cytometric and molecular techniques are used for the detection and quantification 
of MRD. Flow cytometric analysis is based on the detection of so-called “leukemia-
associated phenotypes” (LAPs) that are absent or extremely uncommon within 
normal BM. These LAPs are found in about 80% of AML patients and can be used 
during follow-up to discriminate between residual leukemic and normal cells. 
In routine clinical practice, both flow cytometric and PCR analyses are performed 
on diagnostic AML samples. If at diagnosis a LAP is identified in addition to a PCR-
target, it is recommended to monitor AML patients during and after therapy with both 
MRD-techniques. This is illustrated in Chapter 3.2. Herein we report on a patient 
with a immunophenotypic change of the leukemic cells between diagnosis (AML) 
and relapse (acute lymphoblastic leukemia), while the CBFB-MYH11 fusion gene 
transcript remained stable. If only flow cytometric immunophenotyping was used to 
monitor this patient, the relapse would only have been detected at the moment of 
clinical relapse. For certain AML subtypes (e.g. AML-M3), it has been proven that 
treatment intervention at the time of molecular relapse may result in better clinical 
outcome than treatment intervention at the time of overt clinical relapse. Further 
studies need to investigate whether treatment intervention at the time of molecular 
relapse can also improve outcome in CBFB-MYH11 positive AML patients. 
In Chapter 3.3 we evaluated the possibility to safely replace BM sampling by 
PB sampling for MRD monitoring in CBFB-MYH11 positive AML. RQ-PCR results 
showed that MRD levels in BM samples are generally higher than in PB samples 
(ranges: 0,8 to 100 fold). Nevertheless, monitoring of CBFB-MYH11 transcript levels 
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in PB did have predictive value: MRD levels in PB predicted disease reoccurrence 
2,5 to 4 months prior to the cytomorphological BM relapse. A time frame of at least 
2,5 months should be enough to adjust therapy, thereby increasing the chance to 
reach a molecular remission. 
The hallmark of CML is the presence of the Philadelphia chromosome resulting 
from a translocation between chromosome 9 and 22, with the formation of a 
BCR-ABL fusion gene and hybrid protein. This latter has a constitutively active 
tyrosine kinase activity, which induces aberrant oncogenic signalling. RQ-PCR 
allows the quantification of BCR-ABL fusion gene transcripts during therapy. To 
date allogeneic stem cell transplantation is the only treatment modality with an 
established curative treatment potential for CML. However, recently Gleevec® 
(imatinib mesylate), a selective inhibitor of the BCR-ABL tyrosine kinase, is routinely 
used for treatment of CML. Imatinib mesylate shows superior outcomes for newly 
diagnosed CML patients in chronic phase (i.e. the first stage of the disease), 
frequently with major cytogenetic and molecular responses. We showed that 
Gleevec® can also induce durable complete remission in a patient with advanced 
CML persisting after allogeneic BM transplantation (see Chapter 3.4). 
During the last decades, the prognosis of AML in young patients (≤60 years 
of age) has been significantly improved: current treatment protocols induce a 
complete remission in 75-80% of patients with a 5-years survival of 30-40%. This 
is in contrast to the limited progress in outcome results in elderly AML patients 
(>60 years of age): complete remissions in 50-55% of patients with a 5-years 
overall survival of ~10%. This is partially explained by the limited ability of the older 
patients to tolerate intensive chemotherapy. Recently, new treatment modalities 
have become available including the use of monoclonal antibodies selectively 
targeting the leukemic cells, e.g. Mylotarg® (gemtuzumab ozogamicin). Mylotarg® 
is a humanized CD33 monoclonal antibody chemically linked to calicheamicin, a 
highly potent antitumor antibiotic. Mylotarg® targets the surface CD33 antigen that 
is found on >85% of AML cells. In elderly patients in first relapse, Mylotarg® induces 
a remission in 30% when administrated as two infusions at a dose of 9 mg/m2. 
In Chapter 3.5 we show that after administration of these doses, the CD33 saturation 
in BM is significantly reduced (40-90%) as compared with the CD33 saturation in 
corresponding PB samples (>90%) and that these reduced CD33 saturation levels 
in vitro result in less efficient cell-kill. Our results suggested that the final CD33 
saturation level in BM is not only affected by the peripheral CD33-antigen load, 
but may also be dependant on the total CD33-antigen load present in the BM. 
This implies that for efficient killing of AML blasts in BM, the effective gemtuzumab 
dose should be increased or alternatively, that the CD33 antigen load should be 
reduced prior to Mylotarg® administration, preferably by the design of treatment 
protocols that combine chemotherapy and Mylotarg®.
In conclusion, the results of our study have, 1) contributed to the further 
identification of PCR-detectable MRD targets in AML and CML, 2) showed that BM 
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sampling can be replaced by PB sampling for MRD monitoring in CBFB-MYH11 
positive AML, 3) illustrated that MRD-monitoring with PCR and flow cytometric 
techniques has clinical relevance, and 4) stressed the need for adequate evaluation 
of new (antibody)therapies for the design of future treatment protocols. 
MRD-based treatment interventions are routinely used in the AML-M3 subtype 
and transplanted CML patients. Further studies are needed to evaluate whether 
such MRD-based treatment interventions (treatment intensification or reduction) can 
also improve overall outcome in other AML subtypes. In addition, further research 
for reliable MRD targets, but especially studies focussing on new therapeutics 
might significantly improve the overall outcome in myeloid leukemias.
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SAMENVATTING
Acute myeloïde leukemie (AML) en chronische myeloïde leukemie (CML) zijn 
vormen van bloedkanker gekenmerkt door een ongecontroleerde proliferatie van 
(onrijpe) myeloïde cellen in het beenmerg. De afgelopen jaren is veel vooruitgang 
geboekt in de behandeling van myeloïde leukemie, alsook in de inzichten van de 
ontstaansmechanismen ervan. Patiënten met een myeloïde leukemie worden in het 
algemeen behandeld met chemotherapie, en eventueel een beenmergtransplantatie. 
Sinds kort bestaan er ook nieuwe therapeutische mogelijkheden zoals het gebruik 
van antistoffen en producten die selectief inwerken op het onderliggende moleculaire 
defect van de leukemie (zie Hoofdstuk 1). Ondanks behandeling komt de ziekte bij 
een deel van de patiënten terug (recidief), van wie uiteindelijk een groot deel zal 
overlijden aan de ziekte.
Door een cytomorfologisch (microscopisch) onderzoek van het beenmerg 
kan bepaald worden hoe een patiënt reageert op de therapie. Met microscopisch 
onderzoek kunnen echter slechts 1 tot 5% leukemiecellen worden gedetecteerd, 
hetgeen onvoldoende is voor het herkennen van patiënten die een grote kans 
hebben op een recidief. Immers bij een relatief groot deel van de patiënten bij 
wie na behandeling microscopisch geen leukemiecellen meer aantoonbaar zijn in 
het beenmerg (complete remissie), komt de ziekte toch terug. De kleine aantallen 
leukemiecellen, die ondanks therapie achterblijven, vormen de zogenaamde 
“minimale restziekte” ofwel “minimal-residual disease” (MRD). Het opsporen van 
MRD vereist zeer gevoelige technieken die bij voorkeur minimaal één leukemiecel 
tussen 1x104 normale cellen (sensitiviteit ≤1x10-4) kunnen detecteren. 
Het eerste deel van het onderzoek in dit proefschrift was gericht op MRD-
targets die met behulp van de polymerase ketting reactie (PCR) kunnen worden 
opgespoord. Deze MRD-PCR targets zijn basepaarvolgordes (sequenties) van 
genetisch materiaal (DNA en/of RNA) die uniek zijn voor de leukemiecellen, 
omdat zij afkomstig zijn van (1) chromosomale afwijkingen met de vorming van 
fusiegentranscripten, of van (2) immunoglobuline (Ig) en T-celreceptor (TCR) 
genherschikkingen. Ze vormen dus een soort unieke “vingerafdruk” van de 
leukemiecellen. Met PCR kunnen ze op een relatief eenvoudige wijze worden 
geïdentificeerd en gekarakteriseerd. Door gebruik te maken van een kwantitatieve 
PCR methode, de zogenoemde “real-time quantitative PCR” (RQ-PCR) kan niet 
alleen MRD op een gevoelige manier worden gedetecteerd, maar bovendien kan 
ook het MRD niveau, dus het aantal leukemiecellen, worden gekwantificeerd. 
 In Hoofdstuk 2.2 onderzochten we het voorkomen van “cross-lineage” Ig/TCR 
genherschikkingen in een grote groep AML patiënten. Ig/TCR genherschikkingen die 
we tot op sequentieniveau konden karakteriseren, werden slechts in een klein deel 
(<10%) van de AML patiënten aangetroffen. Een belangrijke bevinding was echter 
dat deze Ig/TCR genherschikkingen veelal complementair zijn aan de aanwezigheid 
van fusiegentranscripten, die we bij 16% van de AML patiënten aantroffen. 
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Dit betekent dat “cross-lineage” Ig/TCR genherschikkingen een complementair 
MRD-PCR target vormen bij AML patiënten en dat met de PCR techniek ongeveer 
20% tot 25% van de AML patiënten kunnen worden vervolgd voor de aanwezigheid 
van MRD. Omdat Ig/TCR genherschikkingen niet frequent worden gevonden bij 
AML patiënten, onderzochten we of hoge expressies van RAG transcripten (dit 
zijn enzymen die betrokken zijn in het proces van Ig/TCR genherschikkingen) 
de aanwezigheid van Ig/TCR genherschikkingen bij AML kunnen voorspellen. 
We konden echter geen correlatie tussen het expressieniveau van RAG en het 
voorkomen van “cross-lineage” Ig/TCR herschikkingen bij AML aantonen, zodat 
het RAG expressieniveau niet als screeningstest kan worden gebruikt voor het 
voorspellen van de aanwezigheid van Ig/TCR genherschikkingen in AML.
In Hoofdstuk 2.3 richtten we ons op fusiegentranscipten als MRD-PCR targets 
waarbij we vooral geïnteresseerd waren in de stabiliteit van deze PCR targets 
tussen staalafname en laboratoriumanalyse. Immers, de tijdspanne tussen het 
moment van staalafname voor PCR-analyses en het verwerken van het staal 
in gespecialiseerde laboratoria kan soms enkele dagen duren; tijdens deze 
transportperiode kan de kwaliteit van het RNA achteruitgaan. We toonden aan 
dat fusiegentranscripten snel afbreken ex vivo, maar belangrijker dat de mate van 
afbraak varieert tussen de verschillende soorten van fusiegentranscripten, tussen 
verschillende staalsoorten (beenmerg of perifeer bloed) en tussen patiënten. Dit 
impliceert dat het niveau van MRD mogelijk foutief wordt ingeschat en dat daarom 
stalen bijvoorkeur dezelfde dag moeten worden verwerkt.
In Hoofdstuk 2.4 hebben wij een zeldzame vorm van het BCR-ABL fusiegen, 
namelijk het µBCR-ABL fusiegen, op DNA niveau gekarakteriseerd. Meestal worden 
MRD PCR-analyses van fusiegenen op RNA niveau uitgevoerd (zoals wij ook deden 
in de Hoofdstukken 2.2 en 2.3). Fusiegentranscripten zijn weliswaar wel leukemie-
specifiek, maar niet patiënt-specifiek, waardoor een contaminatie (besmetting van 
een negatief staal door een positief staal) nooit helemaal is uit te sluiten. Met een 
speciale PCR-techniek (ligatie-gemedieerde PCR) identificeerden we de exacte 
DNA breukpunten van de µBCR-ABL fusiegenen van drie verschillende leukemieën. 
Deze geïdentificeerde DNA codes vormen patiënt-specifieke “vingerafdrukken” die 
uitstekend bruikbaar zijn als MRD-PCR targets. We toonden bovendien aan dat de 
breukpunten relatief sterk geclusterd liggen in het genoom.
Het tweede deel van het onderzoek in dit proefschrift richtte zich op de klinische 
toepassingen van MRD analyses voor de evaluatie van de doeltreffendheid van de 
therapie. Naast PCR is ook flowcytometrische immunofenotypering geschikt om op 
een gevoelige manier MRD te detecteren en te kwantificeren. Flowcytometrische 
MRD analyse is gebaseerd op het opsporen van leukemie-geassocieerde fenotypes 
(“leukemia-associated phenotypes”: LAP’s) die niet of nauwelijks voorkomen in 
een normaal beenmerg. Deze LAP’s die in ~80% van de AML patiënten worden 
geïdentificeerd, kunnen worden gebruikt om gedurende en na de therapie de 
eventueel resterende leukemiecellen te onderscheiden van de normale cellen.
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Bij de diagnose van een nieuwe AML worden steeds flowcytometrische en PCR 
analyses uitgevoerd. Indien hierbij zowel LAP’s als MRD-PCR-targets worden 
gedetecteerd, is het aanbevolen om de AML tijdens en na therapie met de twee MRD 
technieken te vervolgen. De complementariteit van deze twee MRD technieken 
wordt geïllustreerd in Hoofdstuk 3.2, waarin we een patiënt rapporteren waarbij de 
fenotypische kenmerken (LAP’s) van de leukemiecellen veranderden tussen de 
oorspronkelijke diagnose (AML) en zijn recidief (acute lymfoblastaire leukemie), 
terwijl de moleculaire afwijking (een CBFB-MYH11 fusiegentranscript) stabiel bleef 
tussen diagnose en recidief. Indien men deze patiënt enkel zou hebben vervolgd 
met flowcytometrische technieken, zou het recidief pas laattijdig zijn gedetecteerd, 
namelijk op het moment van het klinische recidief. Voor bepaalde types van AML 
(bv. AML-M3) is reeds duidelijk aangetoond dat de prognose van de patiënt verbetert 
indien therapeutisch wordt ingegrepen op het moment dat een recidief met PCR of 
flowcytometrische technieken wordt gedetecteerd. Verdere prognostische studies 
moeten uitwijzen of dit ook geldt voor patiënten met een CBFB-MYH11 positieve 
AML. 
Hoofdstuk 3.3 vat de resultaten samen van een studie waarin we evalueerden 
of een perifeer bloedstaal een waardig alternatief kan vormen voor een beenmerg 
voor het vervolgen van MRD tijdens en na therapie. We focusten hierbij op AML 
patiënten met een CBFB-MYH11 fusiegentranscript. RQ-PCR resultaten toonden 
enerzijds dat het niveau van MRD in beenmerg gewoonlijk hoger ligt dan in perifeer 
bloed (factor 0,8 tot 100), maar anderzijds ook dat MRD-analyses van perifeer 
bloed toch belangrijke prognostische informatie bevatten. Immers, RQ-PCR op 
perifeer bloed stelde ons in staat om recidieven vroegtijdig op te sporen, namelijk 
2,5 tot 4 maanden vóór de patiënt een klinisch recidief vertoonde. Deze periode 
is vermoedelijk voldoende om de behandelend arts de tijd te geven om vroegtijdig 
de behandeling terug op te starten of om de therapie te intensiveren, waardoor de 
kans om opnieuw een moleculaire remissie te bereiken hopelijk wordt vergroot. 
Hét kenmerk van een CML is de aanwezigheid van het Philadelphia 
chromosoom. Dit abnormale chromosoom is het resultaat van een translocatie 
tussen chromosomen 9 en 22, waarbij het BCR-ABL fusiegen ontstaat. 
Het BCR-ABL fusiegen leidt tot een continue doorgaande tyrosine kinase activiteit, 
die een belangrijke rol speelt in het ontstaan van CML. Met behulp van RQ-PCR 
technieken wordt het BCR-ABL fusiegentranscript tijdens de behandeling vervolgd 
om daarmee de effectiviteit van de behandeling te evalueren. Tot voor enkele jaren 
vormde een beenmergtransplantatie de enige kans op een blijvende genezing 
voor CML patiënten. Sinds kort wordt bij de behandeling van CML frequent gebruik 
gemaakt van Gleevec (imatinib mesylate), dat selectief de BCR-ABL kinase 
activiteit inhibeert. Vooral nieuwe gediagnostiseerde CML patiënten in chronische 
fase (dit is de eerste fase van de ziekte) vertonen een zeer goede cytogenetische 
en moleculaire respons op deze therapie. In Hoofdstuk 3.4 toonden wij aan dat 
Gleevec® ook bij patiënten in een vergevorderd stadium van de ziekte na een 
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niet-verwante beenmergtransplantatie, een blijvende moleculaire remissie kan 
induceren. 
 De prognose van AML bij jonge patiënten (≤60 jaar) is de laatste decennia 
significant verbeterd: veelal bereiken 75-80% van de patiënten een complete remissie 
en is er een 5-jaarsoverleving van 30-40%. Dit is in scherp contrast met oudere AML 
patiënten (>60 jaar) waarvoor slechts geringe vooruitgang werd geboekt: complete 
remissies in 50-55% van de patiënten en een 5-jaarsoverleving van ongeveer 
10%. Een gedeeltelijke verklaring is dat ouderen de intensieve chemotherapie 
niet of moeilijk verdragen. Sinds kort zijn er nieuwe behandelingsmethodes ter 
beschikking zoals immunotherapie met het gebruik van antistoffen die selectief 
gericht zijn tegen bepaalde antigenen op de leukemiecellen. Een voorbeeld hiervan 
is Mylotarg® (gemtuzumab ozogamicine), een monoklonale antistof die gekoppeld 
is aan het antitumorale calicheamicine en die gericht is tegen het CD33-antigeen, 
dat aanwezig is op >85% van de AML-cellen. Dertig procent van de oudere AML 
patiënten met een recidief bereiken na 2 intraveneuze toedieningen van Mylotarg® 
(dosis: 9 mg/m2) opnieuw een remissie. In Hoofdstuk 3.5 toonden we aan dat na 
toediening van deze Mylotarg® doses de CD33-saturatie in het beenmerg veelal 
beperkt is (40-90%) -dit in tegenstelling tot saturaties van >90% in het perifeer 
bloed- en dat deze lagere CD33-saturaties in vitro leiden tot een minder efficiënte 
celdoding. Onze experimenten suggereerden dat de mate van CD33-saturatie 
in het beenmerg wordt bepaald, 1) door het totaal aantal CD33 antigenen in het 
perifeer bloed (hoge aantallen antigenen in het perifeer bloed binden hoge doses 
Mylotarg® waardoor er minder product beschikbaar blijft om door te dringen naar 
het beenmerg), en 2) door het totaal aantal CD33 antigenen op de cellen in het 
beenmerg zelf. Deze bevindingen impliceren dat voor een efficiënte en optimale 
doding van de leukemiecellen in het beenmerg hogere of frequentere Mylotarg® 
doses moet worden toegediend of dat de hoeveelheid CD33 antigenen eerst 
moet worden verminderd voordat Mylotarg® wordt toegediend bij voorkeur door 
het ontwerpen van therapieprotocollen, waarin chemotherapeutica en Mylotarg® 
worden gecombineerd. 
Als besluit kunnen we stellen dat de resultaten beschreven in dit proefschrift, 1) 
bijdragen tot de verdere identificatie van PCR-detecteerbare MRD targets in AML 
en CML, 2) aantonen dat een perifeer bloedstaal een beenmerg kan vervangen 
voor PCR-MRD analyses in bepaalde AML-subtypes, 3) illustreren dat MRD 
detectie met PCR en flowcytometrische immunofenotypering klinisch belangrijk is, 
en 4) aantonen dat de evaluatie van nieuwe (antistof)therapieën essentieel is om 
optimale behandelings- en doseringsschema’s te bepalen.
MRD-gebaseerde behandelingsinterventies worden reeds toegepast bij 
bepaalde AML subtypes (bv. AML-M3) en bij getransplanteerde CML patiënten 
met zeer gunstige resultaten. Verder onderzoek is nodig om na te gaan of MRD-
gebaseerde behandelingsinterventies (zowel intensivering van de therapie als 
reductie ervan) ook bij andere AML-subtypes de kans op genezing kunnen 
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verhogen. Verder onderzoek naar de identificatie van nieuwe MRD targets maar 
vooral onderzoek naar nieuwe therapeutische mogelijkheden zullen zeker bijdragen 
tot hogere genezingskansen voor patiënten met myeloïde leukemie. 
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